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Abstract 
Medicinal inorganic chemistry —a sub discipline of bioinorganic chemistry is one of the most 
rapidly developing areas of pharmaceutical research. This field gained momentum after the 
prototypical success story of platinum based anticancer drug cisplatin, cis—diamminedichloro 
platinum(II), cis—[Pt(NH3)2Cl2)] for treating solid cancers in particular, testicular, ovarian, small 
cell lung, head and neck cancers. Despite its success, there were serious concerns of this drug 
regarding its toxicity, intrinsic resistance, narrow spectrum of activity for phenotypes of cancer 
and patient compliance. Therefore, studies pertaining to essential metallo elements received 
much more attention in contrast to Pt, since the drugs designed and synthesized from endogenous 
metal ions may be less harmful and more prone to antiproliferative activity against tumors. 
Consequently, a large number of metal complexes have been designed and are currently under 
evaluation for chemotherapeutic applications. Many studies have been done to elucidate the 
mechanism of action as well to elucidate the mechanism of action as well as to optimize and 
improve the activity in comparison to platinum drugs. 
The importance of ligand scaffold in modifying the biological effects of metal based drugs 
cannot be under estimated. Ligand scaffolds are also considered important in muting the toxicity 
of the metallodrug as well tailored multifunctional ligands offer exciting possibilities by 
providing appropriate anchoring sites for the metal ions, matching the structural motif at the 
molecular target and restricting the geometry. Ligands can modify the oral/systemic 
bioavailability of metal ions, can assist in targeting specific issues or enzymes, can deliver, 
protect or sequester a particular metal ion depending on the requirements of therapy and 
diagnosis. Addition of substituents that either binds preferentially to membrane receptors 
(glycosyl moieties) or asymmetric carbohydrate substituent that is appended rather that bound 
rectly to metal ion permit targeting (metal based glycoconjugate medicinal agents). This 
)ened a new frontier in pharmaceutical research "glycobiology" that has profound effects on 
etal—based pharmaceuticals. Functional ligands that have well defined properties in 
ganometallic chemistry can be exploited in biological system by influencing the redox 
•operties of the metal ion and hence, biological properties of the compound in vivo. 
he choice of metal ions is also a critical feature for the design of metal based chemotherapeutic 
.rugs. The incorporation of endogenously biocompatible metal ion Cu(II), Zn(II) can be utilized 
to optimize the toxicity as they familiarise with the biological environment of the human body. 
Amongst the notable class of antitumor agents in oncology are tin(IV) and organotin(IV) 
complexes, which not only indulge in electrostatic interaction due to the presence of tin(IV) 
(strong Lewis acid) with the exterior phosphate oxygens of the double helix of DNA but also are 
specific apoptotic directors. Therefore, employing a strategy of combining two homo or 
heteronuclear metal centers in biologically active pharmacophore is de novo and unique. Such 
bimetallic complexes are capable of enhanced binding with ultimate biological target DNA at the 
molecular level and also capable to cleave double stranded DNA efficiently. 
The thesis embodies the synthesis and characterization of new metallated chemical entities for 
use as antitumor agents. DNA is the primary cellular target for most of the chemotherapeutic 
agents therefore, preliminary in—vitro DNA binding profile of these metal—based chemical 
entities were carried out by employing various bio—physical techniques. These studies are of 
paramount importance as the mode of binding to DNA gives an insight for the rationale of robust 
drug design. Our studies reveal that these complexes are capable of binding non—covalently to 
DNA and thereby they can act as efficient chemotherapeutic agents. 
ii 
The thesis is divided in six chapters which includes Chapter I "Introduction" which 
emphasizes the aims and significance of this work in context of detailed relevant literature and 
also helps to justify the objectives of the work done. Chapter II "Experimental" describes 
experimental methods and physical measurements employed in this work. Chapter III—VI 
embodies the synthesis and characterization of metal complexes and their in vitro DNA binding, 
pBR322 cleavage and cytotoxicity against human cancer cell lines were investigated. 
Chapter III deals with the synthesis of the heterobimetallic complexes [C28H25N8CuSn2C16] and 
[C28H2sN3NiSn2Ch] derived from monometallic [Cu(en)2].C12 and [Ni(en)2].Cl2, respectively. 
These complexes were thoroughly characterized by spectroscopic (IR, 1 H, 13C, 119Sn NMR, 
XRD, EPR, UV—vis, ESI—MS) and analytical techniques. In the complexes, the geometry of 
copper and nickel ions were square planar while tin ions were present in hexacoordinate 
environment. The in vitro DNA binding studies of [C28H28N8CuSn2CI6] and [C28H28N8NiSn2C16] 
with CT—DNA were carried out by employing various biophysical methods which reveal strong 
electrostatic binding via phosphate backbone of DNA helix, in addition to partial intercalation in 
the minor groove and stabilized by intramolecular hydrogen bonding. To gain further insight into 
the molecular recognition at the target site, UV—vis titrations of [C28H2$N8CuSnCl6] with 5'-
GMP was carried out and validated by 'H and 31P NMR. Complex [C28H2gNRCuSnCI6] cleaved 
pBR322 DNA via oxidative pathway and exhibited high inhibition activity against Topo—I at 20 
µM. Furthermore, the cytotoxicity of [C25H23N8CuSn2CI6] was examined on a panel of human 
tumor cell lines of different histological origins showing promising antitumor activity. 
Chapter IV describes glycosylated heterobimetallic complexes [C22H42N60i,CuSnCl2] and 
[C22H42N60, NiSnCIZ], derived from N—glycoside ligand [C14H28N201o] (L). The complexes 
were synthesized and thoroughly characterized by spectroscopic (IR, 'H, 13C and 119Sn NMR, 
iii 
EPR, UV—vis, ESI—MS) and analytical methods. The geometry of copper and nickel ions was 
square pyramidal while tin(IV) metal was present in the hexacoordinate environment. The X—ray 
powder diffraction (XRPD) confirmed the crystalline nature for the complexes. Interaction 
studies of [Ci4H2gN2O10], [C22H42N6O11CuSnCl2] and [C22H42N6O1,NiSnCl2] with CT DNA in 
Tris—HCI buffer were studied by electronic absorption titration and fluorescence titration to 
examine their DNA binding strength and it was quantified by intrinsic binding constant Kb values 
which follow the order [C22H42N6Oi,CuSnCl2] > [CuH42N6O, jNiSnCl2] > [G4H28N20,D]. 
Complex [C22H42N601,CuSnCl2] cleaves pBR322 DNA via hydrolytic pathway which was 
authenticated by T4 DNA ligase assay. The complex [CuH42N6O,1CuSnCl2] exhibited 
remarkably good anti—tumor activity on a panel of human cancer cell lines (GI50 values < tO 
µg/ml), and to elucidate the mechanism of tumor inhibition, Topo—I enzymatic activity was 
carried out. Finally, confocal microscopy using HeLa cells revealed intracellular localization of 
the complex [CrH42N6O,,CuSnC121 
Chapter V embodies the synthesis of new modulated series of carbohydrate—conjugate 
heterobimetallic complexes [CFlsoN5Oi 3CuSnCl2] and [C22H58N6017NiSnCl2J by utilizing 
biologically active piperazine scaffold derived from monometallic complexes [C2gH52N6Oi 3Cu], 
[CuH6oN6OjiNi] of previously synthesized N—glycoside ligand. The proposed structure of the 
complexes was formulated on the basis of elemental analysis and other spectroscopic data (Ill, 
'H and 13C NMR, EPR, UV—vis and ESI—MS). In vitro DNA binding studies were carried out 
employing absorbance and fluorescence spectroscopy to examine their DNA binding propensity 
as quantified by Kb and K,v values. Cleavage studies with pBR322 plasmid DNA employing gel 
electrophoretic assay demonstrated that complex IC22H50N6O13CusnCl2] is specific groove 
binders and cleave supercoiled pBR322 DNA via hydrolytic pathway, which was further 
iv 
confirmed by T4 DNA ligase assay. Complex [C22H50N6o1 3CuSnCl2J inhibited Topo-1I 
mediated relaxation activity in a dose-dependent manner that appeared in accordance with 
remarkably good anti-tumor activity against MIAPACA2, A498 and HCT15 tumor cell lines. 
The complex [C22H50NfiO13CuSnC12] was docked towards the ATPase domain of human-Topo-
II in order to probe the possible mechanism of inhibition. An important finding of this work was 
that the metal-based chemical entities bearing glycosylated appendage, showed good promise as 
antiproliferative agents, artificial nuclease -hydrolytic cleaving agents and Topo II inhibitors. 
Chapter VI embodies synthesis of new heterobimetallic complexes [Cl6H,6N302SCuSnCl] and 
[C16H16N302SZnSnCI] from their monometallic analogs [C14H12N302SCuCI] and 
[C14H) 2N3O2SZnCI] of Schiff base ligand derived from salicylaldehyde and 5-amino-2- 
mercaptobenzimidazole. These complexes were thoroughly characterized by spectroscopic (IR, 
'H, 13C, 119Sn NMR, EPR, UV-vis, ESI-MS) analytical methods. On the basis of spectral 
studies, the coordination geometry of central metal ion copper (II) and zinc (II) was square 
planar and tetrahedral, respectively, while the Sn(IV) atom was present in four coordinated 
environment. The in vitro DNA binding studies of ligand [C14HI ,N3OS] and its metal complexes 
[C14HJ 2N3O2SCUCI], [C14HI2N3O2SZnCI], [C1 6H16N302SCuSnCI] and [C,6H,6N302SZnSnCI] 
were carried out by employing Uv-vis and fluorescence spectroscopic titration methods. The 
results revealed the electrostatic binding via phosphate backbone of DNA helix, in addition to 
other binding modes viz, coordinate covalent and partial intercalation. Cleavage studies of 
complexes [Ci6N16N3O2SCuSnClJ and [C16H16N302SZnSnCI] with pBR322 plasmid DNA 
demonstrate both the complexes were efficient cleaving agents and were specific groove binders. 
Complex [G4-Tj6N302SCu5nC1] cleaved pBR322 DNA via oxidative mechanism while 
[C16H16N3O2SZnSnCI] followed hydrolytic pathway. Furthermore, the cytotoxicity of 
v 
[C16H16N302SCuSnCl] was examined on a panel of human tumor cell lines of different 
histological origins showing promising antitumor activity. 
Finally, a chapter on bibliography has been incorporated at the end of the thesis which includes 
literature survey in support of the hypothesis and discussion on metal—based chemotherapeutic 
entities designed and accomplished. 
VI 
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DMSO Dimethylsuitoxide 
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ESI Electrospray Ionization 
EthBr Ethidium Bromide 
EtOH Ethanol 
(en) Ethylenediamine 
GMP Guanosine Monophosphate 
IL Intraligand 
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"Iris "I'ris(hydroxymethyl)aminomethane 
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CHAPTER I 
Introduction 
1 
Introduction 
Medicinal inorganic chemistry emerges from the interdisciplinary areas of bioinorganic 
chemistry (which is at the interface between medical biology and inorganic chemistry), 
organometallic chemistry which includes metal—based therapeutics derived from organic 
scaffold/ metal—containing diagnostic agents and supramolecular chemistry [1-5]. This 
field gained momentum after the serendipitous discovery of cisplatin (cis— 
diamminedichloroplatinum(1I), [cis—(NH3hPtCl2]) [6], which was known to prevent 
mitotic division and later developed and approved by FDA in 1979 as an antitumor drug 
for treating solid malignancies; metal—based drugs were traditionally undervalued by 
pharmaceutical manufacturers as they were dominated by organic chemistry. Many other 
coordination compounds attracted considerable attention which includes gadolinium 
complexes in magnetic resonance imaging (MRI) [7], for both therapy and diagnosis, 
titanocene dichloride [8] as a potent antitumor agent and ruthenium polypyridyl 
complexes—as bacteriostatic and an anticancer agents [9-11] (Figure 1). 
The medicinal inorganic chemistry is not a new discipline as it can be traced back to 3000 
BC when metal complexes were explored for their medicinal and pharmacological 
applications. Copper was used to sterilize water in Egypt and the Chinese and Arabs were 
using gold in number of medicines since antiquity in metal—based therapies. Mercurous 
chloride was used as a "diuretic" during renaissance period in Europe while Paul Ehrlich 
the so called "founder of chemotherapy" developed arsenical, Salvarsan, as a drug for the 
treatment of Syphilis in early twentieth century [12]. 
[ 19, 20], anti—hypertensive, etc [21]. 
(a) 
20104 
2 
Coordination complexes offer a diverse arena and their applications in medicine 
encompass cancer chemotherapy [ 13-16], antimicrobial agents [ 17, 18], anti HIV drugs 
(C) 
Figure 1. (a) C'isplatin. (h) A dual function Gct;  * —texaphyrin derivative for cancer 
imaging and therapy, (c) Dwyer Ru(11) complex 
Though medicinal inorganic chemistry was strengthened by the discovery of anticancer 
properties of platinum ammine complexes namely cisplatin, (which was an important 
component in chemotherapeutic regimens for the treatment of ovarian, testicular, lung, 
3 
and bladder cancers); second generation platinum compounds viz. carboplatin, 
oxaliplatin, nedaplatin, and lobaplatin, yet there are well—known drawbacks associated 
with their use such as significant toxicity due to non—specific interactions (severe side 
effects and activity to act in a restricted spectrum of tumors) as well as inherent or 
acquired resistance; these effects limit their successful clinical use. Therefore, a plethora 
of alternative metal—based drugs with broader spectrum of activity and reduced toxic side 
effects were developed and some of these have entered pre—clinical testing and clinical 
trials [22]. 
Transition metals offer potential advantages over the common organic—based drugs, 
which include a wide range of coordination numbers and geometries, accessible redox 
states, electron shuttling thermodynamic and kinetic stability [23]. Metal complexes are 
more appealing for design of new lead therapeutic drugs as metal plays an important role 
in the chaperoning and or delivery of drugs away from the sites where they exert most 
toxicity and toward their sites of action [24, 25]. Additionally, the formation of a metal 
complex will alter the solubility and lipophilicity of the drug, resulting in changes in 
pharmacokinetics, biodistribution and biotransformation [26]. However, platinum—based 
anticancer agents are non—specific resulting in significant toxicity; these effects limit 
their successful clinical use [27]. Therefore, alternative strategies based on non—platinum 
metals and ligand scaffold bearing functionalities are being developed with improved 
pharmacological properties and a broader range of antitumor activity, particularly, based 
on increased understanding of the biochemical differences between normal and cancerous 
tissues. It is now well established that the biological activity and mechanism of action of 
4 
metal complexes can be fine—tuned by an appropriate choice of metal, its oxidation state 
and the ligands [28, 29]. 
Metal ions exist as electron deficient cations (Lewis acid) in the biological system and 
hence are attracted to electron rich (Lewis bases) biological molecules such as protein 
and DNA. Since pharmacological target of the antitumor drugs is cellular DNA and N7 
atom of the imidazole rings of guanine and N3 atom of adenine residues located in the 
major groove of the double helix [30], the most accessible and reactive nucleophilic sites 
for binding to DNA, therefore, search for the DNA binding non—platinum metal 
complexes has gained increased momentum. A novel DNA binding metal complex with 
good anticancer activity and clinical efficacy must fulfill the following key criteria (I) 
good intrinsic properties, including saline solubility and enough stability to arrive intact 
at the cellular target (II) efficient DNA binding properties (111) efficient transport in blood 
and through membranes (IV) the ability to differentiate between cancerous and normal 
cells (V) activity against tumors that are, have become resistant to cisplatin and its second 
generation derivatives [311. 
Cancer is a class of disease in which a group of cells display uncontrolled growth 
(division beyond the normal limits), invasion (intrusion on and destruction of adjacent 
tissues), and sometimes metastasis (spread to other locations in the body via lymph or 
blood). Most cancerous cells divide uncontrollably to form lumps or masses of tissue 
called tumors but some like leukemia (where cancer prohibits normal blood function by 
abnormal cell division in the blood stream) do not. Systems that irreversibly bind to DNA 
such as cisplatin and its analogues have become some of the most important first—line 
treatment for solid tumors [32-36]. On the other hand, complexes that bind to DNA 
Tw ist -33 
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Holl = 6 
Inclrn = 21 
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reversibly have possible application as tools ft r probing the structure and function of 
DNA [ 37—,(fl. 
DNA. an inherently chiral molecule has a polymorphic structure with polyanionic 
nucleotide chains and sugar phosphate back bone [401. The asymmetric D—ribose and D— 
—deox)ribose units contain several stereogenic centers. whose configuration is important 
in overall DNA structure. 
C. Z-DNA 
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Figure 2. L)iffereru confiormational variations of U;1'A structure. 
It is v%ell known that DNA does not exist in a single three--dimensional structure, but can 
adopt difterent conformations which are defined both locally and macroscopically h\ 
different structural parameters (Figure 2). Double stranded DNA commonly adopts a 
right—handed helical conformation that of B— and the A—form, however, they differ in the 
conformation of sugar (C2'—cndo for B—DNA and C3'—endo for A—DNA, and in helical 
parameters). It was discovered that certain sequences of DNA ha \ c the propensity to 
undergo conformational transitions to left—handed helical form termed as 7—DNA 1411. 
A large percentage of the chemotherapeutic anticancer drugs currently used fall into the 
category of DNA—binding drugs. which interact with I)NA duplex by any of the three 
6 
enerai binding modes i hich htrvc been thoroughly characterized from a structural point 
of view. DNA intercalators [42]. groove hinders 1431, and covalent binders l44-7] 
(Figure 3). with some peculiarities %kithin each general category, may he cytotoxic and 
thus therapeutic either by direct interaction with DNA or by inhibition o('topoisomerase 
enzymes (preventing DNA relaxation) [48]. 
 
0 
 
(a) Groove binder (b) Intercalation (c) Insertion 
Figure 3. The three' hin(ling nmcic of metal complexes with /).V.4. (a) groove binding, (b) 
iniercalatio (N1(1 (c) insertion. 
Metal—based pharmaceuticals can he arranged into seven categories depending on the 
t1inction cat'the metal and ligand moieties according to Ilamhlev et al [491: I) the metal 
complex is active in its inert form, 1I) the metal complex is active in its reactive form. III) 
the metal serves as a radiation enhancer. IV) the compound contains a radioactive metal. 
V) the metal or its biotransformation product is active, VI) ligand is biologically active. 
and VII only a fragment of the complex is active. Investigations in this area were 
primaril focused on the use of biologically active complexes firmed by essential metal 
ions, such as copper and zinc. Since, any essential metal ion which escapes its normal 
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metabolic pathway can be very toxic to organism; complexes of such metals can serve as 
effective cytotoxic agents. 
Copper is widely distributed in the biological system and it is the most familiar redox 
metal serving diverse biological functions [50-55]. Copper can be regarded as a "modern 
bio—element" as suggested by Kaim [56], Ochiai [57] and Williams [58]. It has been 
demonstrated that copper accumulates in tumors due to selective permeability of the 
cancer cell membranes [59-62]. Because of this, a number of copper complexes have 
been screened for anticancer activity and some of them were found active both in vitro 
and in vivo [63-66]. Copper(II) complexes are regarded as the most promising 
alternatives to cisplatin as anticancer drugs. Serum copper levels correlate with tumor 
incidence, tumor weight, malignant progression, and recurrence in a variety of human 
cancers: Hodgkin's lymphoma, sarcoma, leukemia, and cancer of the cervix, breast, liver, 
and lung [67-70] as well as brain tumors [71, 72]. Consistently, the high serum and tissue 
levels of copper, found in many types of human cancers, support the idea that copper 
could be used as a potential tumor—specific target. 
Copper binds to DNA with high affinity than any other divalent cation, thus promoting 
DNA oxidation [73]. The binding of copper ions to specific sites can modify the 
conformational structures of proteins, polynucleotides or DNA and bio—membranes [74]. 
This binding is dependent on size, charge, electron affinity and geometry of the formed 
adduct. The properties of copper—coordinated compounds, whether in classical inorganic 
coordination complexes, in organometallic compounds, or in bioinorganic model 
compounds are largely determined by the nature of ligands and donor atoms bound to the 
metal ion [75, 76]. Three oxidation states of the metal can be stabilized: Cu(Ill), Cu(II) 
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and Cu(I). However, copper is dominated by Cu(11) oxidation state with d9 electronic 
configuration which promotes d—d transitions resulting in intense colored species while 
Cu(I) complexes due to the closed—shell d1° electronic configuration are usually colorless 
solids and strongly prefer ligands having soft donor atoms. Copper complexes are a class 
of the most frequently studied metallonucleases due to their biologically accessible redox 
states. 
Zinc is second most abundant essential transition metal ion in human following Fe, 
divalent zinc is an integral part of all biological systems. Zn ions possess nutritional 
features important to human health and health care. Zinc plays important role in genetic 
stability and function [77, 78]. Mechanistically, zinc has significant impact on DNA as a 
component of chromatin structure, DNA replication and transcription and DNA repair 
[79]. Zinc enzymes efficiently catalyse the hydrolysis of nucleic acid under physiological 
condition in the living system. Many proteins possess a Zn-containing motif that serves 
to bind the DNA embedded in their structure. Structural changes induced by zinc(II) on 
DNA suggest that this cation can bind to both the nucleobase and the phosphate group 
[80]. Zinc is vital for recovery of leukemic cells because Zn is required for proper 
functioning of genetics, immunity, formation of red blood cells, organ, muscle and bone 
function, cell membrane stability, cell growth, division, differentiation and genetics [81]. 
Zinc has beneficial interactions with several chemotherapy drugs. Zinc(II) complexes of 
p—isopropyl benzaldehyde and methyl 2—pyridyl ketone thiosemicarbazones show potent 
cytotoxic activity and induction of apoptosis in cells resistant to cisplatin [82]. 
A series of copper—based drugs registered with the name of Casiopeinas® (Cas) has been 
developed by Ruiz—Azuara et al [83]. These compounds are mixed chelate copper(II) 
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complexes with a general condensed formula [Cu(N—N)(A—A)][NO3], where N—N 
represents neutral diimine donors, either phen or bipy, A—A stands for uninegative N-0 
or 0-0 donors, either aminoacidates or acetylacetonate. 
NO3  
Figure 4. Structure ofCasiopeina Ill—ia. 
Cas were designed as a chemotherapeutic alternative for cancer treatment and, according 
to some preliminary experiments, some of them have indeed shown antineoplastic 
activity both in vitro and in vivo and were able to induce apoptosis in murine cancer cell 
lines, such as L1210 and CHI [84]. Experiments in rats employing one of the most 
promising derivatives (Figure 4), showed a strong inhibition of cell proliferation against 
C6 glioma cells. It was observed that the drug promoted an increment in ROS which in 
turn caused subsequent damage to mitochondria followed by apoptosis elicited through 
both, caspase-dependent and caspase—independent pathways [85]. 
The chemical, biological and pharmaceutical properties of tin(IV) and diorganotin(IV) 
complexes have been studied extensively [86. 87]. In the search for better 
chemotherapeutic drug alternatives, organotin(IV) dithiocarboxylates received utmost 
attention on account of their potential apoptotic inducing character [88]. Since 1980, 
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United states national cancer institute (NCI) has tested over one thousand tin compounds, 
and 170 of these were found to be active [89]. 
The binding ability of organotin compound towards DNA depends on the coordination 
number, nature of the groups bonded to the central tin atom [90]. The phosphate group of 
DNA sugar back bone usually acts as an anchoring site. 
Sn 
send 
s era 
Figure 5. Irreversible binding to the peripheral phosphate groups of phosphoribose 
residues by Sn(IV). 
Nitrogen of DNA base binding is extremely effective, stabilizing the tin centre as an 
octahedral stable species. However, researches indicate that there is negligible interaction 
of tin complexes with nucleotide bases, but rather strong and irreversible binding to the 
vicinal phosphate groups of phosphoribose residues (Figure 5) [91]. The presence of 
cyclic groups (aromatic or heterocyclic) in the tin—containing molecules was found to be 
important for anticancer activity [92, 93]. The structure—antitumor relationship of 
diorganotin(IV) derivatives has been well documented in literature [94]. 
Recentl%. a novel organotin complex I—;(2—hvdroxvethvl)amino}-2—amino-1,2— 
dideox%—D—glucose triphen%ltin(IV) (GATPT) (Figure 6), a sugar based apoptosis 
inducer was synthesized by our research group I1• (iA l'P I• was tested for its cvtotoxic 
properties against SYSY. PC-12 and N2A neuronal tumor cell lines, GATPT induced 
significant apoptosis in the PC-12 cell line which was characterized by DNA 
fragmentation and chromosome condensation. 
(a) (d) 
Figure 6. Molecular .structure of ('.l I'T (hi aloleeular docked model with 6'HI?, (c•i 
Detailed hydrogen hortcls between VHR and (IAJTT (d The Ll(;l'L01' showing 
ltvcb•ogen honcic, and spiked resiclues_form hydrophobic conracts with GATPT 
I"reatment of PC-12 cells v' ith GATPT resulted in a dramatic up—regulation of Bax and 
Bak and down—regulation of the anti—apoptotic factor Bcl-2. Apoptotic induction by 
(;AlPi was shown to he mediated in a p53—dependent manner and loss of p53 impaired 
the release of eytochrome c from mitochondria to cytosol. Caspase-3 was t(xmd to he 
indispensable for the GATPT triggered apoptosis signaling pathway. Furthermore, in vivo 
studies using a nude mice model revealed that GATPT exhibits significant 
antiproliferativc activit, against tumor development with minimal cytotoxicity. 
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A novel class of heterobimetallic compound tri—phenyl tin benzimidazole thiol—copper 
chloride (TPT—CuCl2) was reported by Hod et al [96]. The effect of TPT—CuCI> on the 
regulation of apoptosis in HeLa cells, MCF-7 human cervial cancer cell in vitro and in 
vivo on Wistar rat model was evaluated which demonstrated significant anti proliferative 
activity against tumor development with minimal cytotoxicity toward normal 
physiological function of experimental rats. Treating confluent HeLa cells with the —TPT 
and chemotherapeutic drugs cisplatin alone, separately for different time intervals 
resulted in a significant differences in cell viability by MU assay showing that —TPT is a 
stronger inducer of apoptosis than cisplatin. The TPT moiety can efficiently kill tumor 
cells at a very low dose (2 pg/mL) thus minimizing the toxic side effect in contrast to 
high dosage of cisplatin (16 tg/mL) [97]. Combining —TPT with —CuC12 yields more 
efficacious drug regime due to their preferential selectivty at the DNA helix (—TPT 
prefers vicinal phosphate oxygen atoms of phosphate sugar backbone, while —CuC12 
component coordinates to N7 atom of guanine). 
Understanding the concept of combining the metal centres with preferential selectivity 
towards DNA with a new critical feature of chirality was examined in trinuclear 
aminoacid derived complexes Cu—Sn2/Cu—Zr2 by our group [98] (Figure 7). Introduction 
of L—aminoacid additionally enahances / modulates the pharmacological behaviour of the 
metal complexes by adopting specific conformation and target selective binding affinity 
with DNA. The interaction with DNA was carried out in tris buffer by electronic 
absorption titration, luminiscence titration, cyclic voltammetry, circular dichroism and 
4- 
viscometric measurements. The emission quenching of these complexes by (Fe(CN)61 
depressed greatly when bound to DNA. Observed changes in the circular dichoric spectra 
1 	 2 
1 M=OyYA V SbM 
2M-CMII1 -LnM 
)M°ZMHAM°SaOVI 
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of DNA in presence of Cu—Sn2/Cu—Zr2 supported the strong binding of complexes with 
DNA. The relative specific viscosity of DNA bound to Cu—Sn2/Cu—Zr2 decreased, 
indicating that the complexes bind to DNA via covalent binding. To evaluate the 
mechanistic pathway of DNA inhibition, counting experiments and MTT assay was 
employed to assess the induction of apoptosis by Cu—Sn2. 
Figure 7. Chemical structures of heteronuclear Sn(IT7/Zr(IT'7 modulated Cu(II)/Zn(II) 
trinuclear complexes. 
Western blot analysis of whole cell lysates and mitochondrial fractions with Bcl-2 and p-
53 family proteins and caspase-3 colorimetry assay was also carried out on a human 
neuroblastoma cell line SY5Y. Cu—Sn2 complex exhibited selective antitumor activity 
and further studies pertaining to this complex are currently underway. 
The design of heterobimetallic trinuclear architecture utilizes a unique building block 
strategy which involve combination of both the active metal centres exhibiting 
differential behaviour towards the cellular target site on DNA [99-104]. Such complexes 
have been prepared considering the intrinsic DNA—interaction characteristic of the two 
separate active metallic centres. For example, heterodinuclear bifunctional molecules 
containing copper and platinum active metal centres were designed as combination 
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agents, due to their preferential reactivity at site of interaction namely, the nitrogen atom 
N7 of guanine in the major groove for the paltinum component while the minor groove is 
preferred for copper unit [ 105, 106] (Figure 8). The minimum separating distance 
required to achive such concomitant minor and major interaction was determined from 
crystal strucutre of DNA-cispaltin adduct [ 107]. 
LOA 	e.8 A 
Oxidative — — C 	 CooreNnatlon 
DNA \ 	 —~ binding 
aq+ 	N Cu N 	.N 	 N 	to guanlnea from the ~ Pt M the 
minor / ' 	I 	 G C1 	motor groove 
groOYe 	— 	— C 2.6 A of DNA 
Minor groove Cu 	"rye \` Pt Major groove 
DNA chain 	DNA chain 
Figure 8. Strategy adopted for the synthesis of heterodinuclear minor / major groove 
interacting complexes. 
Heterobimetallic complexes exhibit cleavage activities and were able to perform direct 
double strand cuts in contrast to monometallic Cu(3-clip-Phen) alone which was capable 
of carrying out successive single strand cuts (Figure 9). 
Form II 
Form III 
Form I 
Figure 9. Comparison of the oxidative cleavage of OX174 plasmid DNA performed by 
C35H37C14CuN7O2Pt, C39H43C14CuN7QPt, and Cu(3-Clip-Pheny in the presence of 5 mM 
MPA. Lane 1: control DNA. Lane 2: 250 nM C'35H37C'14C'uN7O1Pt without MPA. Lane 3-
5: 100-250 nM C35H37C14CuN7O2Pt. Lane 6: 250 nM C39H45Cl4CuN702Pt without MPA. 
Lane 7-9: 100-250 nM C39H45Cl4CuN7O2Pt. Lane 10: 250 nM Cu(3-Clip-Phen) without 
MPA. Lane 11-13: 100-250 nMCu(3-Clip-Phen). 
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The DNA binding of compounds such as BBR 3464 (Figure 10) was covalent, but a 
significant noncovalent component was observed by the presence of the central platinum 
(tetramine) unit which interacted with DNA only through electrostatic and hydrogen—
bonding effects [108}. The highly charged compound induce BSA and B—~Z 
conformational changes in canonical sequences of DNA. 
BBR3464 
Figure 10. Structure of BBR 3464. 
Noncovalent concept was extended in this complex by use of dangling amines which 
increase the charge and charge dispersion along these linear cations, surprisingly resulted 
in significantly enhanced cellular accumulation. However, the complex with higher 
charge (C) exhibited about 5 times greater cellular uptake than the parent BBR 3464 (4') 
[ 1091. As a consequence of this accumulation, enhanced cytotoxity was observed across a 
panel of ovarian tumor cell lines despite the reversible nature of DNA binding. 
With the objective of lowering the systemic toxicity of metal—based drugs, successful 
modular synthesis of heterotrinuclear complexes has been carried out that combines the 
class of compounds with paltinum(ll) centre, resembling cisplatin and two ruthenium(ll1) 
centres that resemble NAMI by bridging dinitrogen ligands [I 10.  Such design has been 
done to achieve both efficacy and selectivity of the drugs and studies pertaining to these 
complexes have demonstrated that these complexes are potent against both neoplastic 
tumors and metastatic cancer. 
complex I Complex 2 
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More recently, copper—based heteronuclear complexes were explored for displaying some 
intriguing nuclease properties [Ill]. The combination of a site—specific group and a 
scission moiety could enhance the regional selectivity and cleavage efficacy of such an 
artificial nuclease model. A number of natural nucleases require multinuclear metal 
centers to achieve a synergisitic effect in the process of substrate recognition and scission 
[112]. Guo et al have demonstrated the synergestic DNA cleavage effect in 
multicopper(II) centres [113-115]. Two monometallic copper(II) complexes 
CzsH24Cl2CuN4O, C25H24C12CuN4O and heteronuclear complexes C27H30CI4CuN4O2PtS, 
C27H0CI4CuN402PtS. were synthesized using bifunctional ligands [116] (Figure 11). 
Figure 11. Chemical structures of complexes C25H24C12CuN4O (1), C25H24Cl2CuN4O (2), 
C27H30Cl4CuN402PrS (3), C27H30C14CuN9D,PxS (4). 
The DNA bindng ability of these complexes follows an order of C25H24Cl2CuN4O < 
C25H24C12CuN4O < C27H30CDCuN4O2PtS < C27H30CI4CuN,O2PtS. as revealed by results 
of spectroscopic and agarose gel electrophoretic studies. The introduction of Pt(II) centre 
to the Cu(11) complexes induced a significant enhancement in DNA binding and cleaving 
ability, underlining the importance of heterobimetallic complexes in contrast to 
monometallic complexes in drug design regimes. 
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Recent advances in ligand design have resulted in potent antitumor compounds that are 
active in cisplatin resistant cell lines, and also include additional features to allow for an 
increased understanding of the mechanism of action of drug. Ligands can modify the 
reactivity, lipophilicity, oral/systematic bioavailability of metal ions, stabilization of 
oxidation state, substitutional inertness depending on the requirements for chemotherapy 
[117, 118]. They ensure protection of tissues from toxic metal ion or in a contrasting 
strategy, enhance cellular uptake of pharmacological beneficial metal ion [119]. It has 
been well documented in literature that carrier amine ligands of cisplatin analogues 
appear to modulate the antitumor properties of this class of drug [120, 121]. The 
antitumor activity is usually lost or diminished if the primary or secondary amines on 
platinum are replaced by tertiary amines [122]. In addition, the carrier ligands may also 
affect bio—distribution and recognition of DNA adducts by repair enzymes, regulatory 
and DNA binding proteins. 
Recently, Kellett and coworkers have synthesized two square—planar copper(II) 
complexes, [Cu(ph)(1,10—phen)].2H20 (1) (ph = o— phthalate) and [Cu(ph)(2,2'— 
bipy)].2H20 (2) (Figure 12) and investigated their in vitro DNA—binding profile, 
supercoiled plasmid pUC18 DNA cleavage in the presence of exogenous reductant, 
superoxide dismutase (SOD) and catalase (CAT), in addition to anticancer activity 
against human—derived breast (MCF-7), prostate (DU145), colon (HT29), and 
intrinsically cisplatin—resistant ovarian (SK—OV-3) cancer cells. Furthermore, the ability 
of complexes [Cu(ph)(1,10—phen)].2H20 (ph = o—phthalate) and [Cu(ph)(2,2'— 
bipy)].2H20 to induce cellular dsDNA breaks within SK—OV-3 cancer cells was 
■ 
Scission 
DNA 
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presented using immuno detection of y-H?AX ti ci by contbcal microscopy and flow 
cyrtometry [ I23]. 
Figure 12. .%/oiecalar vIructure.5 of (('yelp{►lll.l(1 hlrert)J. 11:O (1) (ph - u /){rthalate) 
crrrcl /(. mPh'l_',?' hipvi/.2ll,O (21 
1.10-phenanthroline (!'hen) is well-known chelating bidentate ligand for transition metal 
ions 	hich played an important role in man\ fields such as coordination chemistr\. 
Metal complexes with phen based ligand have gained much importance in molecular 
recognition of DNA [ 124-126]. 
02 	 OH*  
02 	H 202 
_ n+ 
e- 
Cu(I) 
Figure 13. RU,S generation and I)NJ2 toxicity by 11w ,s ithetic artificial ,nee rllonuelea.se 
f('u(1.1(1 /ilc H).J' 
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The copper(II) salts and 1,10—Phenanthroline form stable bis—phen complexes 
[Cu(Phen)2]2+ which showed nuclease activity in presence of both exogenous reductant 
(red; e.g., L—ascorbic acid) and molecular oxygen (e.g., 02 or H202) and result from a 
cascade of redox reactions that ultimately lead to the formation of hydroxo and metal-
oxo (iv) radical species, which initiate DNA toxicity (Figure 13) [127-130]. Zhuo et al 
have reported that [Cu(phen)2] induced G1—phase specific apoptosis in liver carcinoma 
Bel-7402 cell line [131]. More recently, Cal et all [132] demonstrated that apoptosis 
pathway in Bel-7402 cells treated with [Cu(phen)2J might be initiated by the excessive 
copper in cells transported by the lipophilic phen ligand. 
Carbohydrates have a wide spread occurrence in nature and in dispensable compounds 
for living organisms [1331. They are involved in various processes, such as storage, 
transport and transmission of genetic information, enzymatic reaction and regulation of 
the metabolism [134]. Carbohydrates and their derivatives are qualified as potentially 
attractive molecules for drug designing because they either; (1) may be taken up 
electively into tumors due to the high metabolic rate of tumor cells vs normal cells [135], 
11) their nucleoside may be intracellularly converted to the corresponding nucleotides 
hrough phosphorylation by appropriate enzymes, (111) they may potentially be 
ncorporated into tumors DNA, thereby enhancing the cytotoxicity of the compounds 
136]. 
Yano et al described metal complexes for the first time of N--glycoside derived from 
rious carbohydrates and their derivatives with different amines. Their approach was to 
ach a chelating ligand to a carbohydrate, which subsequently binds to the metal center. 
its tactic offers advantage by providing a number of stable and various spectroscopic 
H, 
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techniques and the results suggested that the stereo structures of these sugar complexes 
(Figure 14) could be modified by varying the polyamines and the metal ion used (137- 
142J. 
Application of carbohydrate—based metal complexes is an example of a targeted approach 
exploiting the biochemistry and metabolic functions of diverse sugar in living organisms 
for transport and accumulation. 
Figure 14. Structure of Nickel (11) complexes containing N—glycoside derived from 
ethylenediamine and (a) D—glucosamine, (b) D-galactosamine 
Advantages of carbohydrate over other ligands are biocompatibility, non—toxicity, 
enantiomeric purity, and water solubility. In recent years, several examples of 
carbohydrate compounds have been developed for diverse medicinal applications ranging 
from antibiotic, antiviral, fungicidal activity and anticancer compounds [143-146]. 
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Figure 15. Structure of Nickel (11) complexes containing N—glycoside derived from 
ethylenediamine and (a) D—glucosamine, (b) D-galactosamine 
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The consequent enzymatic enhancements of tumor cells over many other cell types can 
be exploited by using glucose as a targeting vector for diagnostic or therapeutic 
compounds [ 147] (Figure 15). 
Recently [1481, a different approach to metal—carbohydrate complexes was chosen with 
the aim of forming stable and well defined complexes i.e., attaching a carbohydrate 
moiety via a linker to a specifically designed metal binding domain (Figure. 16). 
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(3) R = a-D-glucopyranosyl, X = Cl 
Figure 16. Structure of nickel (11) bis(sugar) complexes, (h) Peroxo—bridged dinuclear 
cohalt(III) complexes containing N—glycoside 
Heterocyclic ligands and their metal chelates display a wide range of biological activity, 
such as antitumor, antibacterial, antifungal, and antiviral agents [ 149]. The majority of 
pharmaceutical products that mimic natural products with biological activity are 
heterocycles. Therefore, researchers are on a continuous pursuit to design and produce 
better pharmaceuticals, by following natural models. Imidazoline, imidazole and 
benzimidazole rings are important biological building blocks and are present in many 
existing drugs. Most significant is the entry of two octahedral Rule complexes into 
clinical trials for cancer treatment. The first trans—[Him]—[Ru111C14(DMSO)(Im)] (Im = 
imidazole; NAMI—A), is relatively nontoxic to primary cancer cells but exhibits 
iN 
antimetastatic activity, whereas the second, trans—[lln][Ru 1Cla(Ind)z] (Ind = indazole), 
appears to be active against primary tumors (Figure 17) f 150-152]. 
H® 
N 
HN/  
Figure 17. Representative ruthenium complexes with monodentate ligands tested as 
anticancer drugs 
The condensation of primary amines with carbonyl compounds was first reported by 
Schiff and since then condensation products are referred to as Schiff bases [ 153]. Several 
Schiff base complexes were found to inhibit tumor growth [154]. Schiff base are 
considered as `privileged ligands' as they bind with different metal ion in various 
oxidation states [155] and can be considered one of the fundamental goals in medicinal 
chemistry. 
Natarajan et al has synthesized sulfur bridged binuclear copper(l1) complex derived from 
Schiff—base ligand; 2—oxo-1,2—dihydroquinoline-3—carbaldehyde 4(N,N)—dimethyl 
thiosemicarbazone (HL) (Figure 18), and their interaction studies with calf thymus DNA 
(CT DNA) were studied by using absorption and emission spectral studies [156]. 
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Figure 18. Schematic diagrams of ligand 2--oxo-1,2-dihydroquinoline-3-carhaldehyde 
4(N,N)-dimethylthiosemicarhazone (HL) and its copper(II) complex. 
Drug delivery in oncology is of particular interest owing to the narrow therapeutic 
window of anti-neoplastic agents. In the past, numerous research efforts were focused on 
conjugating anticancer drugs with a diverse spectrum of low- and high-molecular-
weight carriers which include sugars, growth factors, vitamins, peptides, antibodies, 
polysaccharides, lectins, serum proteins, and synthetic polymers. In most prodrug 
systems, the drug is bound to the carrier through a spacer that incorporates a pre-
determined breaking point that allows the bound drug to be released at the cellular target 
site. Designing truly tumor-specific carriers remains a challenge in modern drug 
development. In this regard. confocal laser scanning microscopy (CLSM) is among the 
most widely used approaches for the high-resolution, noninvasive imaging of proteins or 
nucleic acids in living cells [157]. Recently, Linjuan Huang reported a one-pot strategy 
for the fluorescent labeling of saccharides with fluorescein-5-thiosemicarbazide (FTSC), 
which introduces the thiosemicarbazide group of FTSC to the aldehyde group at the 
reducing end of saccharides to form stable amino derivatives via reductive amination 
(Figure 19), and evaluated the adaptation of the products to living cells. 
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Figure 19. Labeling reaction of reducing sac•charic/es with FTS(.' and its application n, 
lirini c dll.x. 
The results of Iluorescent labeling procedure have led to the development of a convenient 
and efficient method to prepare fluorescent polysaccharide tags and its utilization for 
imaging target molecules transported in living cells, consequently imaging by conlocal 
microscopy the polysaccharide—FTSC derivatives transported into living IlepG2 cells 
(Fizure 20) [ 158]. 
Figure 20. Imaging o f polw(I('Cbalide .•L'1G 1"[JC clerivativc.r transported in living 
Hap(i2 cells by confocal miar(.cecpv. 
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K. K. -W. Lo et al have designed and synthesized three luminescent rhenium(I) 
polypyridine complexes appended with an a-D-Glucose [Re(N^N)(CO)3(py-3- 
glu)](PF6) (py-3-glu = 3- (N-(6-(N'- (4-(a-D glucopyranosyl)phenyl)thioureidyl)hex- 
yl)thioureidyl)pyridine, N^N = 1,10-phenanthroline (phen) (1), 3,4,7,8-tetramethyl- 
1,10-phenanthroline (Me4-phen) (2), 4,7--Biphenyl-1,I0-phenanthroline (Ph2-phen) (3)) 
and their glucose-free counterparts [Re(N^N)(CO)3(py-3-Et)]-(CF3SO3) (py-3-Et=3- 
(ethylthioureidyl)pyridine, N^N = phen (la), Me4-phen (2a), Ph -phen (3a)) to 
understand the incorporation of a glucose unit towards over-expression of glucose 
transporters (Figure 21). Furthermore, intracellular localization of complex 
[Re(WN)(CO)3(PY-3-glu)](PF6) 	(py-3-glu 	=  
glucopyranosyl)phenyl)thioureidyl)hex-yl)thioureidyl)pyridine, N^N = 4,7-diphenyl-
1,10-phenanthroline (Phrphen) upon internalization by HeLa cells was analyzed by 
laser-scanning confocal microscopy. The complex was diffusely distributed in the 
cytoplasm with punctate staining (Figure 22) [ 159]. 
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Figure 21. Structures of the rhenium(1) polypyridine complexes 
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Figure 22. Laser scar►nin' confucul n►icrc,scupt image of HeLa cells upon incubation 
with cnmhlcx /Rel.1'^Xjl('Oh(pi $ gI►rl/(PFD) (/ OO,uM) in cr glucose—free medium at 37 
('for 5 min. 
I he nucleus gave much eaker or no emission, indicative of negligible nuclear uptake. In 
addition to the perinuclear region, the rhenium(l) polypyridine glucose complex was 
concentrated in specific compartments of the cells, which appeared to be the 
mitochondria. I he fluorescence staining pattern showed that the mitochondria of a typical 
Hel.a cell have been co—stained by the fluorescent dye and the rhenium(l) complex 
(Figure 
Figure 23. Laser—scanning o,nfocal rnic•roscc,1rl' Images of a Ilc•La cell upon incubation 
successive/v with ;L1tttgirurke'r 1)eel, Red FM (100 nm, 20 ruin, i.,.i = 633 nm) and 
complex [Re ( AN)(CO)-?(py-3 glu)](PFol (100 pM, 5 min, i.e , — 405 nm) in ci gluc•ose-
.Jrce methum at 37 C('. 
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The intracellular localization of the rhenium(I) polypyridine glucose complex was 
different to that of its glucose—free complex, which did not show granular appearance, 
but a diffused staining of the whole cytoplasm [ 160J. 
DNA and enzymes involved in replication and transcription represent the most targeted 
bioreceptors for small molecules and a target for the control of gene expression. Most 
anticancer drug binds to DNA and proteins either in a reversible or irreversible manner 
suggesting a direct relationship between their interactions with macromolecules, hence, 
leading to their therapeutic effect. Numerous reports in literature are available for the 
binding studies using various biophysical techniques. 
H. —L. Huang et al [ 161 ] has carried out DNA binding studies of two ruthenium(I1) 
complexes [Ru(bpy)2(APIP)](Cl04)2 and [Ru(bpy)2(HAPIP)](C104)2 where bpy = 2,2'— 
bipyridine, APIP = 2—(2—aminophenyl)imidazo[4,5—f][1,10]phenanthroline) and HAPIP 
= 2-(2—hydroxyl-5—aminophenyl)`imidazo[4,5—fJ[1,10]phenanthroline (Figure 24) by 
employing absorption spectroscopy, fluorescence spectroscopy, viscosity measurements, 
DNA melting experiments and gel mobility shift assays. 
C 
1 	 2 
Figure 24. Structure of the ruthenium(II) complexes. 
Monitoring the effect of adding increasing amounts of DNA on the absorption spectrum 
of a metal complex is one of the most widely used methods for determining overall 
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binding constants. In general, hypochromism and red shifts are associated with the 
binding of the complex to the helix because of the interaction between the aromatic 
chromophore of the complex and the base pairs of the DNA through intercalation. The 
magnitude of the hypochromism and red shifts depend on the strength of the interaction 
between the DNA and the complex [162]. For metallo—intercalators, DNA—binding is 
associated with hypochromism and a red shift in the MLCT and ligand bands [163]. The 
absorption spectra of [Ru(bpy)2(APIP)](CI04)2 and [Ru(bpy)2(HAPIP)](CI04)2 in the 
absence and presence of CT DNA (at a constant concentration of complexes, [Ru]= 20 
pM) (Figure 25). Upon increasing concentration of DNA, both complexes exhibit 
hypochromism, along with a modest bathochromic shift. These spectral characteristics 
may suggest a mode of binding that involves a stacking interaction between the aromatic 
chromophore and the DNA base pairs. 
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Figure 25. Absorption spectra of (a) [Ru(bpy)2(AP1P))(C104)2 and (b) 
[Ru(bpy)2(HA PIP)] (C104)2 in the presence of an increasing amount of CT DNA. [Ru] 
20 pM Inset: (ea  r j) /(eb--CJ) vs. [DNA], and the nonlinear fit curve. 
The intrinsic binding constants "Kb" derived for [Ru(bpy)2(APIP)](CI04)2 and 
[Ru(bpy)2(HAPlP)j(CI0e)2 complexes were 6.08 (±0.29) x 104 and 1.78 (±0.29) x 105 
M-', respectively. 
29 
The luminescence titration experiments were carried out in Tris— HCI buffer at ambient 
temperature with a maximum appearing at 599 and 600 nm. Upon addition of CT DNA, 
the emission intensities of complexes [Ru(bpy)2(APIP)](CI04)2 and 
[Ru(bpy)2(IIAPIP)](C104)2 increase about 1.63 and 1.88 times larger than the original 
and saturate at a ratio of [DNA]/[Ru] = 15.4 and 14.6, respectively. This implies that both 
complexes exhibited strong interaction with DNA, since the hydrophobic environment 
inside the DNA helix reduces the accessibility of water molecules to the complex and the 
complex mobility is restricted at the binding site, leading to decrease of the vibrational 
modes of relaxation (Figure 26). 
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Figure 26. Luminescence spectra of complexes [Ru(bpy)2(AP1P)](ClO4)2 and 
[Ru(bpv)2(NAP1P)J(C/na)1 in Tris—HC1 buffer upon addition of CT DNA. [Ru/ = 5 pM. 
To further explore the interaction with DNA, the specific relative viscosities of the DNA 
were measured by adding increasing concentrations of complexes 
[Ru(bpy)2(APIP)}(CIO4)2 and [Ru(bpy)2(HAPIP)](CIO4r and the known DNA 
intercalator ethidium bromide (EB) for a comparison purpose. The viscosity of CT—DNA 
increases upon successive addition of both complexes, close to the proven DNA 
intercalators EB and previously reported mononuclear complexes [164]. 
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There has been considerable interest in DNA endonucleolytic cleavage reactions that are 
activated by metal complexes thus, DNA mobility shift assay were carried out to 
investigate the ability of complexes to interact with plasmid DNA. Change in the 
electrophoretic mobility of plasmid DNA on agarose gel is commonly taken as evidence 
for direct DNA—metal interactions. When a circular plasmid DNA is subjected to agarose 
gel electrophoresis, the fastest migration will be observed for supercoiled form (Form 1). 
If one strand is cleaved, the supercoils will relax to produce a slower moving open 
circular form (Form 1I). If both strands cleaved, a linear form (Form III) will be generated 
that migrates in between. One of the illustrative examples of concentration dependent 
pBR322 DNA cleavage of novel binuclear copper(II) complex [Cu2L(p—SO4)](PF6)2 (L = 
3,5—bis 	(bis(pyridine-2—ylmethyl )am i—no)methyl)-4H-1,2,4—triazol-4—amme) 	was 
reported by Yan et al [1 65],in  which the enhancement of DNA cleavage activity was 
observed due to variation of complex concentration, Form I plasmid DNA was gradually 
converted into Form 1I (lanes 2-5). When the concentration of complex! added to 0.75 
mM, the Form I completely disappeared and Form Ill remained up to 20% (Figure 27). 
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Figure 27. Gel electrophoresis diagrams showing the cleavage of pBR322 DNA 
(0.lpg/pL) at different complex concentrations in Tris—HCUNaCI huffier (pH = 7.2) at 37 
Cfor 3 h. Lane l: DNA control (3 h): lane 2-5: DNA + [Cu2L(D,S'O4,J('PN&2 (0.15, 
0.35. 0.5, 0. 75 mM). respectively. 
In order to obtain information about the active oxygen species which was responsible for 
the DNA damage, the DNA cleavage in the presence of hydroxyl radical scavengers 
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(DMSO). singlet oxygen quenchers (L-histidine), superoxide scavengcr (SOD). 
hydrogen peroxide scavenger (catalase) and chelating agent (EDTA) was performed. The 
results revealed that, no inhibitions was observed in the presence of DMSO (Figure 28, 
lane 3), L-histidine (lane 4) and catalase (Figure 28, lane 1 I ), ruling out the possibility of 
DNA cleavage by hydroxyl radical, singlet oxygen and hydrogen peroxide. The SOD 
enzyme showed little influence on the DNA cleavage suggesting that the superoxide 
anion was hardly involved in the process. The EDTA, a Cu(11)-specific chelating agent, 
could efficiently inhibit DNA cleavage, indicating Cu(ll) complexes play the key role in 
the cleavage. The addition of SYBR Green, which is known to interact to DNA at minor 
groove, effectively inhibited DNA cleavage, indicating that the complex [Cu2L(4- 
SO4 )](PF6)2 mainly interact through DNA small groove. 
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Figure 28. Agarose gel showing cleavage of pBR322 DNA (0.1µg/lL) incubated with 
[C'u;L(Y-SO4)1(PF6 ):  (0.75 mM) in Tris-HCl/NaCI buffer (pH = 7.2) at 37 ('for 3 h. 
Lane 1: DNA control: lane 2: DNA +[Cu,L(p-SO4)J(PF,)2; lane 3: DNA +[Cu2L(lr-
SO4)J(PF6); + 20 mM DMSO; lane 4: DNA +[C'ziiL(1tSO4)](PFo )2 +20 mM L-histidine; 
lane 5. DNA +[('u2L(p-SO4 )J(PF&2 + 20 U/mL SOD; lane 6: DNA +[Cu2L(u-
SO4 )](PF6) + 5 mil EDT4 lane 7: DNA control: lane 8: DNA +[('uhL(,u—S)4)J(PF6) : 
lane 9. DNA +[('u2L(p-SO4)J(P1.6)2 + 1 mM methyl green; lane 10: DNA +[('u2L(,u-
SO4J(PF6)2 + 10 U/mL SYBR Green; lane 11: DNA +[Cu2L(p-SOd)](PF&2 + 20 U/mL 
catalase. 
Molecular modeling allows the rapid screening of a large library of compounds against a 
nucleic acid target, in order to identify candidate compounds with favorable binding 
interactions which can be further enhanced through structure-based modification and 
development. G. Bifulco et al [166] have designed and synthesized a series of 
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bisnaphthalimide derivatives as hisintercalating agents. In OTdeT to -ain nevc dtlailed 
molecular insights in their DNA binding events, a molecular modeling study has been 
carried out for complexes 1---6 (Figure. 29). the analysis of docking results reveals that 
all ligands share a similar binding mode. The linker of two naphthalimides also plays a 
crucial role in the affinity to nucleic acids, contributing to the complex stability 
interacting with the minor groove of the f)NA. 
Figure 29. 31) models showing inleraclions of his napphthalimide derivaive.s• (1-6) with 
D N1 (a. h, c, J e and!). 
The common planar moieties of the ligands intercalate between base pairs establishing it-
1t interactions with f)NA aromatic rings, with nitro groups extending these intermolecular 
interactions or forming hydrogen bonds with nucleotides. 
Most of the drugs exert their cytotoxic effect and thereby therapeutic effect by direct 
interaction ,pith DNA or by inhibition of topoisomerases (preventing DNA relaxation). 
Thus. ncNN light has been shed on the discos cry of metal—based drugs that inhibit 
enzymatic activities or even target protein directly. There are many reviews which 
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highlight some exciting results published recently on the development of metal as 
enzyme inhibitors for potential therapeutic applications [167]. DNA topoisomerases are 
crucial nuclear enzymes that control the topological state of DNA during replication, 
transcription, recombination and chromosome segregation at mitosis. There are two types 
of DNA topoisomerases: type—I enzymes change the DNA linking number by transiently 
breaking one strand of duplex DNA, and type—Il enzymes transiently break both strands 
[168]. Many studies have shown that topoisomerases targeting agents are considered as 
attractive target for design of cancer chemotherapeutic, because they can cause 
permanent DNA damage that triggers a series of cellular events, inducing apoptosis and 
finally causing cell death [ 169]. To determine whether the complexes interfere with the 
DNA relaxation reaction by inhibiting Topoisomerase inhibition catalysis or by altering 
the apparent topological state of DNA, the DNA strand passage assay was performed. 
(a) (b) 
Figure 30. An ORTEP drawing of (a) [Ru(hpy)2(bfip)J 2+and (b) [Ru(bpy)2(bfrp)J 2` 
Chao et al [ 170] have investigated the concentrations dependent Topo I and Topo 11 
inhibitory activity of DNA—intercalating Ru(II) polypyridyl complexes derived from 
[Ru(bpy)2(hfipH)]2+ (1) and [Ru(phen)2(bupH)]2+ (2) 	(bfipH = 2-(benzofuran 
2yl)imidazo[4,5—f], bpy = bipyridyl and phen = 1.10 phenanthroline) (Figure 30) by gel 
electrophoresis. Both complexes inhibited the ability of Topo I to relax negatively 
34 
supercoiled plasmid DNA (1050 is --17 gM for complex [Ru(bpy)2(bfipH))(C104)2 and —8 
µM for complex [Ru(phen)2(bfipH)](C104)2) (Figure 3 1) . 
I (iiM) 
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Figure 31. Effects of different concentrations of complexes [Ru(hpy)2(hfrpH)](CIU4)2 and 
[Ru(phen)2(bfipH)J(ClO.t)2 on the activity of DNA topoisomerase-1(Topo I) activity. 
The effects of the complexes on enzyme-catalyzed DNA strand passage were assessed by 
comparing the rate of relaxation of negatively supercoiled plasmid in the absence of drug 
to the rate of supercoiling of relaxed plasmid in the presence of EB. The rate of Topo—l-
catalyzed DNA supercoiling in the presence of the Ru(II) complexes was lower than the 
rate of EB, which was identical to the rate of Topo 1—catalyzed DNA relaxation in the 
absence of drug (Figure 32). These findings suggested that Ru(bpy)2(bfipH)](C104)2 and 
[Ru(phen)2(bfipH)](C104)2 were catalytic inhibitors of Topo 1. 
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Figure 32. The time dependence of Topo I DNA strand passage assays in the presence of 
ethidium bromide (EB) and complexes [Ru(bpy)2(bfpH)](C104,)2 and 
[Ru(phen)2(hfi pH)] (C104)2. 
The results of concentration—dependent Topo 11 inhibition assay of Ru(bpy)2(bfipH)]2 
and [Ru(phen)2(bfipl-U)]2+ which showed that both Ru(11) complexes inhibited the activity 
of Topo 11 at a low concentration (1050 < 20 p.M) (Figure 33). 
4 	I (iM) 	2 (iM) 
10 15 20 2 5 10 4 0 S 	st 1 	1; 70 
Form II 
Form 
Figure 33. Effects of different concentrations of complexes (Ru(bpy)2(bfipH)J(ClO4)2 and 
[Ru(phen)2(hfipH)J(ClO. on the activity of DNA topoisomerase Ha (Topo 11). 
Similar to that described above for Topo I, DNA strand passage assay was also used to 
distinguish the effects of Ru(lI) complexes on Topo II function from theirs effects on 
DNA topology. The religation rate of the relaxed plasmid in the presence of Ru(II) 
complexes are lower than that of EB. These findings suggest that Ru(bpy)2(bfipH)]2 and 
[Ru(phen)2(bfipH)]2+ are a catalytic inhibitor (or poison) of human Topo 11(Figure 34). 
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Figure 34. The time dependence of' Topo 1/ DNA strand passage assays in the presence of 
ethidium bromide (EB) and complexes Ru(bpy)2(bfipH)J ' and [Ru(phen)2(bfipH)J 2+. 
Merfort et al [171].  have analysed the molecular docking of diterpenes and compared to 
the docking pose of camptothecin with topoisomerase I. 
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Figure 35. tu) The predicted hi►uling Wroth, uJ camploilecin tvit{r Iopoisonera.sc I (PUR: 
17h. di) Dilerlre'ne clocked inside the 1opoisscnercse I—DAA covalent complex. (c) 
Diterpene clocked in the binding, pocket. (di 1)iterpenec preventing the building of the 
tOpr,icun1L'rUce 1—Ii):V1 complex. 
In contrast to camptothecin. the non—planar conformation ol the diterpenes makes 
intercalation difficult within the cleaved site of the DNA, as observed with camptothecin 
(Figure 35a and b). Subsequently, alternative docking modes were evaluated using the 
DNA—unbound form of 'l opc-I. "These results suggest a direct interaction of the 
diterpenes «ith topoisomerase I in a new described binding mode (binding pocket: Gly 
490. Asn, 491. Thr 501, Lys 532, Figure 35c). 
Younhjoo kwon et at have performed the molecular docking studies of l-1-lydroxy-3— 
(2—hydrox.-3—(prop} lam inu)propox )-9H—xanthen-9—one with A I'P—binding domain of 
human tope Ila to examine their mode of action. An analysis of the docked pose to the 
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ATP-binding domain showed that the compound fits into the ATP-binding site (Figure. 
36a-c)11721. 
Figure 	36. 	Molecular 	(locking 	between 	I-Hvtrnxv^i-(2 {ivdrllrtC-i- 
(prc)ptlanhiilo)I)ropoxv)-911-.r(.rrrtltcrr-9--one and ATP-hincling domain of human tupo ha. 
(a) The ATP-hincling domain 101)0 110 is .s/town as Q ribbon (11Qgram. (h) The residues of 
the .-fTP-hin(ling site of tojw 1/a s/m►t•ing van der Waals contacts. (c) The ATP-hincling 
domain is represented Us a molecular surface (gray). 
The position of the xanthone ring overlaps well with that of the purine ring of ATP. The 
xanthone ring has hydrophobic interaction with Asn9I, Asn95, Asn 120, Phe 142, '1hr215, 
and 11e217. The Nil group in the side chain of the xanthone ring forms a hydrogen bond 
with Serl48. In addition, the hydroxyl group from the side chain Ihrms hydrogen bonds 
with Serl49. 'i'he residues involved in the hydrophobic interactions, such as 11e141. 
Phe142 and Ala l 67. were observed. However, the Ser 149 and Asn 150 involved in the 
ydrogen bond interaction were also conserved. The molecular docking study showed 
at I-Hydroxy-3-(2-hydroxy-3--(propylainino)propoxy)--9H-xanthen-9--one formed a 
able binding complex with the ATP-binding domain in topo I la. 
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Present work 
The development of metal—based chemotherapeutic drugs has gained much emphasis 
owing to their superior binding ability and specific recognition to the molecular target 
DNA and enzymes. Metal—based therapeutic agents are "chemical entities" which 
involve inorganic architecture utilizing a combination of two or more metal ions, organic 
scaffold or ligand and sometimes an additional targeting moiety bound to the ligand viz. 
glycosylated appendage for better uptake and specific targeting at the molecular level. 
The ligands can fine tune or modulate the physico—chemical properties of the metal ions; 
I) by increasing the uptake of core metal ions, II) alter biodistribution among body 
tissues, III) target enzymes, biomolecules, or tissues and IV) predispose towards 
reduction of the core metal ions, (inert to active). The ligand framework is therefore a 
decisive factor, to control potency or efficacy of chemical entities particularly for 
cytotoxic agents. 
Heterodinuclear metal complexes have advantages over monometallic complexes, they 
can be explored as design of DNA/RNA specific cleavage agents, and in 
chemotherapeutic specific targeted drug design. The binding of the heterobimetallic 
complexes with DNA increases manifold as compared to monometallic complexes. The 
discriminating synergistic power of essential transition Cu(II), Ni(II), Zn(II) and non—
transition metal ions, Sn(IV) has been utilized in the synthetic strategy for the 
construction of heterobimetallic complexes to explore their chemotherapeutic potential 
to act as drug candidates. Previous literature reports reveal that copper has a tendency to 
bind covalently to N7 of guanine nucleobase of DNA double helix while Sn(IV) prefers 
to bind to negatively charged oxygen of phosphate backbone of DNA helix via 
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electrostatic binding mode. In this context, new metal—based entities [C28H26N8CuSn2C16] 
and [C28H2gN8NiSn2Cl6] bearing bioactive pharmacophore 1,10—phenanthroline and 
ethylenediamine as a metal coordinating domain have been developed as antitumor 
agents that show promise to overcome inherent resistance and exhibit fewer side effects. 
These chemical entities bearing Cu(I1)—Sn(IV) heterobimetallic core were thoroughly 
characterized by spectroscopic (IR, UV—vis, NMR, ESI—MS) and analytical methods. 
The interesting chemistry which these complexes display towards DNA disposition is due 
to the presence of two different metal ions, Copper an essential biometal has a 
predisposed tendency to bind covalently to N7 of guanine DNA base while tin atoms— a 
strongly apoptotic director prefers oxygen of phosphate diester linkage of DNA 
phosphate backbone. Tin complexes within a narrow concentration range have exhibited 
remarkable `therapeutic effects' and are strongly cytotoxic agents. The in vitro DNA 
binding studies of [C2$H28N8CuSn2C1e] and [C25H28N8NiSn2CIs] with CT—DNA were 
carried out by employing various biophysical methods which reveal strong electrostatic 
binding via phosphate backbone of DNA helix, in addition to partial intercalation in the 
minor groove and stabilized by intramolecular hydrogen bonding. To gain further insight 
into the molecular recognition at the target site, UV—vis titrations of [C28H28NqCuSn2CI6] 
with 5'—GMP was carried out and validated by 'H and 31 P NMR. Complex 
[C28H28N8CuSn2C16] cleaved pBR322 DNA via oxidative pathway and exhibited high 
inhibition activity against Topo—I at 20 M. Furthermore, the cytotoxicity of 
[C23H29N8CuSn2CI6] was examined on a panel of human tumor cell lines of different 
histological origins showing promising antitumor activity. 
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In an another attempt, carbohydrate—conjugate heterobimetallic complexes 
[C22H46N6013CuSnCl2] and [C22H54N6O17NiSnCl2] derived from N--glycoside ligand 
[C14H23N2010] (L) were synthesized and characterized by various spectroscopic and 
analytical techniques. To validate their potential to act as chemotherapeutics, in vitro 
DNA binding studies of the [C14H28N20,0], [C22H46N6O13CuSnCl2J and 
[CuHMN6OI?NiSnCl2] were studied by various biophysical and molecular docking 
techniques. Complex [CnH4,N6Oi3CuSnCl2] cleaves pBR322 DNA via hydrolytic 
pathway which was authenticated by T4 DNA ligase assay. The complex 
[C221-LN60,3CuSnCl2] exhibited remarkably good anti—tumor activity on a panel of 
human cancer cell lines (G150 values < 10 µg/ml), and to elucidate the mechanism of 
tumor inhibition, topoisomerase I enzymatic activity was carried out. Finally, confocal 
microscopy using HeLa cells revealed intracellular localization of the complex 
[CnH46N6Oi3CuSnC12] which supports our claim that these complexes can be used as 
photo probed for nucleic acid structures. Subsequently, a new modulated series of 
carbohydrate—conjugate monometallic complexes [CnH52N6Oi3Cu], [C22HoN6O 7Ni] 
and heterobimetallic complexes [C22N50N60i3CuSnC12} and [C22H58N60,7NiSnCl2] were 
designed and synthesized from previously synthesized N—glycoside ligand. The proposed 
structure of the complexes was formulated on the basis of elemental analysis, and other 
spectroscopic data including 'H, "C and 19Sn NMR (in case of [C22H6,N6O,7Ni] and 
[C11H5sN60,7NiSnCl2]). In vitro DNA binding studies were carried out employing 
absorbance and fluorescence spectroscopy to examine their DNA binding propensity as 
quantified by Kb and K. values. Cleavage studies were carried out by gel electrophoresis 
which demonstrated that the complex [C22HsoN6O,3CuSnCl2] are specific groove binder 
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and cleave supercoiled pBR322 DNA via hydrolytic pathway, which was further 
confirmed by T4 DNA ligase assay. Complex [C22HS0N6Q13CuSnCl2] inhibited Topo—ii 
mediated relaxation activity in a dose—dependent manner that appeared in accordance 
with remarkably good anti—tumor activity against MIAPACA2, A498 and HCT15 tumor 
cell lines. Finally, complex [C22N50N6O13CuSnC12] was docked into the ATPase domain 
of human—Topo--Il in order to probe the possible mechanism of inhibition. An important 
finding of this work is that these metal—based chemical entities bearing glycosylated 
appendage, show good promise as antiproliferative agents, artificial nuclease —hydrolytic 
cleaving agents and Topo II inhibitors. 
New heterobimetallic complexes [C16HI6N3O2SCuSnCIj and [C,61-Ii6N3O2SZnSnCI] 
derived from Schiff base ligand of salicylaldehyde and 5—amino-2— 
mercaptobenzimidazole were synthesized and thoroughly characterized by spectroscopic 
(IR, UV, NMR and ESI—MS) and analytical techniques. The in vitro DNA binding 
studies were carried out by employing different biophysical and optical methods which 
reveal strong electrostatic binding via phosphate backbone of DNA helix, in addition to 
other binding modes viz, coordinate covalent and partial intercalation. Cleavage studies 
employing gel electrophoresis demonstrate both the complexes are efficient cleaving 
agents and are specific groove binders; binding events were further validated by 
molecular docking studies. [C16HI6N3O2SCuSnCIj complex cleaved pBR322 DNA via 
oxidative mechanism while [C151-I16N3O2SZnSnCE] followed hydrolytic pathway. 
Furthermore, the cytotoxicity of [C16Hj6N3O2SCuSnCI] was examined on a panel of 
human tumor cell lines of different histological origins showing promising antitumor 
activity. 
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1. Materials 
CuCl2.2H20, ZnCl2 (anhydrous) (Rankem), NiCl2.6H2O (BDH), SnCl4.5H20 (Lancaster), 
(CH3)2SnCl2, D-glucose and 1,10-phenanthroline monohydrate (Merck), 
Ethylenediamine (Loba chem), Salicylaldhyde (Alfa Aesar), Piperazine hexahydrate and 
5-Amino-2-mercaptobenzimidazole (Sigma). Tris(hydroxymethyl)aminomethane or 
Tris Buffer, Calf thymus DNA (CT DNA), Guanosine 5'-monophosphate disodium salt 
(5'-GMP) were purchased from Fluka and were stored at -20 °C. 6X loading dye 
(Fermental Life Science), Agarose, Ascorbic acid, Sodium azide (NaN3), DMSO, 
Superoxide dismutase (SOD), Methyl green, DAPI, Mercaptopropionic acid (MPA) 
(Sigma-Aldrich) and Super coiled plasmid DNA pBR322 (Genei) were utilized as 
received. T4 DNA ligase enzyme (Calbiochem) was utilized as received. ATP, Disodium 
salt of calf thymus DNA (highly polymerized stored at 4°C) was purchased from Sigma 
chemical Co. All reagents were of the best commercial grade and were used without 
further purification. 
2. Characterization techniques 
Carbon, hydrogen and nitrogen contents were determined using Carlo Erba Analyzer 
Model 1106. The visualization of spots on TLC plates was effected by exposure to iodine 
or spraying with 10% H2SO4 and charring and single spots of the products were observed 
which were different from those of the starting materials. 
2.1 Infrared spectroscopy 
Infra-red spectra of the ligands and complexes were recorded as KBr pellets on Interspec 
2020 FTIR spectrometer. The formation of the ligands and complexes behavior has been 
ascertained by scanning their infrared spectra in 4000-400 cm-1. 
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2.2 Ultraviolet and visible spectroscopy 
The electronic spectral studies of metal complexes provide useful information about the 
stereochemistry, oxidation state of the metal ion and in suitable circumstances, the nature 
of metal—ligand bond. Electronic spectra were recorded on UV-1700 PharmaSpec UV-
vis spectrophotometer (Shimadzu). Data were reported in 2,max/nm. 
2.3 Nuclear magnetic resonance spectroscopy 
The nuclei of certain isotopes possess a mechanical spin or angular momentum. The 
NMR spectroscopy is concerned with nuclei having nuclear spin quantum number I = 
1/2, example of which include I H, 13C, 31P and "9Sn. 
For a nucleus with I = 112, there are two values for the nuclear spin angular momentum 
quantum number m1 = f1/2 which are degenerate in the absence of a magnetic field. 
However, in the presence of the magnetic field, this degeneracy is destroyed such that the 
positive value of m, corresponds to the lower energy state and negative value to higher 
energy state separated by DE. 
In an NMR experiment, one applies strong homogeneous magnetic field causing the 
nuclei to presses. Radiation of energy comparable to AE is then imposed with radio 
frequency transmitter equal to precision or Larmor frequency and the two are said to be 
in resonance. The energy can be transferred from the source to the sample. The NMR 
signal is obtained when a nucleus is excited from low energy to high energy state. 
The 'H, 13C and 119Sn NMR spectra were obtained on a Bruker DRX-400 spectrometer at 
400 MHz, respectively operating at room temperature. Chemical shifts were reported on 
the 8 scale in parts per million (ppm). 
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2.4 Electron paramagnetic resonance spectroscopy 
Electron paramagnetic resonance (EPR) spectra of the Cu(II) complexes were obtained 
on a Varian E 112 EPR spectrometer using tetracyanoethylene (TCNE) as field marker. 
The spectra were recorded for solid and solutions of the complexes in appropriate 
solvents at room temperature (RT) as well as at liquid nitrogen temperature (LNT), 
2.5 Mass spectroscopy 
Mass spectrometry is one of the most accurate micro analytical techniques which require 
only a few moles of the sample to obtain characteristic information regarding the 
molecular mass and to detect within a molecule the places at which it prefers to fragment 
from which the presence of recognizable group within the molecule can be deduced. 
ESI mass spectra is relatively routine technique for mass spectrometric analysis of 
compounds whether charged or neutral but involves complication by redox, 
fragmentation and clustering processes in the study of metal complexes. ESI mass spectra 
were recorded on a Micromass Quattro II triple quadrupol mass spectrometer. 
2.6 Molar conductance measurements 
The conductivity measurement is one of the simplest and easily available techniques used 
to study the nature of the complexes. It gives direct information regarding whether a 
given compound is ionic or covalent. For this purpose, the measurement of molar 
conductance (A,), which is related to the conductance value in the following manner is 
made. 
cell constant x conductance 	
(1) 
concentration of solute expressed in mo! cm 3 
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(onventionally. solutions of I x 10 ' M strength arc used for the conductance 
measurements. Molar conductances were measured at room temperature on a Digsun 
Electronic conductivit\ [3ridge. 
2.7 X—ray powder diffraction analysis (XRPI) 
To obtain further evidence about the structure of the metal complexes. X—ray diffraction 
studies ere performed on Rieaku Mini Flex II Instrument (Figure, 37). 
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IsiIu'f •ncnWU4 I1 
.•  
Irrermcd Qrtentaw+k) 
• 
• 
1 INmdcr 
J 1r.Klt.tll 
~J 	IrJrnhtat I4mn11.qUs,n.I 
Figure 37. Riguku Mini Flax Ii Instrument and its working principle showing diffraction 
of a er1'.G1aljl)1c' •Sl)1i(! in 3L). 
3. DNA binding studies 
All the experiments involN ing interaction of the complexes 	ith (''F DNA were 
conducted in buffer containing "fris(hydroxymethvl)aminomethane or Tris Buffer (0.01 
M) adjusted to p11 7.2 ith 4M hydrochloric acid. The C'I' DNA as dissolved in Tris 
11(1 buffer and was dialyzed against the same buffer overnight. Solutions of CT DNA 
gave ratios of UV absorbance at 260 and 280 nm above I :I.8, indicating that the DNA 
was sufficiently tree of protein [ 1731. I)NA concentration per nucleotide was determined 
by absorption spectroscopy using the molar absorption coefficient 6600 dm mol ' cm ' at 
260 nrn [ 1741. The stock solution was stored at 4 C. 
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3.1 Absorption spectral studies 
The intrinsic binding constant Kb of the complex to CT DNA was determined from 
equation (1), through a plot of [DNA]/ Ca—ef vs [DNA], where [DNA] represents the 
concentration of DNA, and ea, Cf. and eb the apparent extinction coefficient (Aot /[M]), 
the extinction coefficient for free metal complex (M), and the extinction coefficient for 
the free metal complex (M) in the fully bound form, respectively. In plots of [DNA]/ee  
of vs. [DNA], Kb is given by the ratio of slope to intercept [175]. These absorption 
spectral studies were performed on Shimadzu UV-1700 PharmaSpec UV—vis 
spectrophotometers. 
[DNA] _ [DNA] + 	1 	 (2) 
Ea —E f Eb —EJ Kb(EO — E/) 
Absorption spectral titration experiments were performed by maintaining a constant 
concentration of the complex and varying the nucleic acid/nucleotide concentration. This 
was achieved by diluting an appropriate amount of the metal complex solutions and CT 
DNA/5'—GMP stock solutions while maintaining the total volume constant. This results 
in a series of solutions with varying concentrations of CT DNA/y'—GMP but a constant 
concentration of the complex. The absorbance (A) was recorded after successive 
additions of CT DNA/5'—GMP. While measuring the absorption spectra an equal amount 
of CT DNA/5'—GMP was added to both the compound solution and the reference solution 
to eliminate the absorbance of the CT DNA/5'—GMP itself. 
3.2 Fluorescence spectral studies 
The emission spectrum is obtained by setting the excitation monochromator at the 
maximum excitation wavelength and scanning with emission monochromator. Often an 
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excitation spectrum is first made in order to confirm the identity of the substance and to 
select the optimum excitation wavelength. Further experiments were carried out to gain 
support for the mode of binding of complexes with CT DNA. Non—fluorescent or weakly 
fluorescent compounds can often be reacted with strong fluorophores enabling them to be 
determined quantitatively. On this basis molecular fluorophore EthBr was used which 
emits fluorescence in presence of CT DNA due to its strong intercalation. Quenching of 
the fluorescence of EthBr bound to DNA were measured with increasing amount of metal 
complexes as a second molecule and Stem—Volmer quenching constant K was obtained 
from the following equation 3 [176]. 
Io/I=1+Kr 
where r is the ratio of total concentration of complex to that of DNA and Io and I are the 
fluorescence intensities of EthBr in the absence and presence of complex. 
Binding constant K of the metal complexes was also determined from Scatchard 
equations 4 and 5 by employing emission titration [ 177, 178]: 
CF=Cr(I/Io —P) (I—P) 
	
(4) 
r/CF'=K(7tr) 
	
(5) 
where Cr is the free probe concentration, CT is the total concentration of the probe added, 
I and 10 are fluorescence intensities in presence and absence of CT DNA, respectively and 
P is the ratio of the observed fluorescence quantum yield of the bound probe to that of the 
free probe. The value P was obtained as the intercept by extrapolating from a plot of I/I. 
vs 1/ [DNA], r denotes ratio of CB (Cr-CF) to the DNA concentration i.e., the bound 
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probe concentration to the DNA concentration, K is the binding constant and C, is the 
free metal complex concentration and "n" is the binding site number. Emission intensity 
measurements were carried out using Hitachi F-2500 spectrofluorometer at room 
temperature. 
3.3 Viscometric studies 
The hydrodynamic changes are the consequence of the change in length of the molecule, 
the diminished bending between layers and the diminished length—specific mass. 
Viscosity measurements were carried out using Ostwald's viscometer at 29 ± 0.01 °C. 
Flow time was measured with a digital stopwatch. Each sample was measured three times 
and an average flow time was calculated. Data were presented as (fl/q°) versus binding 
ratio ([M]/[DNA]) [179, 180], where rl is viscosity of DNA in the presence of complex 
and ft° is the viscosity of DNA alone. Viscosity values were calculated from the observed 
flow time of DNA containing solution (t >100s) corrected for the flow time of buffer 
alone (t°), rl = t— t°, 
3.4 Gel electrophoresis 
Gel electrophoresis is a technique widely used for separation and analysis of charged 
biomolecules like nucleic acids [181]. Any charged biomolecule migrates when placed in 
an electric field. The ratio of migration of a molecule depends on its net charge, size, 
shape and the applied current (Figure. 38). This can be represented as follows 
V=E.q/f 
	
(6) 
Where V = velocity of migration of the molecule, E = electric field in volts/cm, q = net 
charge on the molecule, f= frictional coefficient which is function of mass and shape of 
molecule. The movement of a charged molecule in an electric field is often expressed in 
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terms of electrophoretic mobility (pt), which is defined as the velocity per unit of electric 
field. 
g=V/E=E.q/f.E 	 (7) 
µ = q/f 	 (8) 
For molecules with similar conformation, 't' varies with size but not with shape. 
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Figure 38. Agarose gel electrophoresis migration showing different forms of pBR322 
plasmid DNA in presence of drug. 
Thus electrophoretic mobility (4) of a molecule is directly proportional to the charge 
density (charge/mass ratio). Molecules with different charge/mass ratio migrate under the 
electric field at different rates and hence get separated. This is the basic principle for all 
the electrophoretic techniques. Depending upon the nature of support medium, 
electrophoresis is of different types such as paper, starch, polyacrylamide and agarose gel 
electrophoresis. We have opted agarose gel electrophoresis, because agarose gels are 
more porous as compared to polyacrylamide gels and are, therefore, used to fractionate 
large macromolecules such as DNA that cannot be readily penetrate into and move 
through other types of supporting materials. Agarose is a linear polymer of D—galactose 
and 3.6—anhydro—L—galactose. When an electric field is applied across agarose gel, DNA 
molecules that are negatively charged at neutral pH, migrate towards oppositely charged 
electrode at rates determined by their molecular size and conformation. DNA molecules 
of the same size but with different conformation travel at different rates. The order of 
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migration velocity in the increasing order of various forms of DNA is: supercoiled DNA> 
linearized DNA> open circular DNA. 
The cleavage experiments of supercoiled pBR322 DNA (300 ng) in (5mM Tris—HCI, 50 
mM NaCI), buffer at pH 7.2 was carried out using agarose gel electrophoresis. The 
samples were incubated for I hour at 37 °C. A loading buffer containing 25% 
bromophenol blue, 0.25% xylene cyanol, 30% glycerol was added and electrophoresis 
was carried out at 60 V for 1 hour in Tris—HCI buffer using 1% agarose gel containing 1.0 
µg/mL ethidium bromide. The DNA cleavage with added reductant was monitored as in 
case of cleavage experiment without added reductant using agarose gel electrophoresis. 
The reaction were also monitored upon addition of various radical inhibitors such as 
sodium azide (NaN3), DMSO, superoxide dismutase (SOD), distamycin, methyl green, 
mercaptopropionic acid (MPA). The samples were incubated for 45 minutes at 37 °C. 
The gel was visualized by photographing the fluorescence of intercalated ethidium 
bromide under a UV illuminator. 
4. Religation experiment with 14 DNA ligase enzyme 
The DNA religation experiments were performed using T4 DNA ligase enzyme to 
support the hydrolytic mechanism of DNA cleavage by following the standard DNA 
religation protocol (Figure 39) [182]. 
Backbone 	 lasert Load) g % eI 
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Figure 39. Agurose gel electrophoresis showing ligation reactions. 
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The complex treated with pBR322 plasmid DNA (2 mg), ligation buffer of 1.5 mL in 
IOX, T4 ligase I mL (2 units) and 2.5 mL of H2O were mixed and incubated at 4 °C for 
lb. Subsequently, the samples were loaded on 1% agarose gel and visualized by staining 
with an ethidium bromide solution. 
5. Topoisomerase inhibition assay 
5.1 Topoisomerase I inhibition assay 
DNA topoisomerase 1, Human (Topo 1) was purchased from CALBIOCHEM and no 
further purification was performed. One unit of the enzyme was defined as completely 
relax I µg of negatively supercoiled pBR322 DNA in 30 minutes at 37 °C under the 
standard assay conditions. The reaction mixture (30 µL) contained 35 mM Tris—HCI (pH 
8.0), 72 mM KCI, 5mM MgCl2, 5mM DTT, 2mM spermidine, 0.1 mg/mL BSA, 0.25 µg 
pBR322 DNA, 2 Unit Topo I and metal complexes. These reaction mixtures were 
incubated at 37 °C for 30 minutes, and the reaction was terminated by addition of 4 µL of 
5X stock solution consisting of 0.25% bromophenol blue, 4.5 % SDS and 45% glycerol. 
The samples were electrophoresed through 1% agarose in TBE at 30 V for 8 hours. Then 
the gel was photographed under UV light. The concentration of the inhibitor that 
prevented 50% of the supercoiled DNA from being converted into relaxed DNA (IC50 
values) was calculated by the midpoint concentration for drug—induced DNA unwinding. 
5.2. Topoisomerase II inhibition assay 
DNA topoisomerase Ila (Topo 1I) was purchased from Sigma and no further purification 
was performed. One unit of the enzyme was defined as completely relax 0.3 µg of 
negatively supercoiled pBR322 DNA in 15 minutes at 37 °C under the standard assay 
conditions. The reaction mixture (30 A) contained 10 mM Tris—HCI (pH 7.9), 50 mM 
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NaCl. 50 mM KCI, 5.0 mM MgCl2, 0.1 mM Na2H2edta, 15 µg/mL BSA, 1.0 mM ATP, 
0.25 jig pBR322 DNA, 5 Unit Topo ti, and metal complexes. The reaction mixtures were 
incubated at 30 °C for 15 minutes. Reactions were stopped, processed, and subjected to 
gel electrophoresis as above. 
6. In vitro antitumor activity 
The cell lines used for in vitro antitumor screening activity were, 786-0, A498 (kidney), 
Zr-75-1 (Breast), SiHa (Cervix), A549, Hop-62 (Lung), SW620, HCF15 (Colon), 
MIAPACA2 (Pancreatic). G—adriamycin, standard anticancer drug was taken as control. 
>a 
These human malignant cell lines were procured and grown in RPMI-1640 medium 
supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics to study growth 
pattern of these cells. The proliferation of the cells upon treatment with chemotherapy 
entities was determined using the Sulphorhodamine—B (SRB) semi—automated assay 
[183.184]. The dose response parameters such as growth inhibition 50% (Glso), total 
growth inhibition (TGI) and lethal concentration 50% (LC50) were calculated. G150 is the 
concentration of drug required to decrease the cell growth to 50%, compared with that of 
4- 
	
	the untreated cell number. All cell lines were seeded into 96 well plates and cells were 
counted and cell count was adjusted according to the titration readings so as to give 
optical density in the linear range (from 0.5 to 1.8) and were incubated at 37 °C in CO2 
incubator for 24 h. The stock solution of the complexes were prepared as 100 mg/mL in 
DMSO and four dilutions i.e. 10 µL, 20 µL, 40 µL, 80 µL, in triplicates were tested, each 
well receiving 90µL of cell suspension. The plates were labeled properly and were 
incubated for 48 h. Termination of experiment was done by gently layering the cells with 
50 gL of chilled 30% TCA (in case of adherent cells) and 50% TCA (in case of 
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suspension cell lines) tur cell fixation and kept at 4 'C for Ill. Plates stained with 50 pl. 
o1'O.4% SRB for 20 min. All experiments were made in triplicate. 
7. Confocal studies 
Comical microscopy is a kind of microscopy that makes use of fluorescence, the ability 
ofa substance to give offa different wavelength of light than it absorbed (Figure 40). 
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In a confocal laser scanning microscope. a laser beam passes through a light 
source aperture and then is focused by an objective lens into a small (ideally diffraction 
limited) focal volume ithin or can the surface of a specimen. In biological applications 
especiaih. the specimen may he fluorescent. Scattered and reflected laser light as well as 
any fluorescent light from the illuminated spot is then re—collected by the objective lens. 
A beam splitter separates off sonic portion of the light into the detection apparatus. «hick 
in fluorescence confocal microscopy will also have a filter that selectively passes the 
fluorescent wavelengths while blocking the original excitation wavelength. After passing 
a pinhole, the light intensit, is detected by a photodetection device (usually 
a photomultiplier tube (PMT)), transtbrming the light signal into an electrical one that is 
recorded h% a computer [18 1. Confocal microscopy provides the capacity for direct, 
'[t, 	L'1 A\ 
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noninvasive, serial optical sectioning of intact, thick, living specimens with a minimum 
of sample preparation. 
Cancer cells were grown on a cover glass kept in a petri dish containing DMEM 
(Delbeco Modified Eagle's Medium) supplemented with 10% FBS (Fetal Bovine Serum) 
in 5% CO2 environment at 37 °C. Cells were incubated with samples for lh, washed 
twice with 1X PBS. Air dried the cover glass and mounted it on a glass slide in DAPI and 
finally cell imaging was conducted on confocal microscope. 
8. Computational studies 
Molecular docking techniques are well—documented computational tool to understand the 
Drug—receptor interactions for the structure—based drug design and discovery. The 
outcome of a docking exercise normally includes some sort of affinity prediction for the 
molecules investigated. 
The rigid molecular docking studies were performed by using HEX 6.1 software [186], is 
an interactive molecular graphics program for calculating and displaying feasible docking 
modes of an enzymes and DNA molecule. Structures of the complexes were sketched by 
CHEMSKETCH (http://www.aedlabs.com) and convert it into pdb format from mol 
format by OPENBABEL (http://www.vcclab.org/lab/babel/). The crystal structure of the 
B—DNA dodecamer d(CGCGAATTCGCG)2 (PDB ID: IBNA) and human—DNA—Topo-
I complex (PDB ID: 1SC7) and were downloaded from the protein data bank 
(http://www.resb.org./pdb). The default parameters used for the docking process via HEX 
docking Software. Visualization of the docked pose has been done by using CHIMERA 
(www.cgl.ucsf.edu/chimera) and PyMol (http://pymol.sourceforge.net/) molecular 
graphics program. 
CHAPTER III 
New heterobimetallic Cu11—Sn21"complex as potential 
topoisomerase I inhibitor: In vitro DNA binding, cleavage and 
cytotoxicity against human cancer cell lines 
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Synthesis 
Monometallic complexes [Cu(en)21.C12 and [Ni(en)21.C12 
To a methanolic solution (50 ml) of CuCl2.2H20 (1.70g, 10 mmol) was added 
ethylenediamine (1.34 ml, 20 mmol) in a 1:2 molar ratio. The dark blue product obtained 
was washed with Et2O and dried in vacuo [1 86]. 
[Ni(en)2]Cl2 was synthesized by using NiC12.6H20 (2.38g, 10 mmol) by a similar 
procedure as reported earlier. 
Heterobimetallic complex [Cu(en)2(phen)2Sn2C14 JCl2 
To a stirred methanolic solution (30 ml) of [Cu(en)2J.C12 (0.255g, I mmol) were 
simultaneously added drop wise methanolic solution (15 ml) of SnC14.5H20 (0.702g, 2 
mmol) and 1,10—phenanthroline monohydrate (0.396g, 2 mmol) to obtain an immediate 
precipitation which was further stirred for ca. 30 min at room temperature. The light 
green coloured product was filtered under vacuum and washed thoroughly with methanol 
and dried in vacuo. Yield, 79%. M.P. > 300 °C. Anal. Calc. for C28H28N8CuSn2Ch (%)C, 
33.96; H, 2.85; N, 11.32. Found: C, 33. 94; H. 2.82; N, 11.31 IR (KBr, cm-1) 3182 v(N-
11), 1598 b(N—H), 2935 v(CI12), 2888 v,(CH2), 850, 727 v(Phen, C—H), 1511 v(C=C), 
1427 v(C=N), 527 v(Cu—N), 428 v(Sn—N); Molar Conductance, AM (1 10-3 M, DMSO): 
121.6 ff 1 cm2 mol-I (1:2 electrolyte) ESI—MS (m/z): 917.1 [C28H2gN8CuSn2Cl6— 
(2C1+1 H)]` 
Heterobimetallic complex [Ni(en)2(phen)2Sn2CI4JCI2 
The heterobi metalIic complex (C28H28N8NiSn2Cl61 was synthesized from [Ni(en)ZLC12 
(0.250g. 1 mmol) by similar procedure as described for [C28H28N8CuSn2Cl,,]. The light 
pink colored product was filtered under vacuum, washed thoroughly with methanol and 
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dried in vacuo. Yield, 73%. M.P. > 300 °C, Anal. Cale. for C28H28N8NiSn2CI6 (%)C. 
34.13; H, 2.86; N, 11.37, Found: C, 34.11; H, 2.82; N, 11.34 IR (KBr, cm-') 3186 v(N-
11). 1585 6(N—H), 2937 v.(CH2), 2833 vs(CH2), 843, 723 v(Phen, C—H), 1509 v(C=C), 
1421 v(C=N), 530 v(Ci —N), 430 v(Sn—N). Molar Conductance, AM (1.10-3 M, DMSO): 
131.2 fl-1cm2 mol-' (1:2 electrolyte). 'H NMR (DMSO—d6, 400 MHz) 6 (ppm); 3.11-
3.67 (—CH2, 8H), 5.80-5.8l (—NH, 4H), 7.94-8.75 (ArH, 16H); 13C NMR (DMSO—d6, 
100 MHz) 6 (ppm): 48.96-51.77 (CH2) 125.59-141.83 (ArC); 19Sn NMR (DMSO—d6, 
146 MHz) 5 (ppm): —619.23; —593.11 F,SI—MS (m/z): 913.7 [C2KH2gNRNiSn2CI6-2Cl]' 
Results and discussion 
New heterobimetallic complexes [C28H2RNgCuSn2Cl6] and [C28H28N8NiSn2C16] were 
synthesized by reacting monometallic complexes [Cu/Ni(en)21C12, followed by drop wise 
addition of SnCl4.5H20 and 1,10—phenanthroline monohydrate in 1:2:2 stoichiometric 
ratio (scheme I). The resulting complexes were stable towards air and moisture and 
soluble in DMSO. 
i 
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Where M = Cu(II) and Ni(1I) 
Scheme I: Synthetic route for the heterobimetallic complexes [C28H28N8CuSn2Cl6J and 
/C28H2& N NISn2CIo] 
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The complexes were characterized by elemental analysis, IR, Uv-vis and EPR spectral 
studies. Molar conductance values of complexes in DMSO (1 x 10-3 M) at 25°C suggest 
their 1:2 electrolytic nature (121.6-131.2 (T'em2 moE') [187]. The X-ray powder 
diffraction (XRPD) confirmed the crystalline nature of both complexes. 
Infrared spectra 
The IR spectra of monometallic complexes exhibits characteristic stretch at 3300-3400 
cm ' attributed to the presence of free NI-I2 group of ethylene diamine moiety. However, 
heterobimetallic complexes [C28H28N8CuSn2Ck] and [C26H28N8NiSn2CI6] exhibited new 
bands around 3182-3186 cm ' and 1585-1598 em-1  attributed to v(N-H) stretching and 
S(N-H) bending vibration, respectively due to presence of the coordinated secondary 
amino group, this contention supports that N142 group of ethylenediamine is deprotonated 
and coordinated to central metal Cu'/Ni" and simultaneously to Sn(IV) metal ion via 
elimination of HCl molecules [188]. The absorption bands observed in the range of 
2935-2937 cm ' and 2833-2888 cm ' have been assigned to C-H asymmetric and 
symmetric stretching vibration of aliphatic -Cl 2 group of ethylenediamine. The strong 
characteristic absorption bands of free phenanthroline which appear at 737 and 853 cm' 
(out-of-plane CH in center ring and heterocyclic rings, respectively), and were shifted to 
lower frequencies region at 723-727 and 843-850 cm ', indicating the coordination of 
two nitrogen atoms of phenanthroline to second metal ion Sn(IV) in [C231-I28N8CuSn2CI6] 
and [C25H28N8NiSn2CL]. Furthermore, the shift of v(C=C) and v(C=N) stretching 
frequencies of phenanthroline from 1505 to 1509-1511 and from 1424 cm' to 1421-
1427 cm', respectively after coordination also confirms the involvement of 
phenanthroline moiety [189]. The medium intensity bands around 527-530 and 428-430 
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cm I  were attributed to v(Cu/Ni-N) and v(Sn-N), respectively revealing the complex 
formation. 
NMR spectral studies 
The NMR spectra of the of heterobimetallic complex [C28H28N8NiSn2C16] was recorded 
in DMSO-d6 solution and the assignments were made by relative comparison with those 
of monometallic complex [Ni(en)2].C12. 'H NMR spectra of monometallic complex 
exhibited sharp signal at 3.93 ppm attributed to -NI-I2 proton. However, complex 
[C28H2sN8NiSn2CI6] revealed downfield shift to 5.80-5.81 ppm, which commensurate 
with the fact that the -NH proton was coordinated simultaneously to the Ni(11) and to 
Sn(IV) metal ion through deprotonation. The resonances at 3.11-3.67 ppm were 
consistent with the presence -Cl-i2 protons of ethylenediamine [190]. The aromatic 
protons of phenanthroline ring appeared as broad multiplets in the range of 7.94-8.75 
ppm. 
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Figure 41. (a) 'H, (h) !3C and (c) 119Sn N.M. R. spectrum of heterohimetallic complex 
fC'28H28N&iSn (-'l6 J. 
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The t3C NMR spectrum of complex [C28H2$N3NiSn2Clb] exhibited distinct signals in the 
region 49.96-51.77 ppm attributed to -Cl2-NH carbons. In addition, aromatic carbon 
signals were observed at 125.59-141.83 ppm [191]. 
119Sn NMR spectrum displayed two signals at -619.23 and -593.11 ppm due to the 
presence of two tin metal centers. These chemical shifts values are consistent with those 
reported for complexes with hexacoordinated geometry of a tin metal atom (Figure. 41) 
[192]. 
Mass Spectroscopy 
ESI mass spectra of the complexes [C28H2$N8CuSn2CI6] and [C2$N28N8NiSn2CI6] were 
obtained to confirm their proposed molecular formulae. The complexes 
[C23H23N8CuSnClb] and 1C23H2sN8N1Sn2C1d displayed characteristic peaks at mtz 917.1 
and 913.7 ascribed to [C28128N8CuSnCI6-(2CI+lH)]+ and [C28H28N8NiSn2CI6-2Cl]+, 
respectively. However, [C28H2aN8CuSnCI6] and [C23H28N8NiSnCl6] showed molecular 
ion peak at m/z 458 and 456 which were assigned to [C28H28NgCuSnCl4]/2 and 
[C28H2$N3NiSnCI4]/2 respectively, suggesting the ionic nature of the complexes. The 
spectrum of [C28H2sN8CuSn2Cl6] exhibit the prominent peaks at m/z 557.3, 414.2, 177.1 
and 114.6 while in case of [C28H28N3NiSnCt6I prominent peaks were observed at m/z 
554.4, 412.4, 171.5 and 114 due to the successive expulsion of two phenanthroline 
molecules followed by the release of four chlorine atoms from the complex and finally 
both the tin atoms and copper/nickel metal ion was ionized. 
EPR studies 
The solid state X-band EPR spectrum (Figure. 42) of polycrystalline complex 
[C2$H2$N8CuSnC16] was recorded at room temperature with tetracyanoethylene (TCNE) 
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as field marker (g = 2.0027). The spectrum displayed an isotropic signal and exhibits 
axial symmetrical line shape with gp=2.188 and g1=2.051 and gav,=2.09 computed from 
the formula gev2=g 2+2g12/3. These parameters are consistent with the square planar 
geometry of the copper(II) metal ion and are quite similar to the values reported for other 
related square planar copper(l 1) systems. 
Figure 42. X—band polycrystalline powder EPR spectrum of complex 
[C2sH23N8CuSn2C16] at room temperature. 
The trend of g values (g>g1>2.0023) observed for the copper(II) indicates that the 
unpaired electrons lies predominantly in the dx2—yz orbital of Cu(II) ion (spectroscopic 
state 2Big) [193]. 
Electronic Spectra 
The electronic absorption spectra of complexes [C25H28N8CuSn2Cl6] and 
[C28H28N&NiSn2Ck] in DMSO solution were carried in the range of 200-1100 rim at 
•oom temperature. The electronic spectrum of the complex [CZ8H25N8CuSn2CI66] revealed 
intense d—d band centered at 658 nm which is assigned to 2Big—~2Ai g transition 
ggesting a square planar geometry around the Cu(II) ion. The diamagnetic complex 
?8H2BNgNiSn2CM] displayed two bands at 588 and 415 rim regions assigned to 
;(F)—.'Big(G) and 'A1g 'A2g transitions, respectively, consistent with a square planar 
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Ni(II) complex [194]. In addition, electronic spectra of [C28H2sN8CuSn2CI6] and 
IC28H28N3NiSnC16] displayed a i—'ø transitions bands at 272 and 274 nm, respectively 
followed by a shoulder at 290 nm attributed to intraligand n_a* transitions of 
coordinated phenanthroline ligand [195]. 
X—ray diffraction analysis 
To obtain further evidence about the structure of the metal complexes, X—ray powder 
diffraction was performed. The XRPD pattern obtained for the complexes 
[C23H2sN8CuSn2CI6] and IC23H28N8NiSn2CI6] (Figure. 43a and b) showed well defined 
crystalline peaks due to their inherent crystalline nature. The X—ray diffractogram of 
[C28H2$N5CuSnCI6] and IC28H2$N8NiSn2Cl6] exhibited reflecting peaks at 20 scattering 
angles of 28.01, 33.15, 37.25, 44.16, 49.62 and 63.52 were assigned to (200), (112), 
(120), (122), (220) and (313) for [C28H23N8CuSn2C16] (JCPDF:71-0339) and for 
[C2sH28N8NiSn2CI6], peaks at 20 scattering angles of 28.41, 33.79, 39.25, 44.81, 59.19, 
and 71.18 were assigned to (101), (110), (200), (201), (202) and (220) crystal planes, 
respectively, (JCPDF:35-1362) which was characteristic of well ordered hexagonal 
arrangement of tin atoms. 
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Figure 43. The XRD pattern of (a) complex [C78H28W8CuSn2Cl6] and (b) complex 
[C18H1p,rY&MSn1Cl6J showing peaks at different scattered angles and their planes (miller 
indices). 
The different lattice parameter found for [C25H28N3CuSn2CI6] and IC28H23NgNiSn2CI6I 
are; a = 7.33, c = 7.86 and a = 5.29, c = 4.24, respectively, which was consistent with the 
known lattice parameters; a = 7.330, c = 7.864 and a = 5.296, c = 4.284 respectively, 
indicating that the complex particles have the same crystal structure as that of the bulk. In 
addition, intense reflections derived from the planes (223), (ill) and (002), (203) for 
[C28H2$N8CuSnCl6] and [C28H28N8NiSnCl6] respectively, reveals the existence of 
central metal Cu(II) / Ni(II) in a cubic system [196]. A summary of the refined XRD 
parameters is given in Table 1. 
Table 1. Summary of the XRD data and the refinement parameters for 
[C28H25N8CuSn2Ce] and [C25N18N8WiSn2C161 
FW 
Temperature(K) 
Method 
Wavelength 
Radiation 
Crystal System 
990.26 
298 
Micro crystalline 
1.540598 
Cu-Ku! 
Hexagonal 
P 
985.44 
298 
Micro crystalline 
1.540598 
Cu-Ku! 
Hexagonal 
P 
Unit cell dimension 
a(A) 7.33 5.29 
b(A) 7.33 5.29 
c(A) 7.86 4.24 
a° 90 90 
p° 90 90 
y° 120 120 
29 range 20-79.2 20-79.2 
Limiting indices 0< h< 5 0< h< 5 
0<k<4 0<k<_3 
OSI <_6 0<I <5 
Intensity (%) 	10.45-100 	5.24-100 
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DNA Binding Studies 
Electronic absorption titration 
Electronic absorption spectroscopy was employed to ascertain the binding modes of 
complexes with DNA by following the changes in the absorbance and shift in the 
wavelength. For our designed molecules, we could anticipate different binding modes on 
the basis of structure, functional ligand and metal ions, viz: groove binding, coordinate 
covalent linkage with nucleobase due to Cu(II) metal ion, intercalation due to 
chromophore of phen ligand and surface interaction through phosphate oxygen backbone 
of DNA due to Sn(IV) metal ion. Upon addition of CT—DNA (0-33.3 x 10 M) to 
[C28H28N8CuSn2CL] and [C2gR28N8NiSn2Cl6] of fixed concentration (6.67 x 104 M), 
hyperchromism of 37% and 31%, was observed (Figure 44a and b). The hyperchromic 
effect suggested that the binding of complexes to CT—DNA may be attribute either to 
external contact (electrostatic or groove binding) or to the fact that complexes could 
uncoil the helix structure of DNA and make more bases embedding in DNA exposed 
[197, 198]. 
In order to quantify the binding affinity of [C2sH2sNsCuSn2Cl6] and [C28H28N5NiSn2CI6] 
with CT—DNA, the intrinsic binding constant, Kb were calculated from Wolfe—Shimer 
Eq. (2), and were found to be 4.15 x 104 and 2.73 x 10° M-', respectively. The Kb values 
suggest that [C28H28N8CuSn2C16] has higher binding affinity as compared to 
[C28U28N8NiSn2CI6] due to the dual mode of action of Cu(II) and Sn(IV) metal ion. Both 
(hard Lewis acid) bind to DNA in a markedly different manner; copper showing 
preference for N7 position of guanine through coordinate covalent bond formation while 
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Sn(IV) prefers to bind to the vicinal anionic phosphate oxygen of the phosphate sugar 
backbone of DNA helix [ 1991. 
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Figure 44. Absorption spectral traces of (a) complex /c28H28N8C'u5n2ci6J and (b,) 
complex [C28H28N8N1Sn2Cl6J in 5 %DMSO/ 5mM Tris HCl/ 50 mMNaCI buffer at pH 7.2 
buffer upon addition of CT—DNA, Inset_ Plots of [DNA]/e,—ef (m2 cm) vs [DNA] for the 
titration of CT—DNA with complexes ■, experimental data points; _full lines, linear fitting 
of the data. [C'omplex] 6.67 x I0 M. [DNA] 0-33.3 x 10 `' M. 
Together with a chelating phen ligand bound to both Sn(IV) atoms contribute to partial 
intercalation, and thus a unique multiple mode of interaction for this molecule can be 
envisioned. 
Interaction of complex [C2sH28NsCuSn2Cl6I with 5'—GMP 
The complex [C28H28N8CuSn2C16] and [C2$H2gN8NiSn2CI6] showed highest binding 
propensity towards CT—DNA, hence to determine the coordination of copper metal ion to 
the specific site of CT—DNA, interaction with low molecular building blocks of DNA 
molecule viz., guanosine5'—monophosphate was carried out by UV—vis absorption 
titrations. On addition of increasing concentration of 5'—GMP (0-33.3 x 10--` ' M), there 
was a sharp increase in absorption intensity, hyperchromism with a pronounced red shift 
of 7 nm of the intraligand band from 272-279 nrn (Figure. 45), which implicates that 
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complex [C2sH28N8CuSn2C16] interacts electrostatically to phosphate oxygen atoms of 
DNA duplex in addition to coordinate covalent linkage to guanine nucleobase. 
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Figure 45. Absorption spectral traces of Complex [C2sH18N8CuSn2C16J in 5 
%DMSO/5mM Tris HCl/50 mMNaC1 buffer upon addition of 5'--AMP. [Complex] 6.67 x 
/GM [GMP] 0-33.3 x 1 D~ M. 
Literature reveals that interaction of 5'-GMP with Cu(1l) ions occur mainly via N7 
coordinating site which induced the breakage of the secondary structure of DNA while 
06 position is favored in other early transition metal ions [200]. The intrinsic binding 
constant Kb value was found to be 3.27 x 104 M-' which agrees well with UV-visible 
titration results followed with CT-DNA. 
To validate our hypothesis, the preferential binding of [C2SH28N8CuSn2CI6] towards 5'-
GMP. 'H and 31P NMR techniques at physiological pH were carried out. The 'H NMR of 
free 5'-GMP in D20 exhibits H8 (adjacent to N7 atom of guanine) resonance at 8.10 ppm 
and proton signals of ribose Hi '-H5'  at 3.87-5.82 ppm. For paramagnetic complexes, the 
chemical shift of proton adjacent to the metal center was significantly perturbed resulting 
in line broadening. On interaction of [C28H28N8CuSn2Cl6] with 5'-GMP, the H8 signal 
was shifted downfield with a slight decrease in the peak intensity (Figure. 46a) from 8.10 
ppm to 8.22 ppm. The downfield shift results due to the desheilding of H8 proton by 
GMP 
coordinate bond formation of Cu(II) ions of [C28H2KNRCuSn2C!61 via N7 atom of 5'-
GMP. However, the ribose proton Hl'-H5' signals were shifted upfield -0.05 ppm, 
which indicate the preference for ribose sugar due to the presence of Sn(IV) hard Lewis 
acid center. The 31 P NMR signal (Figure. 46b) appeared in free 5'-GMP at 3.73 ppm 
which was shifted upfield to 2.16 ppm clearly indicating that Sn(IV) was bound to 
phosphate group. 
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Figure 46. (a) 'H NABZ spectra of 5'—GMP and the reaction of complex 
[C2SH2SVBCuSn2CI6] (2.5 mmol) with 5'—GMP (5 mmol) at 25°C (b) 3'p NMR spectrum of 
5'—GMP and the reaction of complex [C25H2sN8CuSn2C16j (2.5 mmol) with 5'—GMP (5 
mmol) at 25°C. 
Fluorescence spectroscopic studies 
In the absence of CT—DNA, complexes [C28H28N8CuSn2Cl6] and [C2gH28N8NiSn2CI6] 
emit luminescence in Tris—HCI buffer pH 7.2 at ambient temperature, with a fluorescence 
maximum appearing at 453 nm and 427 nm, respectively when excited at 270 nm. Upon 
addition of increasing concentration of, [DNA] (0-33.3 x 10~ M) to the fixed amount of 
complex concentration (6.67 x 10-6 M), there was a gradual enhancement in the 
fluorescence intensity of the complexes with no apparent change in the shape and 
position of the emission bands (Figure. 47a and b). This implies that the complexes 
interacted with CT—DNA due to the inaccessibility of the solvent water molecules to 
reach the hydrophobic environment inside the DNA helix, and the mobility of the 
complexes is restricted at the binding site ultimately leading to decrease in vibrational 
mode of relaxation. To compare the binding affinity of [C281-I28N5CuSn2C16] and 
[C25H2$N$NiSn2Cl°], the binding data obtained from the emission spectra were fitted in 
the Scatchard equation to acquire the binding parameters [201]. A plot of r/Ct vs r gave 
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the binding constants for [C28H28N8CuSn2CL] and [C291-I28N8NiSn2Cl6] as 3.07 x 10° and 
1.33 x 10° NV', respectively. The number of metal complex bound per DNA (n) 
calculated [202] for [C2$H28N8CuSn2C16] and [C26H28N8NiSn2Cl6] was found to 1.62 and 
1.13, respectively, indicating that complex [C2sH28N3CuSnCl6J interacted with DNA 
more strongly as compared to [C28H28NgNiSn2CL]. 
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Figure 47. Emission spectra of (a) complex [CzgH28,NsCuSn2C1b] and (h) complex 
[C23H2gN01SnC16J in the presence of DNA in 5 mM Tris-HC1/50 mM NaCl buffer. 
Arrows show the intensity changes upon increasing concentration of the DNA. Inset: Plot 
of r/Cf vs r; [Complex] =6.67 x 10-6 Al, [DNA] 0-33.3 x 10~ M (.) experimental data 
points; full lines, linear fitting of the data. 
Etbidium Bromide Displacement Assay 
In order to further investigate the interaction mode of complexes with DNA, a 
competitive binding experiment using EB as a probe was carried out. The extent of 
quenching of the fluorescence of EB bound to DNA would reflect the extent of DNA 
binding of complexes [C23H23N8CuSn2CDI and [C28N28N$NiSn2C16]. EB (3,8-diamino- 
5-ethyl--6 phenylphenanthrium bromide) is an intercalator that gives a significant 
increase in fluorescence emission when bound to DNA and it can be quenched by the 
addition of second DNA binding molecule by either replacing the EB and / or by 
accepting the excited-state electron of the EB through a photoelectron transfer 
mechanism [203]. Upon addition of [C2gH23N8CuSnC16] and [C28H28N8NiSn2Cl6] to CT 
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DNA pretreated with EB ([DNA]/[EBJ = 1) caused significant reduction in the emission 
intensity (Figure. 48a and b), indicating that the replacement of the EB fluorophore by 
[C28H28N8CuSn2CI6] and [C28H28N$NiSn2C16], which results in a decrease of the binding 
constant of ethidium bromide to DNA. The quenching extents of [C28H28N8CuSn2Ch] 
and [C28H28N8NiSn2CI6] were evaluated qualitatively by employing Stern—Volmer 
equation and found to be 0.21 and 0.07, respectively. Since EB was not completely 
displaced, partial intercalation in addition to the electrostatic mode of binding cannot be 
ruled out. 
(a) 	 (b) 
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Figure 48. Emission spectra of EB bound to DNA in the absence and presence of (a) 
complex 1C2811 N8CuSn2C16] and (h) complex [C28HZ8NN1iSnClQj in 5 mM Tris-HC1/50 
mMNaCl buffer. Arrows show the intensity changes upon increasing concentration of the 
complexes. Inset: Plots of In/1 vs [complex)/[DNA]. (0) experimental data points; full 
lines, linear fitting of the data. 
Viscosity measurements 
To clarify the mode of interaction of the complexes [C28H28N8CuSn2Cl6] and 
[C28H28NxNiSn2ChI to CT—DNA, viscosity measurements were carried out on CT DNA 
solutions upon addition of increasing amounts of complexes (Figure 49). The addition of 
the complexes results in an decrease in the relative viscosity of DNA indicating that the 
complexes could bend and kink the DNA helix, reducing its effective length and 
consequently its viscosity [204]. Since, DNA is a polyanion, the repulsion between the 
negative charges makes the DNA molecule more extended in solution. The negative 
charges of DNA are partially neutralized when the complexes bind to DNA through 
electrostatic interaction to the phosphate group of DNA backbone leading to contraction 
of the DNA helix, shortening of DNA molecule and decrease in viscosity of DNA. On 
the other hand, a classical intercalative mode causes a significant increase in viscosity of 
DNA solution due to its increase in separation of base pairs at intercalation sites and 
increases in overall DNA length. The decrease in the viscosity of these complexes reveal 
an electrostatic non-classical mode of binding of complexes with DNA [205]. 
1/R 
Figure 49. Effect of increasing amount of complex [C28H28N8CuSn1Cl6J and (a) and 
[Ge1-12dtsNiSnZCT6J (.) on the relative viscosities (rl/rl& of CT—DNA in TrisHC( buffer 
(pH 7.2). 
DNA Cleavage activity 
DNA Cleavage without added reluctant 
The DNA cleavage ability of complex [C25H23N8CuSn2Cl6] was studied by agarose gel 
electrophoresis using pBR322 plasmid DNA as a substrate in a medium of 5mM Tris-
HCU50 mM NaCI buffer, at pH 7.2 in the absence of an external agent. The activity of 
[C28H23N$CuSn2CI6] was assessed by the conversion of DNA Form I (Supercoiled Form) to 
Form 11 (Nicked Circular Form) or Form III (Linear Form). The cleavage reactions have been 
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studied using increasing complex concentrations (5-25 µM) incubated at 310 K for 45 min 
(Figure 50a). It was observed that [C28H28N3CuSn2CI6] exhibits remarkable nuclease activity 
at 5 µM concentration, as evidenced by the conversion of supercoiled DNA to its open 
circular form (Lane 2). With the increase in concentration of complex [C28H28N8CuSn2CI6] 
(10-25 µM), resulted in more efficient cleavage, the linear form were manifested in the gel 
(Lane 3-6) and the amount of linear DNA increased with the increase of the concentrations. 
So, it was clear that cleavage of pBR322 DNA was dependent on metal ions concentration as 
well as presence of an aromatic moiety. The gel pattern of [C28H2gN8CuSn2CI6] with the 
appearance of linearised form (Form III) further validate the direct double-strand scission of 
DNA [206], as a consequence, this complex could be better suited for therapeutic 
applications particularly, in cancer chemotherapeutics [207]. 
In presence of activators 
The nuclease efficiency of the metal complexes is known to depend on the activators 
used for initiating the DNA cleavage. Therefore, DNA cleavage activity of 
[C28H28N8CuSn,C16] in presence of H202, ascorbate (Asc), 3-mercaptopropionic acid 
(MPA) and glutathione (GSH) was evaluated (Figure. 50b, Lane 2-5). The cleavage 
activity of [C2gH25N5CuSn2CI6] was significantly enhanced by these activators and 
follows the order MPA>GSH>Asc>H202. Thus, [C28H25N8CuSn2CI6] exhibited a 
significant DNA cleavage activity in the presence of MPA. 
Effect of reactive oxygen species on DNA cleavage 
Reactive oxygen species generated during the interaction between metal complexes and 
dioxygen or redox reagents are the major cause of DNA damage [208]. To probe the 
potential mechanism of DNA cleavage mediated by complex [C28H28N8CuSn2Ck], 
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reactions were carried out in the presence of hydroxyl radical scavengers (DMSO. 
EtOH), singlet oxygen quencher (NaN3) and superoxide oxygen scavenger (SOD), under 
identical conditions. The experimental results (Figure. 50b) showed that the DMSO and 
tert—butyl alcohol did not show any marked inhibition of DNA cleavage (Lanes 6 and 7) 
suggestive of non—involvement of dit'usible hydroxyl radical as one of the ROS 
responsible for DNA breakage. On the other hand, NaN3 and SOD strongly inhibited the 
DNA cleavage activity (Lanes 8 and 9) which demonstrate the involvement of superoxide 
radical anion and singlet oxygen in DNA strand scission suggesting oxidative cleavage 
mechanism. 
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Figure 50. Agarose gel electrophoresis cleavage patterns showing cleavage of pBR322 
supercoiled DNA (300 ng) by complex [c28H28,NRCuSr2Cr6J at 310 K after 45 min of 
incubation (a) at different concentration; Lane 1: DNA control; Lane 2: 5 1tM of 
[C2pN25N8CuSn1Cl6J+DNA; Lane 3: 10 uM of [C28H281V8CuSn2C'l6J+DNA; Lane 4: 15 
pM of [C'18H28N8CuSn2Cl6J+DNA; Lane 5: 20 pM of [C28H28N8CuSn2C16 / +DNA; Lane 6: 
25 pM of [C18H2&N8CuSn2Cl6J+DNA. (b) in presence of different activating agents; Lane 
1: DNA Control; Lane 2: 25 pM of [C28H28N8(='uSn2Cl6J+H202 (0.4 M)+DNA; Lane 3: 
25 pM of [C28H28N8CuSn2C16J+MPA (0.4 M)+DNA; Lane 4: 25 uM of 
[C18H28N8CuSn2Cl6J+GSH (0.4 +DNA; Lane 5: 25 uM of [C28H18N8CuSn2C16J+ASc 
(0.4 M) +DNA; Lane 6: 25 pM of [C28H2$N8C uSn2C16J+DMSO (0.4 M+  DNA; Lane 7: 
25 pM of [C28H25NRCuSn2C16J+EtOH (0.4 M) + DNA: Lane 8: 25 pM of 
[C18H28N8CuSnCl6J+sodium azide (0.4 M)+DNA; Lane 9: 25 pM of 
f C28H28N8CuSnc16 J +SOD (15 units) +DNA. 
DNA cleavage in presence of recognition elements 
DNA recognition elements (groove binding) minor groove binding agent, DAPI and 
major groove binding agent, methyl green were used to probe the potential interacting 
site of complex [C2gH25N8CuSn2Cl6] with supercoiled plasmid pBR322 DNA. 
Figure SL Agarose gel electrophoresis pattern for the cleavage of pBR322 supercoiled 
DNA (300 ng) by [C2sH28N8CuSn2Ct6] in presence of DNA minor binding agent DAPI 
and major binding agent methyl green at 310 K after incubation for 45 min. Lane 1, DNA 
control; Lane 2, 9 pM of complex [C28H2sN5CuSn2C16J+DNA+DAPI (8 pM); Lane 3, 9 
pM of complex [C23H78N8CuSnC16]+DNA+methyl green (2.5 pL of a 0.01mg/ml 
solution). 
The supercoiled DNA was treated with DAPI or methyl green prior to the addition of 
[C28H2gN8CuSn2CI6]. DNA cleavage was inhibited in the presence of DAPI (lane 2). 
However, no such inhibition of DNA damage was observed in presence of methyl green 
(lane 3), suggesting that minor groove as the preferred interacting site of 
[C28H23N$CuSn2Cl6] (Figure. 51), which was further validated by molecular docking 
studies. 
Topoisomerase I inhibition 
A plasmid DNA cleavage assay was used to investigate the effect of complex 
[C28H28N9CuSn2CI6] on the activity of human Topo—1 by agarose gel electrophoresis. 
This assay provides a direct means of determining whether the drug affects the 
unwinding of a supercoiled (SC) duplex DNA to nicked open circular (NOC) and relaxed 
(R) DNA. When catalytic activity of topoisomerase I was assayed, complex 
[C28H2$N8CuSnCl6] inhibited this process in a concentration—dependent manner [209]. 
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With increasing the concentration of complex [C2RH2sNRCuSn-,Clh] (7.5-20 µM), the 
levels of relaxed form were inhibited (Lanes 3-8) (Figure. 52), supercoiied DNA was 
fully relaxed by the enzyme (Lane 2, Topo-I). The DNA relaxation effect caused by 
Topo-I were totally inhibited by complex [C28H28N8CuSn2Cl6] at 20 pM (IC50 -20 µM, 
Lane 8), comparing with some classical topoisomerase [ inhibitors (Table 2) [210-213]. 
Because the gel mobility of plasmid DNA was slightly retarded at higher concentrations 
of the complex [C28H28N8CuSn2Cl6] with the enzyme, indicating that the DNA-bound 
complex [C2sH2R N8CuSn2Cl6] expels the Topo-1 from approaching plasmid DNA and in 
turn leads to a lower level of DNA relaxation. 
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Figure 52. Agarose gel electrophoresis cleavage patterns showing cleavage showing 
effect of different  concentration of complex [C'28H2 N8CuSn2C16J on the activity of DNA 
topoisomerase I (Topo I); Lane 1, DNA control; lane 2, Topo I+DNA; Lane 3, 7.5 pMof 
[C18NzsN8C'uSnzClnj-DNA+Topo 1; Lane 4: 10µ:1f of [C18Hz8N8C'uSn2C16J +DNA+Topo 
1; Lane 5: 12.5 pM of [C28I12xN 'uSn2C %/+DNA+Topo I; Lane 6: 15 pM of 
[C2sHNCuSn2C1oJ+DNA+Topo 1; Lane 6: 17.5 pM of [C28H18N8CuSn2C16J 
+ DNA +Topo I; 20 pM of /C'28H28N8CuSn2Cl6j+DNA+Topo L 
Table 2: IC30 (pM values of the complex [C2&H28N8CuSn2C16j on topoisomerase I 
activities, some of the classical topoisomerase 1 inhibitors. 
Complexes 1050 (µM) Refs 
Etoposide >1000 [210]  
Camptothecin 17 [211]  
Doxorubicin >100 1211 ] 
Novobiocin >100 [2111 
Topostatin 17 [2111 
Hoechst 33258 30 [212]  
A-[Ru(bPY)2(uip)]2+ -40 [213]  
A-[Ru(bpy)2(uip)]2+ -40 [213] 
[C28H28NgCuSn2C16] 20 This work 
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"These observations suggest that complex ((:l  l,xNx('uSn,('l,4 inhibited -Toped catalytic 
activit\ due to i) its strong DNA binding affinity. ii) direct interference with the enzyme 
(i.e., stabilization of topoisomerase—DNA cleavable complexes) and inactivating its 
proper functioning. iii) ligand that Occupies the topoisomerase binding site may suppress 
the association of topoisomerase with l)NA, thus influencing the topoisomerase activit)- 
Molecular (locking with DN. 
Molecular docking techniques is an attractive scaffold to understand the Drug—I)NA 
interactions in rational drug design, as "ell as in the mechanistic stud,, by placing a small 
molecule into the binding site ot'the target specific region of the DNA nrainl\ in a non—
covalent fashion and to predict the correct binding mode and binding affinities 1? I4]. 
Figure 53. Molecular docked model of complex (a) t('a 1l,,t.xd'USo,C'16J and (hl 
/(',,JI xIViSn,('l6J witft LMA /dodecainer duplex cif .sequence d(('C('GAA77'('G('G), 
(PDB ID: I BNA)J. 
Dit-tcrent structural properties lead to different binding modes, in fact one of the most 
important factors governing the binding mode is the molecular shape. In our experiment, 
rigid 	molecular 	docking 	studies 	of complexes 	I('.,8Il7 NgCuSn2Cl6J 	and 
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[C28H28N6NiSn2Cl6] with DNA duplex of sequence d(CGCGAATTCGCG)2  dodecamer 
(PDB ID:IBNA) were performed in order to predict the chosen binding site along with 
preferred orientation of the ligand inside the DNA minor groove. The energetically most 
favorable conformation of the docked pose (Figure. 53a and b) revealed that 
[C28H28N8CuSn2Cl6] and [C25H23N8NiSn2C16] fitted snugly into the curved contour of the 
targeted DNA in the minor groove within G—C rich region, and slightly bends the DNA 
in such a way that a part of the planar phenanthrolinc rings makes favorable stacking 
interactions between DNA base pairs and lead to van der Waals interaction and 
hydrophobic contacts with the DNA functional groups which define the stability of 
groove [215]. Moreover, the ethylenediamine moiety arranged in a parallel fashion with 
respect to groove walls of the DNA and stabilized by hydrogen bonding (2.8-3.0 A) 
between the —NH groups of ethylenediamine and 04/N2 atoms of C 1OA/ G16B bases in 
DNA double helix. 
The resulting relative binding energy of docked complexes [C23H23N8CuSn2C1e] and 
[C28H28N8NiSn2CI6] with DNA were found to be —292.7 and —278.2 eV respectively, 
correlating well with the experimental DNA binding values. Thus, we can conclude that 
there is a mutual complement between spectroscopic studies and molecular docking 
techniques, which can substantiate our experimental results and at the same time provides 
further evidence of groove binding. 
Molecular docking with Topoisomerase—I 
In order to rationalize the observed Topo-1 inhibitory assay, complex 
[C28H28N8CuSn2CI6] was successively docked with the human—DNA—Topo—I complex 
(PDB ID: I SC7) to search the exact binding site. The X—ray crystallographic structure of 
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the human—DNA—Tope—1 complex (PDf3 ID: f SC7) from Protein Data Rank was 
uploaded in which 	I opo---I is bound to the oligonucleotide sequence 3 — 
\1AAAAGACTTsX—GAAAATTT"I"l'-3'. where 's' is 5'—bridging phosphorothiolate of 
the cleaved strand and 'X' represents any of' the four bases A. (., C or T. The 
phosphoester bond of G 12 in I SC7 was rebuilt and SI 1 of' G II on the scissile strand as 
changed to OI l 1216]. I he complex [C281 I ,8N8CuSn2Cl(,j adopts a characteristic crescent 
shape and flexible enough to adopt a conformation which is complementary to the minor 
roo e. 
z 
Figure 54. Diagram showing in (a) human—DNA—Tupu—I (70 kDa) (P!)1B ID: IS(.'7) (h) 
molecular clocked model of complex /C1I12 N,,•CuSn;(.'1h/ in the cleavage active site of 
human D'L A lopoisumerace I (PD13 ID: IS( ' v ). 
Fhe analysis of best docked conformation (IFigure. 54) with resulting minimum relative 
binding energy revealed that planar heterocyclic phenanthroline rings of complex 
[C,8If ,8N8CuSn2Cl,,J approaching towards the DNA cleavage site in the topoisomerase-
f)NA complex and forming, a stable complex through it-7r stacking interactions between 
purine ring of Gl1 (+1) and pyrimidine ring of 110 (-1) in the minor groove on the 
scissile strand and C 112 and A 113. on the non—scissile strand, parallel to the plane of 
base pairs without having hydrogen bonds with the topoisornerase I. 
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On the other hand, chlorine atoms acts as a hydrogen bond acceptor and forms H—bond 
with Asn 722 residue, which is considered an important amino acids that interact with the 
ligand in the DNA—Topo—t active site, subsequently leading to inhibitory effect on Topo-
1 [217]. Furthermore, DNA intercalating forces was much more important than hydrogen 
bonding of the ligand to the surrounding amino acids residues of the protein, or to the 
base pairs [218]. Thus, computer—aided molecular docking studies afford valuable 
information of drug binding mode in the active site of DNA—Topo—1 leading to the 
rational design of new classes of anticancer drugs targeting Topo—I. 
Antitumor activity assays 
In vitro anticancer activity of complex [C23H28NsCuSn2CI6] has been evaluated in terms 
of G15o, TGI and LC5o  (Table 3) values against nine different human carcinoma cell lines 
of different histological origin: 786-0, A498 (kidney), Zr-75-1 (Breast), SiHa (Cervix), 
A549, Hop-62 (Lung), SW620, HCTI5 (Colon), MIAPACA2 (Pancreatic). The 
Sulforhodamine—B (SRB) assay was used to assess the cellular proliferation [219]. The 
result showed high potential of the complex [C28H23N8CuSn2Cf] as drug candidate, as 
expected from the in vitro DNA binding studies and topoisomerase I catalytic inhibition. 
The complex [C28H25N8CuSn2CI6] exhibited very promising antitumor activity (G150< 10 
µg/ml) against all these human carcinoma cell lines, indicating that it could act as 
efficacious metal—based anticancer drug entity. 
Table 3: Summary of the screening data of complex [M28H18N8CuSn2CI6j for the in vitro antitumor activity f in pglml). 
Human Tissue of origin Kidney Breast Cervix Lung Colon Lung Colon Kidney Pancreatic 
Cell line 786-0 Zr-75-I SiHa Hop62 HCTI5 A549 SW620 A498 MIAPACA2 
[C28H1N8CuSn2Cl6] <10 <I0 <10 <10 Glso 
 
<10 <10 <10 <10 <10 
ADR <10 <ID <10 <10 <10 <10 <10 <10 <10 
[C13H28fi4CuSn2CI6] 35.4 <ID 14.4 <10 26.6 21,9 <10 11.4 35.7 TGI 
ADR 26,5 <10 14,9 10.1 37.0 42.1 17.0 13,9 20,4 
[C 	2BNsCuSn2Cl6] 79.1 18.7 51.1 24,7 64.5 45.8 32,8 35.0 83.6 LCD 
ADR 55.9 22.2 32.6 31.0 66.9 77.8 34.3 35,3 46.8 
Where: 
• G130 = Growth inhibition of 50 % (Glso) calculated from [(Ti—Tay(C—Tz)] x I00 = 50, drug concentration result in a 50% 
reduction in the net protein increase, 
s ADR = Adriamycin (taken as positive control compound). 
• TGI = Tumor growth inhibition 
• LCsp= Lethal concentration of 50 % (LCso) 
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Conclusion 
The new heterobimetallic Cuu—Snz v/Niu—Sn2w complexes [C28H28N8CuSn2CK] and 
[C28H28N3NiSn2C16] were synthesized and characterized by spectroscopic (IR, UV—vis, 
NMR, ESI—MS) and analytical methods. The in vitro DNA binding profile of 
[C28H28N$CuSn2Cl5] and [C2sH28NBNiSn2C16] was studied employing spectroscopic 
titrations viz. UV—vis and fluorescence in accordance with molecular docking techniques 
which reveal strong electrostatic binding mode via phosphate backbone of DNA helix, in 
addition to partial intercalation in the minor groove having G—C rich sequences. Complex 
[C25H2gNgCuSn2CI6] exhibited higher binding ability as compared to [C2SH2gNgNiSn2ClA] 
which was attributed to the selective recognition of Cu(II) ion to guanine base of the 
DNA double helix. The complex [C28H2sN5CuSn2Cl6I shows efficient cleavage activity, 
particularly generating double strand breaks via oxidative pathway involving singlet 
oxygen or singlet oxygen—like entity as reactive oxygen species. Among the exceptional 
biological properties, notably important Topo-1 inhibition assay suggested that 
[C2gH28N8CuSnCl6] was catalytic inhibitor (or poison) of human Topo-1 at a low 
concentration of 20 1sM. This was further corroborated by in vitro cytotoxicity results 
against nine different human cancer cell lines with ((1150 value < 10 µg/ml), indicating 
that these complexes are very promising candidates as antitumor agents. 
CHAPTER IV 
Synthesis of glycosylated heterobimetallic complexes: In vitro 
DNA binding, cleavage, cell imaging and anticancer activity 
against human cancer cell lines 
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Synthesis 
Synthesis of N,N'—di---D—glueopyranosyl ethylenediamine 
The ligand [C14H28N2010] was synthesized by the slight modification of procedure 
described earlier by E. Mitts and R. M. Hixon [220]. To the methanolic solution of 
ethylenediamine 3.5 g (0.06 mol) was added D—glucose 21 g (0.12 mol). This mixture 
was refluxed gently on a water—bath until the glucose was completely dissolved. After 
two hours, the refluxing was discontinued, the flask cooled and left in the refrigerator 
overnight. The compound obtained was isolated as a white precipitate, washed with cold 
methanol and dried in vacuo. Yield = 78%. M.P. = 152-154 °C (dec). Anal.Calcd for 
C14H28N2010 (L): C, 43.75; H, 7.34; N, 7.29. Found: C, 43.79; H, 7.11; N, 7.01. IR (KBr) 
(v,,, /cm ' ): 3442 v(O—H, broad); 3336 v(N—H); 1640 8(N H), 1467 S(O(1H, CH2i CCH); 
1077 v(CO, CC); Uv—vis. (1 x 10-3 M, H2O, nm) 233. 1H NMR (400MHz, DMSO, 8): 
4.70-4.69 (NH(en)); 3.93-3.53 (OH of D—glucose); 3.40-231 (CH2(en), CH of D— 
glucose). 13C NMR (100 MHz, DMSO, 5): 93.44 (C1), 60.66 (CA), 76.90 (C3), 74.06 (C4), 
75.87 (C5), 69.64 (C6) (6C, Glc); 42.46 (2C, amine) ESI—MS: (m/z, 1120): 385.3 
[C14H2sN20joj~ . 
Synthesis of (C22H.2N6O11CuSnC121 
A suspension of N,N'—di—[?^D—glucopyranosyl ethylenediamine (L) (0.384 g, I mmol) in 
30 ml methanol was added CuCl2.2H20 (0.171 g, I mmol), the solution was refluxed 
with continuous stirring for ca. 2 h at 70 °C until the homogenous green colored solution 
appeared. To this in situ generated copper complex, dichlobis(imidazole)dimethyltin(IV) 
(0.352 g, I mmol) in 10 ml methanol was added slowly and was kept on stirring for 24 h 
at room temperature. The solvent was further removed by rotary evaporator to give a dark 
84 
green colored solid product, which was filtered, washed with methanol, and dried in 
vacuo. Yield= 53%. M.P. = 224°C (dec). Anal.Calcd for C22H4kN6O11CuSnCl2: C, 32.23; 
H, 5.16; N, 10.25. Found: C, 32.21; H, 5.15; N, 10.21. IR(KBr) (vm jcm '): 3428 v(O-H, 
broad); 3298 v(N-H); 1613 5(N-H, HOH); 1573 v(C=N); 1419 S(OCH, CHy CCH); 
1038 v(CO, CC); 1319 v(C-N); 531 v(Sn-N); 475 v(Cu-N); Molar Conductance, AM 
(1.10-3 M, H2O): 19.0 tT'cmz mo1-' (non-electrolyte); Uv-vis. (I x i(r M, HZO, nm) 
236, 259, 653. ESI-MS: (m/z, MeOH): 822.7 [C22H42N60nCuSnC12+3H]'. 
Synthesis of [C22H42N601,N1SnC12] 
This complex was prepared by similar method as for [C22H42N6OiiCuSnCl2] with 
NiC12.6H20 (0.237 g, I mmol). A dark brown colored solid product formed was washed 
with methanol and dried in vacuo. Yield= 48%. M.P. = 215 °C (dec). Anal.Calcd for 
CuH42N6O1 i NiSnC12: C, 32.43; H, 5.19; N, 10.31. Found: C, 32.42; H, 5.13; N, 10.35. [R 
(KBr) (v, /cm ' ): 3428 v(O-H, broad); 3325 v(N-H); 1638 S(N-H, HOH), 1543 
v(C=N); 1456 S(OCH, CHZ, CCH); 1071 v(CO, CC); 1329 v(C-N); 575 v(Sn-N); 452 
v(Ni-N); Molar Conductance, AM (1.10-3 M, H20): 23.0 SU'cm2 mol-' (non-electrolyte); 
Uv-vis. (1 x 10-3 M, H2O, nm) 235, 271, 623. 'H NMR (400 MHz, D20, S): 7.35-7.21 
(CH Imidazole); 3.11-4.72 (skeleton protons of D-glucose and (CH2(en)). 13C NMR (100 
MHz, D20, S): 144.04, 135.70, 121.61 (ArC, Imidazole); 89.94 (C1 ), 60.56 (CA), 76.69 
(C3), 74.15 (C4), 75.79 (C5), 69.95 (C6) (6C, Glc); 44.90 (2C, amine). 19SnNMR (149.19 
MHz, D20, 5): -301.23. ESI-MS: (m/z, MeOH): 817.0 [C22H54N60j7NiSnC12+3H]+. 
Results and discussion 
The 	glycoconjugate heterobimetallic entities [C22H42N601iCuSnC(2] 	and 
[CnHa2N6O1 ,NiSnC12] were 	synthesized by reacting 	dichlorobis(imidazole) 
dimethyltin(IV) (A) [221J with corresponding 1:1 metal complex of N,N'-di-[3-D-
glucopyranosyl ethylenediamine N-glycoside ligand [C14H28N20,o], derived from 
ethylenediamine and .-D-glucose (scheme II). The compositions of the complexes were 
confirmed by elemental analysis and spectral data. On the basis of spectral studies, the 
coordination geometry of the central metal ion (Cu". Nill) was found to be square 
pyramidal while the SnIV atom was present in hexacoordinated environment. Both the 
complexes [C22H42N6O„CuSnCl2] and [C~H42N6OiiNiSnCl2] were highly hygroscopic 
in nature and soluble in H2O and DMSO. The growth of single crystals of these 
complexes for X-ray studies was very difficult, however, XRPD measurements 
confirmed the crystalline nature of the complexes. The molar conductance (AM) value at 
25 °C suggests their non-electrolyte nature (19-23 LT'cm2 mol-' ). 
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IR spectroscopy 
The IR spectrum of ligand [C,4H28N20101 displayed a characteristic band in the range 
3500-3200 cm-1  assignable to v(O-H) stretching vibration of free saccharides. However, 
complexes [C22H42N6OijCuSnCl2] and [CnH42N6O 1NiSnClz] exhibited merged and 
broadened band at 3444 cm-' as compared to intense band of free saccharide moieties, 
due to overlapping with the -OH stretching vibration band of the coordinated H2O 
molecule [222]. The absorption bands observed in the range of 3325-3298 cm 1 was 
attributed to v(N-H) stretching vibration of the coordinated secondary amino functions of 
the complexes [223]. Other medium intensity bands observed at 1638-1613 cm`' were 
attributed to S(N-H) vibration of the glycosidic ligand [224]. The strong characteristic IR 
bands at 1456-1419, 1071-1038, and 892-860 cm-1  were attributed to S(OCH, CH2, 
CCH), v(CO, CC) and S(CCH, CH), as well as v(CC, CO) vibrations, respectively, 
indicating the presence of metal-saccharide adducts. Strong coupling between the bands 
resulted in merging and broadening in the spectra and complicated the assignment of 
these to individual vibrational modes [225]. Additionally, the signals at 1573-1543 cm 
were assigned to v(C=N) vibration of the imidazole ring [226]. The coordination of metal 
ion was further supported by the appearance of new medium intensity bands at 475, 452 
and 575-531 cm' assigned to v(Cu-N), v(Ni-N) and v(Sn-N) stretching vibration, 
respectively. 
NMR spectroscopy 
The 'H and 13C spectra of ligand [C14H2sN2O10] was recorded in DMSO-d6 solution 
exhibited signal at 4.70-4.69 ppm attributed to C, and glycosylic -NH proton, indicating 
the glycosylation process followed by the condensation between the two glucose rings 
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and amino protons of linker ethylenediamine at Ci centre [227]. The signals at 3.53-3.93 
ppm were assigned to C2, C3, C4, C6hydroxyl protons [228]. The signals at 2.91-2.85 and 
2.71-2.78 ppm were attributed to -CH2 proton of linker ethylenediamine at C-1, together 
with other distinct sugar proton resonances at 3.40-3.32 ppm (Co proton), 3.28-3.24 ppm 
(C3 and Cs proton), 3.08-3.13 ppm (C2 and C4 proton) [229]. However, 'H and 13C NMR 
spectra of the complex [CaH42N0O1 1NiSnCl2] was recorded in D20 and the assignments 
was made by relative comparison with those of free ligand. The 'H NMR spectra of 
complex [C22H42N60nNiSnCl2] revealed a series of multiplets in the range of 3.11-4.72 
ppm were attributed to the strongly coupled skeletal proton signals of saccharides moiety, 
and CH2 protons of linker ethylenediamine. Due to these factors, the assignment of the 
individual resonances was could not be resolved. The aromatic protons of the imidazole 
ring were observed at 7.21-7.35 ppm. Additionally, the sharp signal at 0.77 ppm 
corresponded to methyl proton bound to tin atom. 
The 13C NMR spectra of the [C 4H28N2010] and the complex [CuN42N6Q1,NiSnCl2] 
corroborated well with the proposed structures. In the 13C NMR spectrum of 
[Ci4H28N20,o], the sharp signals at 42.46 ppm attributed to the two Cratoms of the 
ethylenediamine (en)-based linker, together with six distinct carbon atoms of the D-
glucose resonances at 93.44 (C j), 60.66 (C2), 76.90 (C3), 74.06 (C4), 75.87 (C5), and 69. 
64 (C6). However, significant changes were observed in the spectrum of complex 
[C221-142N60,,NiSnCl2] for the aromatic carbons of imidazole which appeared in the 
range 144.04-121.61 ppm, and the two methyl groups attached to tin atom displayed 
chemical shift signal at 9.11 and 9.15 ppm [230, 231]. The ~ 19Sn NMR spectrum recorded 
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a sharp single peak at —301.23 ppm, which was quite in agreement with the hexa-
coordinated environment of diorganotin (IV) metal ion (Figure. 55) [232]. 
(a) 
(b) 
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(c) 
Figure 55. (a) 'H, (b) '3C and (c) "9Sn N.M.R. spectrum of heterobimetallic complex 
(C' 2H42N6O>>NiSnC'I2J. 
EPR spectrum 
The X—band EPR spectra of complex [C22H42N6O11CuSnCl2] (Figure. 56a and b) were 
recorded at room temperature in solid state and at liquid nitrogen temperature (LNT) in 
aqueous solution using TCNE as a field marker (g = 2.00277). 
Figure 56. X—hand EPR .spectrum of complex fC'21H42N601 ,CuSnC12/ at (a) LNT (in 
liquid state) and (b) RT (in solid .state). 
The spectrum shows an isotropic pattern and exhibits axial symmetrical line shape with 
g1 =2.l25 and g1  = 2.082 and g;,,, = 2.09 computed from the formula g15,, = (gig +2g )/3, 
consistent with square pyramidal geometry [2331. The trend g11> g1> 2.0023 revealed 
that the unpaired electron is present in the dxz_/Z  orbital [234]. For a Cu(II) complex, gii  is 
a parameter sensitive enough to indicate covalence. For a covalent complex, g11 is < 2.3 
and for an ionic environment, g = 2.3 or more. In the present complex gp < 2.3 indicates 
an appreciable metal—ligand covalent character [235]. 
UV—Vis spectra 
The electronic spectrum of ligand [C14H28N20,o] shows a sharp hump at 233 nm in UV 
region exhibiting n—n" transition. However, the UV—vis spectrum of complex 
[C22Ha2N6O,iCuSnCl2] revealed a broad band in the lower frequency region centered at 
653 nm attributed to dxz, dyz—+dx2—y2 ligand field transition suggesting a square 
pyramidal geometry around Cu(II) ion [236]. The electronic spectrum of complex 
[C22H42N6O11NiSnCl2) displayed, spin allowed transition at 623 nm assigned to 
3E(F) transition suggesting a pentacoordinate geometry around Ni(II) metal ion [237]. 
Additionally, electronic spectra of both complexes [C22H42N6011CuSnC12] and 
[CnH42N6O, iNiSnC12] exhibit an intense absorption bands at 268-271 nm followed by a 
shoulder at 285 nm attributed to the intraligand n—n' transition and the ligand to metal 
charge transfer (LMCT) band. 
X—ray diffraction analysis 
X—ray diffraction was performed to obtain further evidence about structure of the metal 
complexes. The diffractograms obtained for the metal complexes {C221-L*2N6OiiCuSnCl2] 
and [C22H42N601INiSnCl2], indicating the crystalline nature of complexes (Figure. 57a 
and b). 
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Figure 57. The XRD pattern of (a) [C22H42N601;CuSnC12] and (b) [C22H42N6Ot1NiSnC12J 
showing crystalline nature of the complexes. 
DNA binding studies 
Absorption titration with CT DNA 
Electronic absorption spectroscopy was employed to ascertain the binding modes of 
ligand [C14H28N2Qj0], complexes [CnHa2N6O1iCuSnCl2] and [CuH42N6OiiNiSnCl2] 
with DNA followed by the changes in the absorbance and shift in the wavelength. In the 
UV region, the intense absorption bands at 233-271 nm were observed in the spectra of 
the [Cl4H2gN2Oio], [CnH42N6O11CuSnCl2] and [C22H42N6O11NiSnCl2] attributed to the 
intraligand n—n* transition. Binding of the complexes to DNA is expected to perturb the 
ligand centered transitions of complexes. Upon addition of increasing amounts of CT 
DNA (0-33.3 x l0~ M) to [C14H28N2010], [C22H42N6OijCuSnCl2] and 
[C2A2N6O11 NiSnCl2J of fixed concentration (6.67 x 10-6 M), resulted in hyperchromism 
of 26, 38 and 33%, respectively with no band shift (Figure. 58a—c). Hyperchromism was 
attributed to the presence of synergic non-covalent interactions: external contact 
(electrostatic binding), hydrogen bonding and groove surface binding (major or minor) 
along outside of DNA helix [238]. Since the observed hyperchromic effect revealed no 
band shift (bathochromic or hyposochromic shift), it can be inferred that 
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[C,4H28N20,0], [C22H42NhO,,CuSnCl2] and [C22H42N6O„NiSnCl2] exhibit groove 
binding interactions. 
In order to quantify the binding affinity of [C14H28N20,o], [C22H42N60,,CuSnCl2] and 
[C22H42N60i,NiSnCl2] with CT DNA, the intrinsic binding constant, Kb were calculated 
from Wolfe—Shimer Eq. (2) and were found to be 2.98 x 103, 9.41 x 104 and 6.28 x 104 
M-', respectively, indicated that [C22H42N60,,CuSnCl2] has higher binding affinity as 
compared to [C,4H28N20,0] and [C22H42N60,,NiSnCl2] due to the dual mode of action of 
Cu" and Sn1v metal ion (both hard Lewis acid); Cu showing preference for N7 position of 
guanine while Sn'v prefer to binds to the vicinal anionic phosphate oxygen of DNA helix 
[239]. 
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Figure 58. Absorption spectral traces of (a) Ligand [C14H28N2O10J (b) complex 
[C22H42N6O11CuSnC12] and (c) complex [C2I142N6O1 ,NiSnCl2] in 5 %DMSO/ 5mM Tris 
11(7/50 mM NaCl buffer at pH 7.2 upon addition of CT DNA. Inset: Plots of [DNA/I &-
Ef (m cm) is [DNA] for the titration of CT DNA with complexes ■. experimental data 
points; full lines, linear fitting of the data. [Complex] 6.67 x l0 M, [DNA/ 0-33.3 x I (T6 
M. 
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Additionally, a heterocyclic imidazole ring in [C22H42N6OI1CuSnCl2] and 
[C22I-l42NoOjjNiSnCl2] bound to Snw atoms could contribute to partial intercalation. 
Moreover, complexes bearing —NH— and -0H— groups or the ligand—N atom may be 
involved in the secondary interactions like hydrogen bonding with DNA possessing 
several hydrogen bonding sites accessible both in major and minor grooves [240]. The 
ligand framework possessing carbohydrate functionality plays a crucial role in molecular 
recognition in many anticancer drugs, as it binds to DNA in a sequence selective manner. 
Therefore, carbohydrate conjugate scaffold in complex drives it to attain electrostatic 
interactions with negatively charged sugar phosphate backbone of DNA. Similar effect of 
carbohydrate residues have been studied under calicheamicin y1i antibiotic, which 
belongs to a class of compound called enediyne antibiotics [2411. 
Etliidium bromide displacement assay 
To further investigate the mode of binding of the ligand [C14H28N20 o], complexes 
[CuI-I42N6Oi1CuSnCl2] and [C22H42N601NiSnCl2] with DNA, the ethidium bromide 
displacement assay was carried out. The extent of quenching of the fluorescence of EB 
bound to DNA would reflect the extent of DNA binding of complexes. EB (3,8—diamino-
5—ethyl--6--phenylphenanthrium bromide), a phenanthridine fluorescence dye, a typical 
indicator of intercalation form soluble complexes with nucleic acids and emits intense 
fluorescence when intercalated into the base pairs of DNA. The addition of a second 
DNA—binding molecule can quench the DNA—EB adduct emission by either replacing 
the EB and/or by accepting the excited—state electron of the EB through a photoelectron 
transfer mechanism [242]. Upon addition of [Cl4H28N2010], [CnH42N5O11CuSnCl2] and 
[C22H42N6Q11NiSnCl2], to CT DNA pretreated with EB ([DNA]/[EB]=1) solution caused 
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appreciable reduction in emission intensities (Figure. 59a—c), indicating that the 
replacement of the EB fluorophore by the [C14112 N2O1o], [C22H42N6O11CuSnC12] and 
[C22H42N60„NiSnCl2], which results in a decrease of the binding constant of ethidium 
bromide to DNA. 
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Figure 59. Emission spectra of EB bound to DNA in the ah.sence and presence of (a) 
Ligand [C141-128N2O10J (h) complex IC22H42NoO,,C'uSnCl2J and (c) complex 
fC2 N47N6O,,NiSnCl'J in 5 mM Tris-11C'1/50 mM NaCl buffer. Arrows show the intensity 
changes upon increasing concentration of the complexes. Inset: Plots of &1 vs [complex 
]/(DNA]. (U) experimental data points; full lines, linear fitting of the data. 
The quenching efficiency for [C14H28N2010], [C22H42N60„CuSnCl2] and 
[C22H42N601 j NiSnCl2] is evaluated by the classical Stern—Volmer constant KS,,, which 
varies with the experimental conditions. The Ks,, values for [C14H28N2Oio], 
[C22FL2 N6O1 CuSnCl2] and [C22H42N6011 NiSnCl2] was found to be 0.67, 1.92 and 0.94, 
respectively. The highest K5,, value of [C22H42N6O11CuSnCl2] suggesting its stronger 
ability to displace EB from the EB—DNA system as compared to [C14H28N2O10 and 
[C22H.a2N6O11 NiSnCl2]. 
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DNA cleavage activity 
The DNA cleavage ability of complex [C22H42N6O1 1CuSnCl2] was studied by agarose gel 
electrophoresis using supercoiled pBR322 plasmid DNA as a substrate in a medium of 5mM 
Tris—HCI/50 mM NaCI buffer, at pH 7.2. The activity of complex [C22H42N601 jCuSnCl2] 
was assessed by the conversion of DNA from Form I (supercoiled form) to Form II (nicked 
circular) and then to Form Ill (linear form). With increase in concentration of complex 
[C22H42N6O11CuSnCl2], the amount of Form I gradually diminishes whereas Form 11 
increases (Lane 2-6), suggesting the single strand DNA cleavage. At 30 pM concentration, 
complex [C22H42N6011CuSnCl2] exhibited efficient nuclease activity and there was complete 
conversion of Form I into Form 11 without concurrent formation of Form III (Figure. 60a). 
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Figure 60. Agarose gel electrophoresis diagram showing cleavage of pBR322 
supercoiled DNA (300 rig) by complex [C22H42N601 ,CuSnCl2J at 310 K after 45 min of 
incubation; Lane 1, DNA control, Lane 2, 10 pM of [C22H42N60;,CuSnC12]+DNA; Lane 
3: 15 pM of [C22H4 N60 j 1CuSnClz j + DNA; Lane 4: 20 pM of [C22H42N6O1 ,CuSnCl2J + 
DNA; Lane 5: 25 pM of [C22H4eN6011CuSnCl2J+DNA: Lane 6: 30 pM of 
[C22H41N601ICuSnCl2J+DNA; (b) in presence of different activating agents; Lane 1: 
DNA Control; Lane 2: 9 pM of [C22H42N60,1CuSnCl2]+H202 (0.4 Al) +DNA; Lane 3: 9 
pM of [C12H42N6O11CuSnC12J+MPA (0.4 M)+DNA; Lane 4: 9 pM of 
[C22H42N6O j  jCuSnCI;J+GSH (0.4 M) + DNA; Lane 5: 9 pM of [ 2 H42N ()gCuSnC''lJ + 
Asc (0.4 M) + DNA; Lane 6: 9 pM of [C22H42N601rCuSnC!21 + DMS0 (0.4 M)+DNA; 
Lane 7: 9 pM of [C22H42N60,KuSnCl2/+tert—butyl alcohol (0.4 M)+DNA; Lane 8: 9 pM 
of [C22H42N6Oi1CuSnCl2/+sodium azide (0.4 M +DNA Lane 9: 9 pM of 
[C22H42N6O,,CuSnC1gg SOD (15 units)+DNA. 
Many copper complexes have been proven to cleave DNA more efficiently in the 
presence of exogenous agents viz; H202, ascorbate (Asc), 3—mercaptopropionic acid 
(MPA) and glutathione (GSH). The cleavage activity of [C221-2No0i,CuSnCl2] was 
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significantly enhanced by these activators which follows the order 
MPA SH>Asc>H202 (Figure. 60b). Thus, complex [C22H42N60nCuSnCl2] exhibited a 
significant DNA cleavage activity in the presence of 3—mercaptopropionic acid which 
could be correlated to other previous studies on bis(o—phenanthroline) copper(II) 
complexes [243]. 
Mechanistic investigations were done using various additives to understand the nature of 
reactive oxygen species (ROS) such as hydroxyl radical scavengers (DMSO, EtOH), 
singlet oxygen scavenger (NaN3) and a superoxide scavenger (SOD) involved in the 
DNA cleavage reactions (Figure. 60b). The experiment results showed that the DNA 
breakdown mediated by [C22H42N601 CuSnCl2] was clearly inhibited in the presence of 
DMSO and ter—butyl alcohol (Lane 5 and 6), indicating that the freely diffusible 
hydroxyl radical is one of the reactive species involved in the DNA strand scission. On 
the other hand, addition of NaN3 and SOD did not show significant quenching of the 
cleavage revealing that singlet oxygen and superoxide anion were not involved in the 
cleavage process (Lane 8 and 9). Since, the complex [CnH42N601 iCuSnCl2] was able to 
cleave DNA in the absence of any reducing agent, which implies that DNA might be 
cleaved by a discernible hydrolytic pathway. Hydrolytic pathways usually depend on the 
Lewis acidity of the central metal ion, which serves to activate the phospho-diester bonds 
towards nucleophilic attack via charge neutralization. Also the presence of aqua ligands 
in the complex provide an inbuilt nucleophile in the complex, which attack the 
phosphorus atom thereby leading to direct hydrolysis of the diester bonds [244]. The 
coordinated water molecule of complex [C22H42N601CuSnCl2 facilitates the 
nucleophilic attack of water oxygen to phosphorus, followed by a five—coordinate 
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intermediate and subsequent rearrangement of the phosphate allows the DNA to be 
cleaved readily. 
The potential interacting site of [C22H42N6O11CuSnCl21 with pBR322 DNA was further 
explored in presence of the minor groove binding agent, DAPI and the major groove 
binding agent, methyl green. The supercoiled DNA was treated with DAPI or methyl 
green prior to the addition of [C22H42N6O11CuSnCl2]. The DNA cleavage patterns 
demonstrated that the activity of [C221-I42N6O1 CuSnCl2J was inhibited in presence of 
DAPI while it remains unaffected in the presence of methyl green indicating minor 
groove-binding propensity of the complex [C22H42NFO> > CuSnCl,] (Figure. 61). 
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Figure 61. Agarose gel electrophoresis pattern for the cleavage of pBR322 supercoiled 
DNA (300 ng) by complex [C, H42N6O11CuSnc!2) in presence of DNA minor binding 
agent DAP! and major binding agent methyl green at 310 K after incubation for 45 min. 
Lane 1: DNA control; Lane 2: 9 uM of [C22H42N60!Cu.Sm12J+DNA+DAP! (8 NM); 
Lane 3: 9 NM of [C22H4 N601,CuSnCl2J+DNA+methyl green (2.5 pL of a 0.01 mg/ml 
.solution). 
T4 DNA ligation experiment 
Direct evidence for a hydrolytic mechanism was carried out from ligation experiments of 
the linear DNA cleavage products generated by complex [C22H42N6O11 CuSnCl2] in which 
supercoiled pBR322 DNA was treated with T4 ligase enzyme and subjected to gel 
electrophoresis. It is well known that in DNA hydrolytic cleavage 3'-0H and 5'-OP03 
(5'-OH and 3'-OP03) fragments remain intact and that these fragments can be 
enzymatically ligated and end-labeled. In some cases, the hydrolytic products either did 
not end at the required 5'-phosphate and 3'-OH (ribose) termini or the complex 
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sometimes bound to the termini of cleaved DNA [245]. Complex [C221-I42N6O1 1CuSnCl2] 
yielded linearized DNA which was religated by using T4 ligase enzyme (Figure. 62). In 
our case, DNA religation was complete and after ligation there was complete repair 
which was quantitatively ascertained by comparison of complex treated DNA and with 
the control DNA alone in supercoiled form. Hence, this result implied that the process of 
DNA cleavage by [C22H42N6O11 CuSnCl2] occurs via a hydrolytic pathway. Complex 
[C22H42N6O11 CuSnCl2] could therefore, be useful not only in drug design but also in 
elucidating the precise role of metal ions in enzyme catalysis [246]. 
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--+ Form I 
3 1 	_'  
Figure 62. Agarose gel electrophoresis pattern for the ligation pBR322 plasmid DNA 
linearized by complex [C22H42N6011C.'uSnCl2j: Lane 1: DNA control; Lane 2: pBR322 
plasmid DNA cleaved by [C22H42N60«CuSnC12]; Lane 3: ligation of linearized pBR322 
plasm id DNA by 74 DNA ligase. 
Topo-I inhibition assay 
A plasmid DNA cleavage assay was used to investigate the effect of complex 
[C22H42N6Oi jCuSnCl2] on the inhibitory activity of human-Topo-1 by agarose gel 
electrophoresis. "I'his assay provides a direct means of determining whether the drug 
affects the unwinding of a supercoiled (SC) duplex DNA to nicked open circular (NOC) 
and relaxed (R) DNA. When catalytic activity of topoisomerase I was assayed, complex 
[C22H42N6011CuSnCl2] inhibited this process in a concentration-dependent manner 
[247]. With increasing the concentration of complex [C2:H42N6011CuSnCl2] (5-20 µM), 
the levels of relaxed form were inhibited (Lane 3-6). At 20 µM, the DNA relaxation 
effect caused by Topo-1 was significantly inhibited by complex [C22H42N6O11CuSnCl2] 
(Figure. 63). These observations suggest that complex [C221-I42N6O„CuSnC12] inhibited 
topoisomerase I catalytic activity due to the relatively strong DNA binding affinity of 
complex [C22H42N6O11CuSnCl2], which prevents the enzyme from efficiently binding to 
the DNA and exercising its function. Thus, the metal—based drug entity can exert its 
antitumor activity via topoisomerase inhibition as it was found that cancerous cell 
showed significantly increased intracellular levels of topoisomerase, which is required for 
rapid and unchecked proliferation of cancer cells [248]. 
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Figure 63.7he cleavage patterns of the agarose gel electrophoresis diagram showing 
effect of different concentration of complex [C12H42N60,,CuSnC11J on the activity of 
DNA topoisomerase 1(Topo--1); Lane 1, DNA control: Lane 2: Topo-1+DNA; Lane 3: 5 
pM of [C22H42N64«CuSnC121 f DNA + T opo-1: Lane 4: 10 jiM of [C'_ 2H42N6011CuSnCl2J 
+DNA+Topo-1; Lane 5: 151iM of lC22H42NbUUC.'uSnCl2J + DNA +Topo-1; Lane 6: 20 
NM of [C 2H42N6O11CuSn('12J+DNA + Topo-1. 
Cellular uptake 
The cellular uptake of metal—based anticancer drugs is of importance for its effectiveness 
against tumors and their antiproliferative efficacies. Literature revealed that in vitro and 
in vivo monitoring of glucose utilization in rapidly growing cancer cells has attracted 
much attention due to over—expression of glucose transporters (GLUTs), particularly 
GLUT—l. in rapidly growing HeLa cells which catabolize glucose at high rates and 
entering the cells through a GLUT—mediated glucose—uptake pathway [249]. 
In order to assess the intracellular localization of complex [C22H42N60„CuSnCl2] inside 
the human cervical carcinoma (HeLa) cells, confocal microscopic experiment was 
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conducted. The emission for JC24 kN6Oi1CuSnCl2J was observed at 561 nm, while the 
DNA stain was observed at 740 nm_ The untreated HeLa cells showed negligible 
background fluorescence at the 510 nm emission wavelength (no auto fluorescence 
emanates from unstained cells: cell without staining). 
Complex 1 	DAPI 	Merged 
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Figure 64. C'onfcw•al microscopic visualization of cellular uptake and localization of 
complex /C'22N42NoOgC'uSnC12J in HeLa cells. (a) ('ells incubated solely for 4 h with 
complex /('221142N60,1CuSnCl2/ (20 pM) at 3' °C showed the efficient cellular uptake in 
the cytoplasm and nearby nucleus region [reel . fluorescence]. (h) DNiI was 
counterstained blue with 1)APl (blue fluorescence]. (c) (h'erlaid image of complex 
f( '2 l!42N6O, ,('uSn('12]  and DAPI. 
However, after incubation of Hel.a cells with the [C22H42N601 1 CuSnCI7J at 37 °C under a 
5% CO, atmosphere for 4 h resulted in efficient cellular uptake. The weak red 
fluorescence in the cytoplasm with no specific localization revealed that 
[C2;H42N6O, i CuSnC12] was taken by any cytoplasmic organelle and thus suggesting very 
little accumulation of [C2~H42N6O1 1CuSnCl2y in the cytoplasm (Figure 64a). I lowever, 
intense luminescence was observed in the nuclear region indicating the nuclear 
localization of the [CH42N6O„CuSnCl,f in HeLa cells. To confirm its nuclear 
localization, the cell was subjected to staining for which the cell treated with 
I('22HkN,,O u u CuSnCl,I was thoroughly washed, stained with a blue nuclear dye, DAN 
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(4',6-diamidino-2—phenylindole), a DNA selective fluorescent probe and after fixation 
[250], the images were recorded (Figure. 64b). The superimposed images (Figure. 64c), 
clearly indicated that the [C22H42N6O11CuSnCl2I was localized in DNA—containing areas. 
Molecular docking with DNA 
To study the molecular basis of interaction mode and affinity of binding, ligand 
[C1aH28Nz0i0], complexes [C1H42N60i,CuSnClz] and [C22H42N6O11NiSnCl2] were 
docked into DNA duplex of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: 
I BNA). Targeting the minor groove of DNA through binding to a small molecule has 
long been considered as an important tool in molecular recognition of specific DNA—
sequence. The resulting docked pose (Figure. 65), revealed that the [C14H28N20j0] 
strongly binds to the narrow minor groove region of DNA within G—C rich region and 
lead to van der Waals interactions and hydrophobic contacts with DNA functional groups 
that define the groove. Moreover, —NH and —OH groups of the ligand [C14H25N2010] may 
be engaging in hydrogen—bonding interactions with DNA nucleobases available in the 
minor grooves [251]. Additionally, [C22N42N6O11CuSnCl2] and [C22F4ZN6O1 iNiSnCl2] 
(Fig. 5b and c) exhibited more effective a—a stacking interactions between imidazole 
rings and DNA base pairs. The resulting relative binding energy of docked 
[C14-128N2010], complexes [C22H42N601 iCuSnClz] and [C221-L42N6O1jNiSnC12] with DNA 
were found to be —204.6, —258.6 and —248.9 eV respectively, follows the order 
[C22Hg2N6O1 CuSnC12]>[C22H42N6Oi1NiSnCl2]>[C14H28N2010] which is also in 
accordance with our hypothesis that [C221-142N6011CuSnCl2] is more prominent DNA 
binder than [C22N42N60uNiSnCl2] and free ligand [C,4H23N2010]. Thus, we can conclude 
that there is a mutual complement between spectroscopic techniques and molecular 
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docked model, which can substantiate our experimental results and provide valuable 
information about the mode of interaction between complex and DNA. 
4 
(a) 	 (I►) 	 (c) 
Figure 65. Molecular docked model of (a) Ligand [C,4H20201,J (b) complex 
[C221142N1UiiCu.Sn(:12] and (C) complex [C'221142N60,,NiSn('I2J with DNA [dodecumer 
duplex of sequence d(('(;( 'GM TT( '(;('G) (PDB ID: IBNA)J 
Molecular docking with human-1)NA-Topo-I 
To further validate the observed -I'opo--I inhibitory assay, complex 
IC 21142N6011CuSnClfl was successively docked with the human-DNA-Topo-1 complex 
(PD13 ID: I SC7) to search the exact binding site. The X--ray crystallographic structure of 
the human-1)NA-Topo-1 complex (PDB ID: ISC7) from Protein Data Bank was 
uploaded in which Topo-1 is bound to the oligonucleotide sequence 5'- 
AAAAAGACITsX-( AAAM Iii T-3'.  where 's' is 5'-bridging phosphorothiolate of 
the cleaved strand and 'X' represents any of the ihur bases A. G, C or T. The 
phosphoester bond of G 12 in I SC7 was rebuilt and SI I of G I I on the scissile strand was 
changed to 01112521. 
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Figure 66. Diagram showing in (a) human—DNA—Toles--1(70 kDa) (PDB 11): 1 S(:'7) (h) 
molecular docked model of complex 1C22N4 2N6O,1CuSnCl2J in the cleavage active site of 
human DNA lopoisomerase I (PDB ID: LSC7). 
The resulting docking model (Figure. 66) revealed that the heterocyclic imidazole rings 
of IC22l 142N,Oi iCuSnClj approaching towards the DNA cleavage site in the Topo—I-
DNA complex and forming a stable complex through it—it stacking interactions between 
the GI 1 (f 1) and pyrimidine ring of '110 (—I) in the minor groove on the scissile strand 
and ('112 and A 113, on the non--scissile strand, parallel to the plane of base pairs, 
whereas the OH groups of sugar probably interacting through hydrogen bond to Arg 364, 
which is considered an essential amino acid that interacts with the ligand in the DNA-
Topo—I active site. On the other hand, the ethylenediamine group of 
[C22H42N6O,1 CuSnCl2] was involved in H—bond with the oxygen atom of Gil 
ribofuranose in the scissile strand, which could strongly block the religation process, 
subsequently leading to inhibitory effect on Topo—I [253, 254]. Furthermore, DNA 
intercalating forces was much more important than hydrogen bonding of the ligand to the 
surrounding amino acids residues of the protein, or to the base pairs [255]. Our molecular 
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docking study proved the importance of DNA intercalating ability of 
[C22H42N6O1iCuSnCl2] as well as 1+-bond with the enzyme in the cleavage site. This 
result suggests that blocking the religation of the Gil hydroxyl group could be the main 
design point for novel Topo-I inhibitors. 
Antitumor activity assays 
In vitro cytotoxic activity of complex [C22I-l42N6O11CuSnC12] has been evaluated in terms 
of GISo, TGI and LC50 (Table 4) values against nine different human carcinoma cell lines 
of different histological origin: 786-0, A498 (kidney), Zr-75-1 (Breast), SiHa (Cervix), 
A549, Hop-62 (Lung), SW620, HCT15 (Colon), MIAPACA2 (Pancreatic). The in vitro 
anti-tumor screening of [C22H42N6011CuSnCl2] was evaluated by employing 
microculture Sulforhodamine B test (SRB) [219]. The result showed high potential of the 
complex [C22H42N601,CuSnCl2] as drug candidate, as expected from the in vitro DNA 
binding studies and topoisomerase I inhibition assay. Surprisingly, complex 
[C221a2N6Q11CuSnCl2] exhibits promising antitumor activities (with G150 <10 ).tg/ml) on 
a panel of human carcinoma cell lines, indicating that its remarkable potential to act as 
efficacious metal-based anticancer drug. 
106 
Conclusion 
In this work, we have designed and synthesized new metal-based cancer 
chemotherapeutic glycoconjugate entities containing heterobimetallic core 
[C22H42N6011CuSnCl2] and [Cy2H42N6O11NiSnCl2] derived from N,N'-di-fi-D- 
glucopyranosyl ethylenediamine N-glycoside ligand [CI4H2RN2OIo]. The general 
hydrophilic nature of carbohydrate molecule and their high density of hydroxyl groups 
(hydrogen bond donors and acceptors) could increase the cellular uptake of the 
compounds as well as their facile transport at the molecular level. In vitro DNA binding 
studies revealed that complex [C22H42N6O11CuSnCl2] binds more strongly to CT DNA 
than [C22H42N601  NiSnCIz] and [C14H2gN2O10] via electrostatic groove binding mode, 
synergized by partial intercalation in G-C rich sequences. Complex 
[C221442N601 CuSnCl2] cleave pBR322 DNA double strand scission, which proceeds via 
hydrolytic pathway as further validated by T4 DNA ligase 	assay. Complex 
[C221i42N601 CuSnCl2] is also a notable Topo-1 inhibitor exhibiting remarkably high 
Topo-I inhibition activity at a very low concentration (20 µM). Furthermore, complex 
[C22H42N6OnCuSnCh] showed potent in vitro cytotoxicity (Glso value c 10 gg/ml) on a 
panel of selected human cancer cell lines; also confocal cell imaging studies using the 
HeLa cell line depicted localization in the cells of its nuclear localization. Thus, complex 
[C22H42N6OiiCuSnCl2] is an exceptional anticancer agent which involves Topo-I 
inhibition mechanism and at the same time can also be utilized as a biocompatible 
fluorescent probe. Furthermore, molecular docking studies were performed with 
molecular target DNA and the active site of Topo-I in order to validate the experimental 
results. 
CHAPTER V 
Molecular drug design and synthesis of heterobimetallic 
carbohydrate—conjugate: In vitro DNA binding, cleavage and 
cytotoxicity against human cancer cell lines 
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Synthesis 
Synthesis of N,N'-di-VD-glucopyranosyl ethylenediamine ([C14.H NZOto]) 
The ligand [C14H28N20101 was synthesized by the slight modification of procedure 
described earlier in the chapter IV. 
Synthesis of monometallic complexes [C22H52N6O13Cu] and [C22H60N6O17Ni] 
The monometallic complexes [C22H52N6O13Cu]  and [C221-looN6017Ni]  were prepared by 
following procedure. 
To a methanolic suspension (30 ml) of ligand [C14H28N2010] (0384 g, I mmol) was 
added CuC12.2H20 (0.171 g, 1 mmol) and allowed to reflux at 70 °C for 2 h until the 
homogenous green colored solution appeared. A solution of piperazine hexahydrate 
(0.388g, 2 mmol) in 10 ml methanol was added slowly to the reaction mixture, a 
fluorescent green colored precipitate formed was filtered and washed thoroughly with 
methanol and dried in vacuo. 
[C22H52N6O13Cu] [Yield: -61%]. M.P. 234 °C (dee), Anal.Calcd for 
C22H52N6O13Cu: C, 39.31; H, 7.80; N, 12.50. Found: C, 39.32; H, 7.81; N, 12.52. 
IR(KBr) (v../cm-1): 3386 v(O-F1, broad); 3342 v(N-H); 1649 8(N-H, HOH); 1542 
v(C=N); 1412 S(OCH, CH2, CCH); 1024 v(CO, CC); 1348 v(C-N); 534 v(Sn-N); 419 
v(Cu-N); Molar Conductance, AM (1.10-3 M, DMSO): 16.0 LT'cm2 mol-' (non-
electrolyte); Uv-vis. (I x 10-3 M, DMSO, nm) 244, 292, 590. ESI-MS: (m/z, DMSO): 
634.9 [C22H52N6O13Cu-2H20-211)]'. 
[C22H6oN6Oi,Ni] [Yield: 56%], M.P. 228 °C (dee), Anal.Calcd for 
CrI-kN6Oi7Ni: C, 35.73; H, 8.18; N, 11.37. Found: C, 35.52; H, 8.14; N, 11.32. IR 
(KBr) (v../cm-1 ): 3386 v(O-H, broad); 3299 v(N-H); 1627 5(N-H, HOH), 1574 (C=N); 
1Dl:] 
1503 6(OCH, CH2, CCH); 1071 v(CO, CC); 1321 v(C-N); 530 v(Sn-N); 439 v(Ni-N); 
Molar Conductance, AM (1.10-3 M, DMSO): 21.0 S2-'cm2 mol-' (non-electrolyte); Uv- 
vis. (1 x i0-3 M, DMSO, nm) 246, 295, 641. 'H NMR (400 MHz, DMSO-d6, 25° 8): 
4.82-4.79 (N-H(en)); 3.48-4.50 (CH2(en), H2O, CH2(ppz), skeleton protons of D- 
glucose). 13C NMR (100 MHz, DMSO-d6, 25° S): 90.02-60.50 (6C, (lic); 44.00-39.09 
(CH2 of amine and piperazine). ESI-MS: (m/z, DMSO): 631.1 [C22H60N6O17Ni-6H2O]`. 
Synthesis of heterobimetallic complexes [C22H50N6O13CUSnCl2] and 
[C22HHN6ODN1SnCl2] 
The heterobimetallic complexes [C22H50N6O13CuSnCl2J and [C22H58N60,7NiSnCl2] were 
prepared by refluxing methanolic solution of the monometallic complexes 
[CnH52N6O,3Cu] and [C22H6ON6Qi7Ni] (0.672/0.739 g, 1 mmol) and dropwise addition 
of SnCL•5H20 (0.350g, 1 mmol). After 5-6 h the solutions were filtered and the filtrate 
was reduced to one-third of its volume on a vacuum evaporator, affording the 
heterobimetallic complexes. 
[CuHsoN6O 3CuSnCl2]: [Yield: 46%]. M.P. >280 °C (dec). Anal.Calcd for 
C22H~N6O,3CuSnCl2: C, 30.73; H, 5.86; N, 9.77. Found: C, 30.72; H, 5.81; N, 9.71. 1R 
(KBr) (vm./cm ' ): 3420 v(O-H, broad); 3246 v(N-H); 1646 S(N-H, HOH), 1559 (C=N); 
1436 S(OCH, CH2, CCH); 1079 v(CO, CC); 1321 v(C-N); 559 v(Sn-N); 420 v(Cu-N). 
Molar Conductance, AM (1.10-3 M, DMSO): 28.0 [F'cm2 mor, (non-electrolyte); Uv-
vis. (1 x 10-3 M, DMSO, nm) 247, 296, 630. ESI-MS: (m/z, DMSO): 841.8 
[CnHsoN6O13CuSnCIr-HZO]' 
[C22H53N6O17NiSnCl2] [Yield: -37%]. M.P. > 265 °C (dec). Anal.Calcd for 
C22U5gN6O7NiSnCl2: C, 28.50; H, 6.31; N, 9.07. Found: C, 28.51; H, 6.32; N, 9.05. IR 
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(KBr) (v,,, /cm ' ): 3428 v(O-H, broad); 3301 v(N-H); 1634 5(N-H, HOH), 1559 
v(C=N); 1440 8(OCH, CH2, CCH); 1071 v(CO, CC); 1321 v(C-N); 575 v(Sn-N); 456 
v(Ni-N). Molar Conductance, AM (1.10-3 M, DMSO): 28.0 ST'cm2 mol-1 (non-
electrolyte); Uv-vis. (I x 10-3 M, DMSO, nm) 245, 295, 674. 'H NMR (400 MHz, 
DMSO-d6, S): 5.19-5.00 (N-H(en)); 3.19-4.43 (CH2(en), H20, CH2(ppz), skeleton 
protons of D-glucose). 13C NMR (100 MHz, DMSO-d6, 25°, S): 89.74-60.86 (6C, Glc); 
46.22-40.28 (CH2 of amine and piperazine). 119SnNMR (149.19 MHz, DMSO-d6, 8): 
-570.47 ppm. 119SnNMR (149.19 MHz, D20, 6): -570.47. ESI-MS: (m/z, DMSO): 
801.1 [C22H5gN6O»NiSnCIr7H2O+H]+ 
Results and discussion 
The 	synthesis 	of heterobimetallic complexes (C22H5oN60i3CuSnCl2] 	and 
[C22H5sN6O17NiSnCl2] were 	achieved by 	reacting monometallic 	complexes 
[C22H52N60,3Cu] and [CuH6ON6Oi7Ni] with SnCI4.5H20 in 1:1 stoichiometric ratio 
(scheme 1). Emperical formulae and proposed structure were ascertained by elemental 
analysis and various spectroscopic techniques (IR, UV-vis, ESI-MS and NMR 
spectroscopy). All the complexes were hygroscopic in nature and soluble in H2O and 
DMSO. Molar conductance (AM) values of complexes in DMSO (16-28 (Y'cmz mor') at 
25 °C suggest their non-ionic nature. On the basis of spectral studies, the coordination 
geometry of the central metal ions Cu°/Ni° was square pyramidal, while the Sn(IV) 
atoms was present in a hexacoordinated environment. 
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Scheme III: Synthetic route for the ligand, monometallic and heterobimetallic complexes 
Spectral characterization 
IR spectroscopy 
The IR spectrum of ligand [C14H2gN201o] displayed a characteristic band in the range 
3500-3200 cni 1 assignable to v(O—H) stretching vibration of free saccharides. However, 
IR spectra of the complexes exhibited a characteristic broad envelop at around —3400 cm 
1 due to the stretching vibrations of coordinated water molecule [256]. The absorption 
bands observed in the range of 3342-3246 and 1649-1627 em 1 were assigned to v(N—H) 
stretching and S(N—H and HOH) bending vibration of the coordinated secondary amino 
functions of the complexes. The strong characteristic IR bands at 1503-1412, 1079-1024 
and 883-864 cm" were attributed to S(OCH, CH2, CCH), v(CO, CC) and 6(CCH, CH) 
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vibrations, respectively, indicating the presence of sugar moiety [257]. Additionally, the 
bands at 1321-1348 cm' was assigned to v(C-N) stretching vibration of the piperazine 
ring. The medium intensity bands around 419-439 and 575-559 cm ' were attributed to 
v(Cu/Ni-N) and v(Sn-N), respectively revealing the complex formation. 
NSIR spectroscopy 
The 'H and 13C NMR spectra of ligand [C14H23N2010] was recorded in DMSO-d6 
solution. 'H NMR spectra of [C,4H28N20,a] exhibited signal at 4.70-4.69 ppm attributed 
to C1 and glycosylic -NH proton, indicating the condensation between the hydroxyl 
group of saccharides positioned at C-1 center and amino protons of ethylenediamine. The 
signals at 3.53-3.93 ppm were assigned to C2, C3, C4, C6 hydroxyl protons. The signals at 
2.91-2.85 ppm were attributed to -CH2 proton of linker ethylenediamine at C-1, together 
with other distinct sugar proton resonances at 3.40-3.32 ppm (C6 proton), 3.28-3.24 ppm 
(C3 and C5 proton), 3.08-3.13 ppm (C2 and C4 proton). However, -NH proton shifted 
downfield to 4.82-4.79 and 5.19-5.00 ppm in complexes [C22H60N60iiNi] and 
[C2H58N6O,7NiSnC12], respectively, which revealed the coordination of glycosylic 
nitrogen to the metal centre. The 'H NMR spectra of complexes [C22HooN6OE7Ni] and 
[C22H58N60vNiSnCl2] revealed broad envelope at 3.48-4.50 and 3.19-4.43 ppm, 
respectively were attributed to the skeletal protons signal of saccharides moiety, -CH2 
proton of linker ethylenediamine and piperazine ring [258]. Due to the saccharide-typical 
strongly coupled system, the resonances arising from different saccharide protons 
generally overlap in the same region resulting in the broadening of signals, and thereby 
individual resonances was difficult to identify [259, 260]. The '3C NMR spectra of the 
[C,4H28N20,o] and the complex [C22H6ON60,7Ni] and [C22H5$N6017NiSnC12] 
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corroborated well with the proposed structures. In the 13C NMR spectrum of ligand 
[C14H28N2010], the signal at 42.46 ppm attributed to the Cratom of the ethylenediamine 
(en)—based linker, together with six distinct carbon atoms of the D—glucose resonances at 
93.44 (C,), 60.66 (C2), 76.90 (C3), 74.06 (C4), 75.87 (C5), and 69. 64 (C6). However, the 
13C NMR spectrum of complex [C22H6oN6O i7Ni] and [C22H58N6O17NiSnCl2] exhibited 
distinct signals at 44.00-39.09 and 46.22-40.28 ppm, respectively attributed to —CH2 
carbons of piperazine and ethylenediamine moiety. The peaks for the carbon atoms of the 
D—glucose were observed in the range of 92.02-60.50 and 89.74-60.86 ppm for complex 
[C22H6oN6O17Ni] and [C22H55N6O17NiSnCl2], respectively. 19Sn NMR spectroscopy has 
been found to be a useful technique for structure elucidation and the nature of 
coordination of tin atom in complexes. The 19Sn chemical shift, S (1 '9Sn) is sensitive to 
the chemical environments of the tin atom. 19Sn NMR spectrum of the heterobimetallic 
complex [C22H58N6O17NiSnCl2] displayed a sharp single peak at —570.47 ppm, which 
was in agreement with the hexacoordinated geometry of tin metal atom (Figure. 67) 
[261]. 
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Figure 67. (a) 'II, (h) '3C and (c) ' `9Sn N. MR. spectrum of heterohimetallic complex 
[C 2 z Ns KNh c), 7Ni,nCl2 J 
EPR spectrum 
The X—band EPR spectra of complex [C22H50N6O13CuSnCl2] (Figure. 68) was recorded 
at liquid nitrogen temperature (LNT) under the magnetic field strength 3000 f 1000 G 
using tetracyanoethylene as a field marker. The spectrum shows an anisotropic signal 
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with g1 = 2.32 and g1  = 2.05 and gay = 2.14 computed from the expression gave = (g112 + 
2g12)/3. The trend of g values (g11 >g-> 2.0023) revealed that the unpaired electrons lies 
predominantly in the {dx2—y2} ' ground state of the Cu(1I) ion, in a square pyramidal 
geometry [262]. For a Cu(II) complex, g ji is a parameter sensitive enough to indicate 
covalence. For a covalent complex, g11 < 2.3, and for ionic environment, gp = 2.3 or more. 
In the present complex g1 < 2.3 indicates an appreciable metal—ligand covalent character. 
The exchange interaction parameter G < 4 (2.42), indicates considerable exchange 
interaction between the Cu(I1) centers in the solid phase [263]. 
Figure 68. X—band EPR spectrum of complex IC12N50NDC,3CuSnCHJ at LNT. 
UV—Vis spectra 
The electronic absorption spectra of ligand [C14 H28N2010] and complexes 
[C22H52N6O1 3Cu], [C22H60N6O»Ni], [('221 150N601 	and [G22H55N6017NiSnCl2] 
were recorded in DMSO solution at room temperature in the range of 200-1100 nm. The 
ligand displayed high—energy band at 233 nm in UV region corresponds to tin* 
transition. The electronic absorption spectra of complexes displayed intense absorption 
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bands at 244-247 nm followed by a shoulder at 292-296 nm attributed to the intraligand 
n—n* transition and the ligand to metal charge transfer (LMCT) band. Besides this the 
electronic spectrum of complex [C22H52N6O13Cu] displayed a low intensity broad band at 
590 nm attributed to a d—d transition, typical for square pyramidal geometry around the 
Cu(!I) metal ion [264]. Similarly, complex [Cz2HboN6OnNi] also exhibits a low energy 
metal centered d—d absorption band at 641 nm which was assigned to  
transition suggesting a pentacoordinate geometry around Ni(II) metal ion [265]. The 
heterobimetallic complexes [C22H5oN6QHCuSnC12] and [CnH58N6O17NiSnCl2] exhibited 
a broad and intense d—d band in the visible region with a maximum at 630 nm and 674 
nm, respectively, consistent with the pentacoordinate geometry around Cu(II)/Ni(II) 
metal. 
DNA binding studies 
DNA is the primary pharmacological target of antitumor drugs and therefore, it is 
essential to explore the interactions of metal complexes with DNA for the development 
of effective chemotherapeutic agents. Particularly, metal complexes in a well—tailored 
ligand framework are responsible for specific shape and surface features that complement 
the molecular target site usually major/minor groove of the DNA double helix and metal 
complex—DNA interactions are therefore, of paramount importance. The mode and 
propensity of binding of the ligand and its metal complexes to CT DNA were examined 
by using absorption and emission spectra. 
Absorption titration with CT DNA 
The absorption spectra of ligand [C14H28N201o] and the complexes [C22H52N6O13Cu], 
[C11H6oN6O17Ni], [C22HsoN6O13CuSnCl2] and [CnH55N&OiiNiSnCl2j exhibited intense 
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absorption bands around 233-249 nm, attributed to it n* intraligand transition. Upon 
addition of incremental amount of CT—DNA (0-33.3 x 10 M) to a fixed concentration 
of Ligand/complex (6.67 x l0~ M) resulting in "hyperchromism" at the intraligand 
absorption bands (Figure. 69a—e). 
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Figure 69. Absorption spectral traces of (a) Ligand 1C14H28N2OI0J (b) complex 
[C22H52N6013Cu1, (c) complex [C12H6(N6017NiJ (d) complex IC22H50N6O13CuSnCl4J (e) 
complex [C?2H58N60J7NiSnC11J in 5 %DMSO/ 5mM Tris HC!/ 50 mMNaCI buffer at pH 
7.2 upon addition of CT DNA. Inset: Plots of [DNA J/e —ej (M2 cm) vs /DNAJ for the 
titration of CT DNA with complexes ■, experimental data points; full lines, linear fitting 
of the data. [Complex] 6.67 x 10-6 M, [DNA] 0-33.3 x 
Table 5: Change in .spectral features of Ligand/complexes on interaction with CT—DNA 
in 5 mM Tris—HCI/50 mM NaCI buffer (pH 7.2). 
gand/complexes 	 Kh(M-1 ) 	Monitored at (nm) % Hyperchromism 
14H28N2010] 2.98 x 10 233 44 
22H52N6013Cu] 6.20 x 103 244 46 
22H~N6017Ni] 4.35 x 103 246 48 
22H50N6013CuSnCl2] 8.67 x 104 247 52 
22HS8Nb0i,NiSnCl2 4.00 x 104 245 51 
ie "hyperchromic effect" was due to the dissociation of ligand aggregates or due to its 
Kternal contact (electrostatic binding) with the duplex by engaging in hydrogen—bonding 
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interactions between coordinated —NH and —01-i with functional groups positioned on the 
edge of DNA bases. Since, complexes are appended with the carbohydrate functionality 
which features novelty not only from the structural point of view but also it provides 
molecular recognition at the specific site; it drives the complexes towards the phosphate 
sugar backbone of DNA double helix [266]. Hyperchromic effect and hypochromic 
effects are the spectral features of DNA concerning its double helix structure. 
Hyperchromism results from the damage of DNA double helix structure while 
hypochromism results from contraction of DNA in the helix axis [267]. Furthermore, 
there was no change in the position of the absorption bands of the complexes in the 
presence of DNA, indicating the possibility of groove binding for all complexes to DNA. 
The intrinsic binding constants (Kb) were calculated (Table 5), which follows the order 
[C22H5oN6013CuSnC l2]>[C22H53N6017NiSnCl2]>[CnH32N6O13Cu]>[C22H60N601 7Ni]> 
[C14H28N2010}, consistent with our hypothesis that heterobimetallic complexes are more 
prominent DNA binders than the monometallic in comparison to the free ligand. The 
higher binding propensity of heterobimetallic [C22HsoN6O13CuSnCl2] and 
[CuH58N6O17NiSnC12] is due to the introduction of Sn cations in the monometallic core; 
tin ions have a hard Lewis acid which has preferential selectivity for phosphate sugar 
backbone of the DNA double helix [268-270], in addition to the presence of second 
metal ion Cu"/Ni" which prefers coordinate covalent binding to nucleobases of DNA 
helix. 
Ethidium bromide displacement assay 
In order to further investigate the interaction modes of the ligand/complexes with DNA, 
fluorimetric competitive binding experiment was carried out using ethidium bromide as a 
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probe. Ethidium bromide (EthBr) emits intense fluorescence in the presence of DNA due 
to its strong intercalation between the adjacent DNA base pairs [271]. This enhanced 
fluorescence can be quenched by the addition of a second DNA binding molecule, which 
can be used to monitor the mode of binding thereby indicating the ability of a molecule to 
prevent intercalation of EthBr to DNA [272]. On addition of ligand/complexes to CT 
DNA pretreated with EthBr ([DNA]/[EthBr] = 1), there was reduction in emission 
intensity (Figure. 70a—e), indicating that they competitively bound to DNA and displaces 
the EthBr. 
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Figure 70. Emission spectra of EB bound to DNA in the absence and presence of (a) 
Ligand [C,4H28N2010J (b) complex jC22H52N6DI3CuJ, (c) complex [('zZHhaNg()»Nif (d) 
complex [('22N50NoOi3CuSnC12J (e) complex [C22H58N6O17NiSnCIJ in 5 mM This-
HCl/50 mM NaCI buffer. Arrows show the intensity changes upon increasing 
concentration of the complexes. 
The 	values for ligand [C14H2sN2O1o] and complexes [C22H52N6O13Cu], 
[C22FI(N-)Ol7Ni], [C22H50N6Ol3CuSnCl2] and [C22H58N6gNiSnCl2] were found to be 
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0.67, 1.82, 1.51, 2.66 and 2.31, respectively. The highest Ksv value of complex 
[C22H5()N6OI3CuSnCl2] suggesting its stronger ability to displace EB from the EB—DNA 
system. Since EB was not completely displaced, the electrostatic mode of binding cannot 
be ruled out. 
Gel electrophoresis 
Since heterobimetalIic complexes [C22H50N6O13CuSnCl2] shows maximum binding 
propensity with CT DNA, therefore the DNA cleavage activity of [C22H50N6O1 3CuSnCl2] 
was evaluated by agarose gel electrophoresis using supercoiled pBR322 plasmid DNA in 
a medium of 5 mM Tris—HCI/50 mM NaCI buffer solution (pl1 7.2). The reaction mixture 
was subjected to agarose gel electrophoresis with increasing complex concentrations 
incubated at 310 K for 45 min. 
(a) 	 (b)  
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Figure 71. Agarose gel electrophoresis diagram showing cleavage of pBR322 
supercoiled DNA (300 ng) by complex [C22H501V6O13CuSnCl JJ at 310 K after 45 min of 
incubation (a) at different concentration; Lane 1, DNA control; Lane 2, 101 M+ DNA; 
Lane 3: 15 pM+DNA: Lane 4: 20 pM+DNA; Lane 5: 25 pM+ DNA; Lane 6: 30 
uM+ DNA. (h) in presence of reactive oxygen species at 310 K after incubation for 45 
min. Lane 1: DNA Control; Lane 2: DNA+(C22HSfN6OI3CuSnC1J+DMSO (0.4 M); Lane 
3: DNA +[C22H50N6O13CuSnCl2J+ethyl alcohol (0.4 Al); Lane 4: DNA+ 
[C22H50N6O13CuSnC'12J+sodium azide (0.4 M); Lane 5: 9 pM of 
[C12Hs N6O,3(.:uSnCl2J+.SOD (15 units)+DNA. 
The activity of complex [C22H50N6DI3CuSnCl.2] was assessed by the conversion of DNA 
from Form [ (Supercoiled Form) to Form 11 (Nicked Circular Form) and then to Form Ill 
(Linear Form). It was observed that both the complex [C22H50N6O13CuSnCl2] was found 
to exhibits nuclease activity at different concentration (10-30 p.M), followed by 
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conversion of supercoiled DNA (Form 1) into NC DNA (Form II) without concurrent 
formation of Form III, suggesting single strand DNA cleavage (Figure. 71a). 
In order to investigate the DNA cleavage mechanism (oxidative or hydrolytic) induced by 
complex [C22H50N6Ol3CuSnCl2], we have monitored the quenching of DNA cleavage in 
the presence of some standard radical scavengers like DMSO and ethyl alcohol as 
hydroxyl radical scavenger (110), sodium azide (NaN3) as singlet oxygen (1 02) quencher 
and superoxide dismutase as superoxide anion radical (02`) scavenger (Figure. 71 b). The 
experiment results revealed that the DMSO and ethyl alcohol showed complete inhibition 
of nuclease activity (lane 2 and 3), indicating that the hydroxyl radicals is one of the 
reactive species involved in the DNA strand scission. Thus, OH free radicals participate 
in the oxidation of the deoxyribose moiety, followed by hydrolytic cleavage of the sugar 
phosphate backbone of DNA [273]. On the other hand, addition of NaN3 and SOD did 
not show any significant inhibition of the DNA strand scission, and even in presence of 
NaN3 the cleavage reaction is enhanced suggesting the non—involvement of the singlet 
oxygen radical and superoxide anion radical in the mechanistic pathway of DNA 
cleavage (lane 4 and 5). 
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Figure 72. Agarose gel electrophoresis for the ligation of pBR322 plasmid DNA nicked 
by complex [C22H jNN6Oi3CuSnCl2J Lane 1: DNA control; Lane 2: pBR322 plasmid DNA 
cleaved by complex [C22H50N6O13CuSnCL/; Lane 3: ligation of nicked pBR322 plasmid 
DNA by T4 DNA ligase in presence of [C22HmN6O13C uSnC12J. 
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Since the complexes cleave DNA in the absence of any external agents, the mechanism 
occurred through a hydrolytic pathway [274]. Therefore, hydrolysis promoted by metal 
ions mainly depend on the Lewis acidity, which serves to activate the phospho—diester 
bonds towards nucleophilic attack via charge neutralization as well as metal—coordinated 
water molecules provide an inbuilt nucleophile, which attack the phosphate back bone of 
DNA double helix to give a five—coordinate phosphate intermediate and thereby leading 
to direct hydrolysis of the diester bonds [275]. To ascertain the hydrolytic nature of the 
DNA cleavage reaction mediated by complex [C22HsoN6013CuSnCl2] DNA religation 
experiment was performed in which supercoiled pBR322 DNA was treated with T4 
ligase enzyme and subjected to gel electrophoresis [276]. The complex 
[C22H50N601 3CuSnCl2] yielded nicked DNA which was religated by using T4 DNA 
ligase enzyme; nicked form (Form 11) was religated to a large extent in the presence of T4 
ligase enzyme in comparison to control DNA alone in supercoiled form (Figure. 72). 
DNA cleavage in presence groove binding agents 
The potential interacting site of complex [C22H50N601 3CuSnCl2] with pBR322 DNA was 
determine in presence of minor groove binding agent, DAPI and the major groove 
binding agent, methyl green. 
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Figure 73. Agarose Gel electrophoresis for the cleavage of pBR322 supercoiled DNA 
(300 ng) by complex [C11H50N6013UuSnC!J presence of DNA minor binding agent DAPI 
and major binding agent methyl green at 310 K after incubation for 45 min. Lane 1: DNA 
control; Lane 2: 9 pM of [C1zHsoN6O13CuS'nCl2J+DNA+methyl green (2.5 pL of a 
0.01 mg/ml solution): Lane 3.' 9 pM of [C22H5oN6O13C'uSnCl2J  i DNA+DAPI (8 pM). 
When supercoiled pBR322 was treated with DAM or methyl green prior to the addition 
of complex, the cleavage reaction mediated by [C22HSON6O13CuSnCl2] was quenched in 
presence of DAPI while it enhances in the presence of MG indicating minor groove—
binding preference of the complex [CuH50N6Oi3CuSnC12] (Figure. 73). 
Topoisomerase H inhibitory activity 
The enzyme—mediated supercoiled pBR322 DNA relaxation assay was used to 
investigate the effect of complex [C11H5oN6013CuSnCl2] on the inhibitory activity of 
human—Topo—II by gel electrophoresis. When enzymatic activity was assayed 
supercoiled plasmid DNA converted to relaxed circular and then linear DNA. The 
presence of each type of DNA indicates a different behavior by the enzyme: relaxed 
DNA reveals that the enzyme's isomerase activity remains intact; supercoiled DNA 
suggests that the enzyme's action was inhibited; linear DNA reveals the formation of 
permanent double strand breaks during the catalytic cycle [277]. The effect of dose—
dependent Topo—Il inhibition assay of complex [C22H50N6O13CuSnCl2] was observed in 
the relaxation assay using supercoiled pBR322 plasmid DNA in the presence of ATP 
(Figure. 74). It was observed that the treatment with 10 µM (Lane 3) of 
[C22H50NtO13CuSnCl2] afforded partial inhibitory activity. As the concentration increases 
(20-40 µM), complex [C22H50N6O13CuSnCl2] successively inhibited the DNA relaxation 
activity of Topo II. These observations suggest that complex [C22H5ON6Oj3CuSnCl2] was 
selective towards Topo—II inhibition via ATPase binding domain due to the presence of 
hydroxyl moiety which may anchor in the entrance of ATP—binding pocket resulting in 
increased binding affinity and reduced ATP competition, thereby leads to a higher Topo-
II catalytic inhibitory activity. Thus, we conclude that [C221-I50N6O13CuSnCI1] was 
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catalytic inhibitor and not topoisomerase poisons because topoisomerase poisons give 
rise to permanent DNA cleavage by binding to the Topo–DNA complex covalently, 
stabilizing it and preventing the religation of the cleaved DNA by the Topo enzyme. On 
other hand, Topo-11 catalytic inhibitors interact non–covalently with enzyme (e.g. 
substrate competition) to impede enzymatic activity during the catalytic cycle, thus, alter 
their normal functioning resulting in cell death. 
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Figure 74. The cleavage patterns of the agarose gel electrophoresis diagram showing 
effect of different  concentration of complex [C22H50N60j3CuSnCl2J on the activity of 
DNA Topo—I1 a (Togo-11, 5 units); Lane 1: DNA control; Lane 2: Topo-11 control 
(Topo–II+DNA); Lane 3: 10,uM of [C.2H5DN6DHCuSnC14] +DNA+Iupo-11; Lane 4: 20 
pM of [C22H50N6O13CuSnC1J+DNA+Topo–IL Lane 5: 30 pM of[C221150N60!3CuSnCl2J 
+DNA + Topo–II; Lane 6: 40pMof[C22HSON6O13CuSnC12]+ DNA +Topo–IL 
Molecular docking with DNA 
Molecular docking technique is a well–documented computational tool to understand the 
Drug–DNA interactions for the development of rational drug design and to predict the 
exact binding site available at the molecular target DNA mainly in a non-covalent 
fashion, which can substantiate the spectroscopic results. Different structural properties 
lead to different binding modes; infact, one of the most important factors governing the 
binding mode is the molecular shape. 
Herein, molecular docking studies of the ligand and complexes with DNA duplex 
of sequence d(CGCGAATTCGCG)2 dodecamer (PDB ID: I BNA) were performed in 
order to predict the proper binding site along with preferred orientation of the ligand 
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(C'i4112RN,GIDJ molecules inside the 1)NA minor groove. The resulting docked pose 
(Figure. 75a--c), revealed that the ligand (C14H28N20+++{ hinds to the narrow minor groove 
region of DNA within G-C rich region and lead to van der Waals interactions and 
hydrophobic contacts with DNA functional groups that define the groove. Moreover, - 
NH and -OH groups of the ligand attached to the complexes acts as strong H-bond donor 
or acceptor were engaged in hydrogen-bonding interactions with DNA nucleobases 
available in the minor grooves. Furthermore, the potential energies of complex-DNA-
binding system after intercalation are much less than those of the system before 
intercalation, which may be attributed with electrostatic interaction and space matching. 
the total potential energy of complex-DNA binding system formed by complex 
intercalating into ('5(16 region from minor groove is less than those of other systems, 
illustrating that the minor groove binding of the complex in C5G6 region is the most 
preferential binding interactions between the complex and DNA base pairs. Although a 
narrow minor groove is considered to enhance ligand-1)NA interaction in the formed 
complex, it may not represent the most favorable geometry for the approximation and tit 
of the ligand [278). 
(b) 	 (c) 	(d) , 	 (e) 
Figure 75. Molecular docked model of (a) Ligand /('r.,H28N20,0/ ( h) complex 
/(',j1ISb11F6013('uJ (c) complex [C'22NBN6U,7NiJ (d) complex /('2.31154N60I3Cu.Sn('12J (e) 
complex [('231Iis ,N s(l7Ni.Sn('l2/ with DNA fdodecamer duplex of sequence 
d(( -(;('GAA77 'G('G) 2 (PDB ID: I BN.4)J. 
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The resulting relative binding energy of docked ligand [C14 H2sN2Q10J and complexes 
IC22H52N6Ol3Cu], [C22I1 N6O17NiJ, [(:21rly)NDQ13CuSnCl2 j and [Cl l N60i7NiSnCl21 
with DNA were found to be -204.6, -248.2, -227.9, -292.4 and -267.5 eV, respectively. 
correlating well with the experimental DNA binding studies and minor groove binder 
using DAM assay. The larger negative value of the binding energy establishes the 
greater binding potential of the metal complexes with DNA. 
Molecular docking with topoisomerase 
to study the molecular basis of interaction and rationalize the observed enzymatic 
activity, molecular docking studies of complex [C22H%N6013CuSnCl2J with the Topo-II 
was carried out using the genetic algorithm docking program HEX version 6.3. The 
complex 1C,-,HsoNoO13CuSnCl2 I was docked separately into the DNA binding site (PDB 
ID: 2rgr) and N-terminal domain in ATP binding sites (PL)B ID: l zxm) of Topo-11. 
Figure 76. Molecular docked model of complex [C22II5~N6013CuSn(.'12J into the human 
7opo Ii bound to DNA_ 
126 
The docked conformation into the DNA binding site of Topo—I1 revealed that complex 
[C22HsNoO13CuSnCl2 I was located in the hydrophilic pocket of the enzyme and it is in 
close proximity to residues Asn 828. (sly 766 and Tyr 760 (Figure. 76). Moreover, the 
hydroxyl group of sugar moiety was potentially involved in hydrogen bonding contact 
with the carboxylate of Asp 687. 
Figure 77. (a) Molecular docked model of complex [C»HSON4S(1,.?('z n('/2/ in to the ATP 
binding Jacket of human Topo Ha parallel to the Mg' ` ion. (h) The AT P—binding domain 
is represented as a molecular surface (purple), and complex /('22HsoN,6O,3('u.Sn(12/ in 
stick repre senation. The green ball represents Mg' ' ion. 
It also forms a water mediated hydrogen bond with Asn 769, which is considered an 
important amino acids that interact with the ligand in the DNA binding site of Topo II, 
subsequently leading to inhibitory effect on Topo 11 [279]. The presence of the hydroxyl 
group modifies the binding properties of the molecule to the DNA—binding domain of the 
i'opo II enzyme and serves to stabilize the enzyme—DNA complex (the "cleavable 
complex"). The docking model of complex [CI1;oN,,O„CuSnCl2] with ATP-binding 
domain of human Topo lla revealed that the sugar moiety of complex 
[C4,H;()Nf,0ssCuSnCI21 was fitted into the middle of the cavity, and stabilized by strong 
127 
hydrophobic interactions with Asn9l, Asn95, Lys123,G1y124 and Arg184 residues 
(Figure. 77).Other hydrophobic residues such as 11e217, Ile 118, I1e88 and A1a92, form a 
small subpocket at the bottom of the binding site filled with water molecules that 
establish a hydrogen bond network connecting the side chain of Asn 120 to that of Asn9l 
[280]. On the opposite side, three residues, lle125 together with Arg98 and Ser149, 
constitute the entrance of the cavity. Moreover, the hydroxyl group from the side chain 
forms hydrogen bonds with Serl49. These multiple interactions between complex 
[C22R5oN6Oj3CuSnC12] and residues in the ATPase domain and the magnesium ion 
suggest that the metal complex can form a strong binding interaction with Topo II, 
preventing the entry of ATP. The resulting relative binding energy of docked complexes 
[C22HsoN6Oi3CuSnC►2] with DNA binding site of Topo 11 and ATP domain were found to 
be —284.6 and —312.9 eV, respectively, indicating the best results into the ATP pocket 
than for the DNA binding site. 
Antitumor activity assays 
The observations of the biological studies for complex [CnH5oNoO 3CuSnC12] viz, in 
vitro DNA binding studies, pBR322 plasmid DNA cleavage and Topo—II inhibition 
revealed remarkable potential of complex [C22HSON6O13CuSnC12] to act as cancer 
chemotherapeutic agents, therefore their in vitro cytotoxic activity was evaluated. The 
activity of complex [C22HsDN6Qi3CuSnC12] was evaluated in terms of Gl50, TGI and 
LCso values against nine different human carcinoma cell lines of different histological 
origin: 786-0, A498 (kidney), Zr-75-1 (Breast), SiHa (Cervix), A549, Hop-62 (Lung), 
SW620, HCT15 (Colon), MIAPACA2 (Pancreatic). The in vitro anti—tumor screening of 
[C22H5ON6OHCuSnCl2] was evaluated as a consequence of their binding affinity towards 
Table 6: Summary of the screening data of complex (C12Hj0N60t3CuSnCl2] for the in vitro antitumor activity (in pg rnl). 
Human Tissue of origin 	Kidney 	Breast 	Cervix 	Lung 	Colon 	Lung 	Colon 	Kidney 	Pancreatic 
Cell line 	786-0 Zr-75-1 	SiHa 	Hop62 NCT15 A549 SW620 A498 MIAPACA2 
[C22HsoNy013CuSnCl2J 	35,9 76.1 40.0 	>80 25.2 	53,4 >80 	25.0 	14.7 GISD 	
ADR 	<10 <10 <I0 	<10 <10 	<10 <I0 	<10 	<10 
TGI 	[C22H
50N6013CuSnCl2] 	68.6 >80 74,1 	>80 46.8 	>80 >80 	43.8 	26,2 
ADR 	26.5 <10 14,9 	10.1 37,0 	42.1 17.0 	139 	20.4 
[C22H50N6G13CuSnCl2] 	>80 >80 >80 	>80 68,3 	>80 >80 	62,6 	37,7 LC50 	
ADR 	55,9 22.2 32.6 	31.0 66.9 	77.8 34.3 	35,3 	46.8 
Where: 
G130 = Growth inhibition of 50 % (Glsr) calculated from [(Ti—Tz)I(C—Tz)] x 100 = 50, drug concentration result in a 50% 
reduction in the net protein increase, 
ADR= Adriamycin (taken as positive control compound). 
TG1= Tumor growth inhibition 
LCsa = Lethal concentration of S0 % (LC50) 
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DNA by applying microculture Sulforhodamine B test (SRB) [219].The initial cytotoxic 
screening data (Table 6) shows that the (C22H5oN6O13CuSnCl2I act as a potential selective 
anticancer agent with a significant Gl5o values specifically towards MIAPACA2, A498 
and HCT15 tumor cell lines. 
Conclusion 
In the present work, we have described the synthesis and characterization of cancer 
chemotherapeutic carbohydrate—conjugated heterobi metallic core [C22H5oN6013CuSnC12] 
and [C22H58N6017NiSnCl2] derived from their monometallic complexes [C22H52N6013Cu] 
and [CnH6oN6Oi7Nl]. In vitro DNA—binding profile of ligand [C14H2$N2010] and 
complexes [C22H52N6013Cu], [CuH6oN6O17Ni], [C22H'50I`16O13Cu5nCl2] and 
[CnH53N6O1,NiSnCl2] were carried out by using various biophysical techniques which 
reveal strong electrostatic binding mode via phosphate backbone of DNA helix, in 
addition to selective binding to the minor groove of DNA. Complex 
[C22H50N6O13CuSnCl2] cleaves supercoiled plasmid pBR322 DNA via hydrolytic 
pathway (supported by DNA relegation assay employing T4 DNA ligase). The Topo—II 
inhibition activity of the complex [CnH50N6O13CuSnCl2] has been evaluated using 
pBR322 plasmid DNA cleavage assay which showed inhibitory effect at a concentration 
—40 µM. This work therefore, features the design of novel metal—based topoisomerase 
inhibitors, which are specific DNA groove binders. Furthermore, in vitro antitumor 
activity of [G22H50N6O13CuSnCl2I was evaluated by SRB assay, which exhibited 
moderate results against MIAPACA2 (human Pancreatic carcinoma), HCT15 (human 
Colon carcinoma), and A498 (human Renal carcinoma) cell lines. 
CHAPTER VI 
Synthesis, characterization and DNA—binding studies of 
heterobimetallic complexes Cu°—Snw/Zn°—Sn v with Schiff base derived 
from salicylaldehyde and 5—amino-2—mercaptobenzimidazole 
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Synthesis 
Synthesis of 5-{](lE) -(2-Hydroxyphenyl)metlrylene]amino}-2-hydroxybenzoic 
acid: [C141111N30S] 
The ligand [C14Hi1N3OS] was synthesized with 5-amino-2-mercaptobenzimidazole 
(0.165g, Immol) and salicylaldehyde salicyaldehyde (0.122 g, I mmol) in ethanol on 
stirring for half an hour at room temperature according to the procedure reported earlier 
[281]. 
Synthesis of monometallic complexes [C,4H12N3O2SCuCI] and [C,J JuN3O2SZnCI] 
The monometallic complexes [C14HI2N302SCuCI] and [C14H12N302SZnCl] were 
prepared by the following procedure: 
To a methanolic solution (20 ml) of CuC12.2H20 (0.170 g, I mmol)/ZnC12 (0.136 g, I 
mmol) was added DMF solution (2 ml) of ligand (0.269 g, I mmol) in a 1:1 molar ratio. 
The reaction mixture was refluxed for 2 h, a brown color precipitate was obtained in case 
of CuCl2 and pale yellow color precipitate was collected with ZnCl2. The product 
obtained was filtered, washed thoroughly with methanol and dried in vacuo. 
[C14H12N3O2SCuCI]: Yield 63%. M.P. 233-235 °C. Anal. (%) Calc. for 
Cj4H12N302SCUCl: C, 43.64; H, 3.14; N, 10.91. Found: C, 43.61; H, 3.18; N, 10.88. 1R 
(KBr, cmj 3054 v(N-H), 2589 v(S-H), 1648 v(HC=N), 871, 766 (H20 rocking and 
wagging), 460 (C -N), 416 v(Sn-N). Molar Conductance, AM (1 x 10-3 M, DMSO): 82.0 
S2-'cm2 mol-' (1:1 electrolyte). UV-vis (DMSO, 1, nm): 255 nm, 300 nm and 550. 
ESI-MS (m/z): 348.7 [C14H,2N302SCuCI-CI-H]' 
[C14Hj2N3O2SZnCl]: Yield 65%. M.P. 241-245 °C. Anal. (%) Calc. for 
Ci4Hi2N3O2SZnCI: C, 43.43; H, 3.12; N, 10.85. Found: C, 43.48; H, 3.11; N, 10.81. JR 
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(KBr, cmj 3054 v(N-H), 2569 v(S-1-1), 1688 v(HC=N), 853, 750 (H20 rocking and 
wagging), 472 v(Cu-N), 420 v(Sn-N). Molar Conductance, AM (1 x 10-3 M, DMSO): 
78.01 1i'cm2 mol-' (1:1 electrolyte). UV-vis (DMSO, X,, nm): 240 and 334. 'H NMR 
(400 MHz, DMSO-d5, 6, ppm): 8.96 (HC=N), 6.93-7.64 (ArH), 3.38 (SH); '3C NMR 
(100 MHz, DMSO-d6, S, ppm): 162.71, 160.64, 143.48, 133.61, 133.48, 132.96, 131.98, 
119.86, 119.58, 117.57, 116.99, 110.36, 102.11, 99.99, 69.55. ESI-MS (m/z): 350.2 
[C 4H12N3O2SZnCI - Cl-H]+. 
Synthesis of heterobimetallic complexes [C16H16N3O2SCuSnCII and 
[C16H,6N3O2SZnSnCI] 
The complexes were prepared by a general synthetic method in which a solution of 
monometallic [C14H1 2N3O2SCuCI] (0.385 g, I mmol)/ [C14H12N3O2SZnCIJ (0.387 g, 
lmmol) in DMF (2 ml) was added dropwise to a methanolic solution of (CH3)2SnCl2 
(0.219 g, I mmol) with constant stirring. The resulting solution was allowed to reflux for 
2 h and the precipitate obtained was filtered, washed thoroughly with methanol and dried 
in vacuo. 
[C16Hj6N3O2SCuSnCI]: Yield 54%. M.P. 280-283 °C. Anal. (%) Calc. for 
C16H16N3O2SCuSnCI: C, 36.12; H, 3.03; N, 7.90. Found: C, 36.11; H, 3.21; N, 7.78. IR 
(KBr, cm') 1608 v(HC=N), 853, 760 (H20 rocking and wagging), 472 (Cu-N), 435 
v(Sn-N). Molar Conductance, AM (I x 10-3 M, DMSO): 84.13 n-'cm2 mor e (1:1 
electrolyte). UV-vis (DMSO, X, nm): 262, 318 and 592. ESI-MS (mlz): 495.3 
[CI6Hf6N302SCvSnCl - C1-H]+  
[C,&H16N3O2SZnSnCTf: Yield 58%. M.P. 281-284 °C. Anal. (%) Calc. for 
C,4-1,tN3O2SZnSnCI: C, 35.99; H, 3.02; N, 7.87. Found: C, 35.89; H, 3.01; N, 7.71. IR 
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(KBr, cm) 1609 v(HC=N), 853, 750 (1-120 rocking and wagging), 460 (Cu—N), 412 
v(Sn—N). Molar Conductance, AM (1 x 10-3 M, DMSO): 89.13 Q cm2 mol-1  (1:1 
electrolyte). UV—vis (DMSO, 2,n., nm): 320, 351, 570. 245 and 390. k H NMR (400MHz, 
DMSO-d6 , S, ppm): 8.99 (HC=N), 6.95-7.67 (ArH); 13C NMR (100MHz, DMSO-d6, S, 
ppm): 162.72, 160.64, 143.48, 133.61, 133.49, 132.97, 131.97, 119.87, 119.58, 117.58, 
117.00, 110.36, 110.36, 102.10, 54.16, 21.77, 14.23; ' 19Sn NMR (146MHz DMSO -d6, 6, 
ppm): —221.18. ESI—MS (m/z): 480.4 [C J6H)6N3O2SZnSnCI — CI—H2O]+. 
Results and Discussion 
All the complexes were stable towards air and moisture and soluble in DMSO and DMF. 
The complexes were thoroughly characterized from analytical and physicochemical data. 
On the basis of spectral studies, the coordination geometry of central metal ion copper(II) 
was square planar, while the zinc(II) and Sn(IV) atom was present in a distorted 
tetrahedral environment (Scheme I). Molar conductance values of both the complexes in 
DMSO (I x 1(-3 M) at 25 °C suggest their 1:1 electrolytic nature. 
Scheme IV: Synthetic route for the ligand [C14H IJ N30S], monometallic 
([C14H12N,O2SCuCI] and [C)4H12N3O2SZnCIJ) and heterobimetallic complexes 
([C16H16N3O2SCuSnCIJ and [C,6H16N3O2SZnSnCI]). 
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Spectral characterization 
IIt spectroscopy 
The IR spectra of ligand and complexes were recorded in the region of 4000-400 cm ' by 
using the KBr pellet technique. It is interesting to note that the ligand [C,4HnN3OSJ 
exists both in thiol and thione forms due to tautomerism. In the solid state, the v(S-H) 
band at 2565 cm' was absent, indicating that the ligand remained in the thione form. 
However, solution state exhibited a medium intensity band at 2560 cm ' which was 
assigned to stretching vibration of v(S-H) group which indicates the thiol form of the 
ligand [C14H11N30S]. The band at 3054 em-1  was attributed to the presence of v(N-H) 
group in complexes [C14H12N3O2SCuCI] and [C14H12N3O2SZnCI]. The band around 3332 
cm' due to phenolic OH were disappeared in the monometallic complexes 
[C14H12N3O2SCuCIJ and [C14H12N3O2SZnCI] which supports the coordination of OH 
group of phenol coordinated to central metal Cun/Zn" via deprotonation. The 
characteristic band appeared at 1610 cm' due to v(-C=N) stretching vibration in the free 
ligand [C14Hi1N3OSJ was shifted towards lower wave number (1608-1588 cm') in the 
complexes indicating coordination via azomethane nitrogen to the metal center. The 
bands at 600-632 and 680-756 cm ' were corresponds to (-C-S-H stretching of the 
mercapto group) while the bands at 1370-1400 cm ' assign to -S--C stretching vibration. 
The coordination of the water molecules to metal ions was further supported by the 
appearance of bands in the region 853-871 cm ' attributed to rocking and wagging mode 
of water [282]. Other medium intensity bands at 749-755 cm-1  were attributed to the 
characteristic signatures of aromatic ring vibration. The IR spectra of heterobimetallic 
complex [C161-I16N3O2SCuSnCI] and [C16H16N3O2SZnSnCI] exhibit absence of band 
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around - 2650 cm 1 (v(SH)) and 3400 cm 1 (v(NH)), indicating the coordination through 
sulphur and nitrogen atom via deprotonation [283]. The medium intensity bands around 
460-472 and 412-435 cm' were attributed to v(Cu/Zn-N) and v(Sn-N), respectively 
revealing the complex formation. 
NMR spectroscopy 
The NMR spectra of the Schiff base ligand [C14H11N30S] and their monometallic 
([C14H12N3O2SZnCI]) and heterobimetallic complex ([C16H16N3O2SZnSnC1]) were 
recorded in DMSO-d6 solvent and their expected resonances were assigned on the basis 
of their intensity and the observed chemical shift values. 'H NMR spectrum of ligand 
[C14H1iN3OS] shows azomethine proton signal at 8.72 ppm which was shifted to 8.96 
and 8.99 ppm in complexes [CitHi2N3O2SZnCI] and [C115 h6N302SZnSnCI], 
respectively, indicating the coordination through azomethine nitrogen [284]. The signal 
of the phenolic (OH) proton in the free ligand observed at 13.24 ppm was absent in the 
spectrum of the complex [C14H12N302SZnCI] indicating the coordination of phenolic 
group to metal center via deprotonation. The signal due to SH (thiol form) and -NH 
proton moiety of mercaptobenzimidazole appears at 3.38 and 12.62 ppm, respectively, 
remains unperturbed in the [C14H12N3O2SZnCI] indicating the non-involvement of SH 
and NH group, respectively [285]. However, in the 'H NMR specrum of heterobimetallic 
complex [C16H16N3O2SZnSnCI], the signal due to SH and NH proton of ligand 
disappeared indicating the involvement of sulphur and nitrogen in the coordination via 
deprotonation and the sharp signal at 1.99 ppm corresponded to methyl proton bound to 
tin atom. The aromatic protons appeared as multiplets in the range of 6.95-7.67 ppm 
[286]. 
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The 13C NMR spectrum of the ligand [C 4HijN3OS] exhibits signals at 169.53 (C=N), 
162.53 (C-0), 143.41-102.07 (Ar—C) and 79.67 (C—SH). However, the 13C NMR 
spectrum of complexes [Cj4H12N302SZnCI] and [C16H16N3O2SZnSnC1] exhibited signals 
at 162.71, 160.64 and 143.48-99.99, 69.55 and 162.72, 160.64 and 143.48-102.10, and 
54.16 ppm, respectively, were attributed to the azomethine, phenolic, aromatic, and thiol 
carbon atoms of the ligand, respectively. Additionally, significant changes was observed 
in the spectrum of heterobimetallic complex [Ci6H16N3O2SZnSnCI] for the two methyl 
groups attached to tin atom displayed signal at 21.77 and 14.23 ppm. 
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Figure 78. (a) 'H, (h) 13C and (c) 119Sn N.M.R. spectrum of heterobimetallic complex 
[C,6H16N3O2SZnSnC1]. 
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To support the findings from 'H NMR and 13C NMR 119Sn NMR were also recorded in 
DMSO—d6. 119Sn NMR spectroscopy has been found to be a useful technique for structure 
elucidation and the nature of coordination of tin atom in complexes. 1 19Sn NMR spectrum 
of the complex [C,6Hi6N3O2SZnSnCI] displayed a signal at —221.18 ppm. The chemical 
shift value was consistent with the previously reported four coordinated environment 
around tin metal ion (Figure. 78) [287, 288]. 
EPR spectrum 
The solid state X—band EPR spectra (Figure. 79) of the heterobimetallic complex 
[Ci6H16N3O2SCuSnCI] was acquired at a frequency of 9.1 GHz under the magnetic field 
strength 3,000±1,000 Gauss using tetracyanoethylene (TCNE) as field marker (g = 
2.0027) at room temperature. The spectrum displayed a well resolved anisotropic signal 
with gp = 2.15 and g1= 2.07 and g,, = 2.10 computed from the formula g,yz = g 2+2g12/3. 
These parameters are consistent with the square planar geometry of the copper(I1) metal 
ion and are quite similar to the values reported for other related square planar copper(l1) 
systems and are typical of axially symmetrical d9 Cu(II) complexes [289]. 
Figure 79. X—band polycrystalline powder EPR spectrum of complex 
[C16Rr5lvjO2SCuSnC1] of room temperature. 
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The trend of g values (g>g1>2.0023) observed for the copper(II) indicates that the 
unpaired electrons lies predominantly in the dx2—y2 orbital of Cu(11) ion (spectroscopic 
state 2B1g) [290]. For a Cu(Il) complex, g is a moderately sensitive parameter to indicate 
covalence. In case of covalent environment gq <2.3 and for ionic environment gp = 2.3 or 
more. In the present complexes gi < 2.3 indicates an appreciable metal—ligand covalent 
character [291]. 
Electronic spectra 
The electronic absorption spectra of ligand [C14HIIN30S] and complexes 
[C14HI2N3O2SCuCI], 	[C14HI2N3O2SZnCI], 	[C 16Hj6N3O2SCuSnCI] 	and 
[C16H16N3O2SZnSnCI] were recorded in DMSO solution at room temperature in the 
range of 200-1100 rim. The electronic spectrum of ligand [Ci4H11N3OS] exhibits two 
bands at 210 nm and 335 nm, which has been assigned to (n—n*) and (n—n*). The 
complex [C 14H12N3O2SCuCI] reveals three bands at 255 nm, 300 nm and 550 nm, 
which were assigned to (a—n*), (n—n) and 2Big '2Aig, transitions, respectively, while 
complex [C14H12N3O2SZnCI] revealed two bands at 240 and 334 due to intraligand and 
LMCT transitions, respectively. The complex [C16H16N3O2SCuSnCI] revealed two bands 
at 262 nm and 592 nm which have been assigned to LMCT transitions and 2Big +2Aig. 
These results was consistent with the square planar environment around Cu(I1) metal ion 
[292]. For complex tG6H16N3D2SZnSnCI] band at 245 nm was attributed to the 
intraligand transition. However, the absorption spectrum of complexes 
[C16H16N3O2SCuSnCI] and [C16Hj6N3O2SZnSnCIj revealed bands at 318 nm and 390 nm 
due to LMCT transitions, respectively. 
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DNA Binding Studies 
The DNA binding ability of ligand and complexes in the absence and the presence of 
CT-DNA were carried out by absorption titration experiment. Upon addition of 
incremental amount of CT-DNA (0-33.3 x 10-6 M) to a fixed concentration of ligand 
[C i4H11 N30S], monometallic complexes [C 14 H12N3O2SCuCI], [C1 4H12N302SZnCl] and 
their heterobimetallic complexes [C I 6H16N3O2SCuSnCI], [CI 611 N3O2SZnSnCl], an 
increase in the absorbance ('hyperchromic effect') of the intraligand band was observed 
(Figure. 80). The "hyperchromic effect" is typical of cationic complexes involving ligand 
with extended hydrophobic regions or surfaces usually bind to DNA noncovalently: 
external contact (electrostatic binding), hydrogen bonding and groove surface binding 
(major or minor) along outside of DNA helix. 
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Figure 80. Absorption spectral traces of (a) Ligand [CiuH2sN2O,oJ (b) complex 
[Cj4HJ2N3OIS'CuClJ, (c/ complex IC,4N11N3O2.SZnCIJ (d) complex 
/C16H16N3O2SCuSnClJ (e) complex [CmMI,6N3O2SZnSnClJ in 5 %DMSO/ 5mM Tris HCII 
50 mM NaCI buffer at pH 7.2 upon addition of CT DNA. Inset: Plots of'[DNA//e- (M 
cm) vs [DNA] for the titration of CT DNA with complexes ■, experimental data points: 
full lines, linear fitting of the data. [(:'omplex] 6.67 x I e M. [DNA] 0-33.3 x 10 6 M 
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Since, the observed hyperchromic effect revealed no band shift (bathochromic or 
hyposochromic shift), it can be inferred that ligand and complexes exhibit groove binding 
interactions by the external contact with the DNA duplex. To compare quantitatively the 
binding strength of [C14H1 N3OS], [C141-I12N3O2SCuCl], [C14H12N3O2SZnCI], 
[C16H16N3O2SCuSnCI] and [C 16H16N3OZSZnSnCI] towards CT DNA, the intrinsic 
binding constant Kb were calculated (Table 7) 
Table ': Change in spectral features of ligand/complexes on interaction with CT—DNA in 
5 mM Tris—HC1/50 mM NaC1 buffer (pH 7.2) 
ligand/complexes K t,(M-') Monitored at (nm) 
[C14 H 11 N30S1 1.06x 103  275 
[C14H12N3O2SCuCI] 4.20 x 103  272 
[Ci4H1 2N3O2SZnCI] 2.31 x 103  274 
[Ca4llhN3O1SCuSnCI] 6.81 x 104 273 
[C161116N3O2SZnSnCI] 4.67 x 104 275 
The higher Kb value of heterobimetallic complexes [C16111 N3O2SCuSnC1] and 
[C16H16N3O2SZnSnCI] show greater propensity for DNA as compared to monometallic 
complexes [C1 4H12N3O2SCuCI] and [C,4H1 2N3O2SZnCI] and free ligand 1C14H i ,N3OSJ 
due to the presence of Sn(IV) metal ion center which is attributed to its strong tendency 
for phosphate binding, in addition to the presence of second metal ion Cu(ll)/Zn(ll) 
which prefers coordinate covalent binding to N7/N3 of the nucleobases. These complexes 
show dual mode of action at the molecular target site and exhibit novelty due to 
preferential selectivity and recognition toward nucleobases inside the cells [293]. 
Ethidium bromide displacement assay 
In order to further investigate the mode of binding of the ligand [C1 4H 11 N3OS], 
monometallic complexes [C14 H12N3O2SCuCI], [C141-I l 2N3(2SZnCI] and their 
heterobimetallic complexes [C16H16N3O2SCuSnCI] and [C16H16N3O2SZnSnCI] with 
DNA, the ethidium bromide displacement assay was carried out using the emission 
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intensity of ethidium bromide bound to DNA as a probe [294]. EB is an intercalator that 
gives a significant increase in fluorescence emission when bound to DNA and its 
displacement from DNA results in a decrease in fluorescence intensity. The fluorescence 
intensity of EB bound to CT DNA pretreated with EB ([DNA]/[EB]=1) solution at 590 
nm showed remarkable decreasing trend with increasing concentration of the ligand 
[C14Hi1N30S], monometallic complexes [C14H12N3O2SCuCI], [C14 H12N3O2SZnCl] and 
their heterobimetalIic complexes [C 16H16N3O2SCuSnCIJ and [C16Hi6N3O2SZnSnCI] 
(Figure. 81). 
Figure 81. Emission spectra of EB bound to DNA in the absence and presence of (a) 
Ligand [C l4HI8N2O,oJ (b) complex [C ,4H12N302.SCuCIJ, (c) complex [C 14H,2N3O2SZnCIJ 
(d) complex [C16rI6N3O2SCuSnCIJ (e) complex [C16H16N3C)2SZnSnC.1J in 5 mM Tris-
HC 1/50 mM NaCI bufer. Arrows show the intensity changes upon increasing 
concentration of the complexes. 
The resulting decrease in emission intensity was caused due to the change in hydrophobic 
environment to an aqueous environment by the displacement of EB from a DNA 
sequence by a quencher and the quenching is due to the reduction of the number of 
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binding sites on the DNA that are available to the EB. The extent of reduction of the 
emission intensity gives a measure of the binding propensity which was evaluated 
qualitatively by employing Stem—Volmer equation. The K, values for ligand 
[C14HnnN3OS], and complexes [C14H12N3O2SCuCl], [C14H12N3O2SZnCl], 
[C16Hi6N3O2SCuSnCI] and [C16H16N30ZSZnSnCI] were found to be 0.16, 1.93, 1.64, 
3.02 and 2.86, respectively. The highest Ksv value of heterobimetallic complex 
[Ci6H16N3O2SCuSnCI] suggesting its stronger ability to displace EB from the EB—DNA 
system. 
Gel electrophoresis 
Concentration dependent DNA cleavage 
It is known that plasmid DNA cleavage produces relaxation of the supercoiled circular 
conformation to the nicked circular and/ or linear conformations. When circular pBR322 
DNA is subjected to gel electrophoreses, relatively fast migration is observed for the 
intact supercoiled form (Form 1). If scission occurs on one strand (nicking), the 
supercoiled form will relax to generate a slower—moving open circular form (Form II). If 
both strands are cleaved, a linear form (Form 111) is generated that migrates in between 
Forms I and II. Metal complexes are known to cleave DNA by oxidative and/or 
hydrolytic pathways. Hydrolytic cleavage of DNA takes place with hydrolysis of the 
phosphodiester linkage forming fragments that could be subsequently religated. The 
oxidative cleavage of DNA, on the other hand, leads to the degradation of DNA molecule 
to fragments either due to the abstraction of the deoxyribose sugar hydrogen atom(s) or 
the oxidation of the guanine base [295, 296]. 
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The DNA cleavage ability of [C 6Hi6N3O2SCuSnCl] and [C16H16N3O2SZnSnCI] was 
studied by agarose gel electrophoresis using supercoiled pBR322 plasmid DNA as a 
substrate. Upon gel electrophoresis of the reaction mixture, a concentration dependent 
DNA cleavage was observed. A significant conversion of supercoiled pBR322 DNA to 
Form II and Form III was observed with increase in concentration of complex 3 (Figure. 
82a). The most impressive cleavage feature observed for complex [C16H1 6N3O2SCuSnCI] 
was that Form Ill DNA appears before the disappearance of Form I DNA (Lanes 2, 3, 4, 
5 and 6). This phenomenon indicates that the complex [C16H16N3O2SCuSnCI] was 
capable of performing direct double—strand scission [297]. The complex 
[Co}116N3O2SZnSnCl} exhibited discernible DNA cleavage with the increase in 
concentration, more intensified nicked (Form 11) while no linear (Form 11I) was observed 
(Figure. 82b). 
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Figure 82. Agarose gel electrophoresis diagram showing cleavage of pBR322 
supercoiled DNA (300 ng) by complex (a) [CruH16N3O2SCuSnC1] and (b) 
[Cj6H,6N3O2SZnSnC1J at 310 K after 45 min of incubation; Lane 1: DNA control; Lane 
2: l0,uMqfcomplex+DNA; Lane 3: 20 pM of complex+DNA; Lane 4: 30 pM of complex 
+ DNA; Lane 5: 40 pM of complex +DNA; Lane 6: 50 pM of complex+DNA. 
Reactive oxygen species responsible for DNA cleavage 
The interaction between metal complexes and dioxygen or redox reagents are believed to 
be a major cause of DNA damage [298]. To postulate a mechanism responsible for DNA 
cleavage mediated by complexes [C16H16N3O2SCuSnCI] and [Ci6H16N3O2SZnSnCI], 
electrophoretic study with some standard radical scavengers was also carried out, viz., 
-1 
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DMSO and ethanol as hydroxyl radical scavengers, sodium azide and SOD as singlet 
oxygen scavenger and superoxide radical scavenger, respectively (Figure. 83). The 
addition of DMSO and EtOH to complex [C16H16N3O2SCuSnCI] scarcely inhibited the 
DNA cleavage activity (Lane 2 and 3) which was indicative of non—involvement of 
diffusible (HO') hydroxyl radicals as one of the ROS responsible for DNA breakage. On 
the other hand, addition of sodium azide slightly decreased the cleavage efficiencies 
(lanes 4) which reveals that 1 02 was not the activated oxygen intermediate responsible for 
the cleavage. 
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Figure 83. Agarose gel electrophoresis diagram showing cleavage of pBR322 
supercoiled DNA (300 ng) by complexes [Cl6H,6N301SC'uSnClJ and 
[CmH16N3O2SZnSnC1t (40 ,uM) in presence of reactive oxygen species at 310 K after 
incubation for 45 min. Lane 1: DNA Control; Lane 2: DNA + [C16H16N3O2SCuSnC1]+ 
DMS() (0.4 M); Lane 3: DNA+[C 16H16N3O2SCuSnC1J+ ethyl alcohol (0.4 M); Lane 4: 
DNA+ [C,6H16N302SCuSnC7J+sodium azide (0.4 M): Lane 5: 9 PM of 
[C,6HI6N3O2SCuSnClJ + SOD (15 units) + DNA; Lane 6: DNA +[CB[j6 N3O2SZnSnC1J 
+DMSO (0.4 M); Lane 7: DNA +[C,6HwJJ3OrSZn]nClJ+ethyl alcohol (0.4 M); Lane 8: 
DNA +[C,6H,6N3O2SZnSnC.7J+sodium 	azide 	(0.4 	M); 	Lane 	9: 
DNA+[C16HJbN30;SZn.SnC.'1t + SOD (15 units). 
However, there was complete inhibition in case of SOD (superoxide dismutase) (Lane 5) 
which demonstrates the involvement of superoxide radical in DNA scission suggestive of 
oxidative cleavage mechanism [299]. Superoxide dismutase (SOD) is one of the most 
important antioxidant enzymes that catalyzes superoxide neutralization by converting it 
to hydrogen peroxide and oxygen. The mechanistic pathway proposed for the interaction 
of complex [C16H16N3O2SCuSnC1] with DNA is given below: The first step is the 
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interaction of Cu(II) complex with DNA through outer sphere, and then in the second 
step, reduction of the Cu(II) to Cu(I) complex by the reaction with the reducing agent. 
Reaction of the cuprous state with dioxygen leads to the generation of anion radical 02 
quencher, the cleavage was improved which indicated that 02 might be an inhibitor 
in the cleavage of the plasm Id and reducing the amount of O2 could improve the 
cleavage effect. 
Cu(1)+ 02 —. Cu(II) + 02 	 (1) 
In this system, it is thought that superoxide dismutases to 11201, 
202 + 2W,  02 + H202 	 (2) 
The ROS formed are responsible for initiating DNA strand scission chemistry [300]. 
ROS species + DNA --* DNA cleavage. 	 (3) 
In the case of complex [C16H16N3O2SZnSnCIj, the addition of DMSO and ethyl alcohol 
(Lane 6 and 7), DNA cleavage is inhibited suggesting the possibility of hydroxyl radical 
as one of the active species. Thus, free radicals participate in the oxidation of the 
deoxyribose moiety, followed by hydrolytic cleavage of the sugar phosphate back bone in 
the absence of the scavengers. On the other hand, addition of NaN3 and SOD (Lanes 8 
and 9, respectively), the cleavage ability was enhanced, particularly SOD displayed 
concomitant conversion of Form 11 to Form III, suggesting the non—involvement of the 
singlet oxygen radical and superoxide anion radical in the mechanistic pathway of DNA 
cleavage. Therefore, an oxidative cleavage pathway of DNA by complex 
[C 6H,6N3O2SZnSnCI] has been excluded and evidently the cleavage proceeds by a 
hydrolytic mechanism [3011. 
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DNA cleavage in presence of minor and major groove binding agent 
Minor groove binding agent DAN and major groove binding agent methyl green were 
used to probe the potential interacting site of complexes [C16 H16N302SCuSnCI] and 
[C16H16N302SZnSnCI] with plasmid pBR322 DNA. When supercoiled pBR322 was 
treated with DAPI or methyl green prior to the addition of complexes, the cleavage 
reaction mediated by both complexes was quenched in presence of DAPI while it 
enhances in the presence of MG indicating minor groove—binding preference of the 
complexes (Figure. 84). 
Form 11 
Form Ill 
Form I 
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Figure 84. Agarose gel electrophoresis for the cleavage of pBR322 supercoiled DNA 
(300 ng) by complex [C,6H,6N3O2SCuSnCIJ and IC 16H16N3O2.SZnSm1J (40 uM) in 
presence of DNA minor binding agent DAPI and major binding agent methyl green at 
310 K after incubation for 45 min. Lane 1: DNA control; Lane 2. DNA+ 
[C,6H16N3O2SCuSnC1J+DAP1 (8 	Lane 3: DNA+ jC16H16N3O2SC'uSnCIJ + methyl 
green (2.5 ,uL of a 0.01mg/ml solution); Lane 4: DNA +[CI6H,6N302SZnSnC1J+DAP1(8 
pM): Lane 5: DNA +[C16H16 N3O SZn.SnC1]+methyl green (2.5 uL of a 0.01 mg/ml 
solution). 
Antitumor activity assays 	 - 
In vitro anticancer activity of complex [C16H16N3O2SCuSnCI] has been evaluated in 
terms of Glso, TGI and LC50 (Table 8) values against nine different human carcinoma cell 
lines of different histological origin: 786-0, A498 (kidney), Zr-75—I (Breast), SiHa 
(Cervix), A549, Hop-62 (Lung), SW620. HCT1 5 (Colon), MIAPACA2 (Pancreatic). The 
Sulforhodamine—B (SRB) assay was used to assess the cellular proliferation [219]. The 
result showed high potential of the complex [C16Il16N302SCuSnCI] as drug candidate, as 
expected from the higher DNA binding constant value. 
Table 8, Summary of the screening data of hetero6imetalIic complex [C1 JI16NjO,SCuSnCI] for the in vitro anti—tumor acriviry (in 
{rg!mlj, 
Human Tissue of origin Kidney Breast Cervix Lung Colon Lung Colon Kidney Pancreatic 
Cell line 786-0 Zr-75-1 SiHa Hop62 HCTIS A549 SW620 A498 MIAPACA2 
[C16H,6NASCuSnCI] <10 <10 <10 <10 <10 <10 <10 <10 <l0 
GI5o 	
ADR 	<10 	<10 	<10 	<10 	<10 	<10 	<10 	<10 	<10 
	
TGI [C16H16NASCuSnCI] 24.4 <10 16.5 <10 28.0 IN 15.5 15,3 	<10 
ADR 	26.5 	<10 	14.9 	10,1 	37,0 	42.1 	17.0 	13,9 	204 
LC 
sQ [Cl6HiaN3O1SCuSnCI] 	48.9 	18.5 	37.8 	24.8 	53.7 	41,4 	34.2 	38.6 	22,4 
ADR 	55.9 	22.2 	32.6 	31.0 	66.9 	77.8 	34.3 	33.3 	46,8 
Where: 
• Glso = Growth inhibition of 50% (Glso) calculated from [(Ti—Ta)1(C—Tz)] x 100 = 50, drug concentration result in a 50% 
reduction in the net protein increase. 
1 ADR = Adriamycin (taken as positive control compound). 
• TGI = Tumor growth inhibition 
• LC%=Lethal concentration of 50% (LC50) 
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The complex 1Cr c,Il1(,N;O,S('uSn('I] exhibited very promising antitumor activity (G1 
10 µgiml) against all these human carcinoma cell lines. indicating that it could act as 
efficacious metal—based anticancer drug entity. 
Molecular Docking 
Molecular docking technique is an important computational method to understand the 
drug—DNA interactions for the rational drug design and discover\ and to predict the 
binding site available at the molecular target. DNA mainly in a noncovalent fashion 
[3021. 
Figure 85. iAlolecu/ar c1ae•ka1 muck/ o/ ra. Ligura! L (h) complex [(',41InN3(,S('u('1/ 
cute! /c) complex /('/,HPN.iO'SZ_n( 7/ (c1) cumIlex /('16H16JV;O1S('uS'n('1/ (e) (nm/~Iex 
/(. 1 ,11,,,,' ,O SZrr.S'n(.'1/ wit/i DNA /c/oileoauner duplex u/'sequentce d(G(i(YGAA7I C(i('G/ 
(PDB ID: I BAA)/. 
Different structural properties lead to different binding modes, intact. one of' the most 
important factors governing the binding mode is the molecular shape. herein, 
comparative molecular docking studies of the Ligand [C13H11 N30S], and complexes 
[C14 111 :NO2SCUCl], 	jC14112N;O,SZnCI]. 	[C,RiNO:SCuSnCl1 	and 
[(,, ,I B,,N ,O,SZnSn('l j \p ith DNA duplex of sequence d(CGCGAATTCGCG)2 
dodecamer (PI)H II):1 RNA) were performed in order to predict the proper binding site 
along with preferred orientation of the ligand molecules inside the f)NA. The complexes 
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adopts a characteristic shape and flexible enough to adopt a conformation which is 
complementary to the minor groove. The docked model (Figure. 85) revealed that L 
[Cl4H11N30S] 	and 	complexes 	[C141-112N3O2SCUC1], 	[C14N12N3O2SZnCI], 
[Ci61-I16N3O2SCuSnCI] and [C16H16N3O2SZnSnCI] located into the curved contour of the 
targeted DNA minor groove mainly through benzimidazole ring and situated within 
narrower A-T (-10.8 A) regions compared to G-C (-13.2 A) ones, due to preferential 
binding of benzimidazole moiety to A-T regions compared to the G-C region and leads 
to van der Waals interaction and hydrophobic contacts with DNA functional groups 
which define the stability of groove [303]. It is well known that the interactions of 
chemical species with the minor groove of B-DNA differ from those occurring in the 
major groove, both in terms of electrostatic potential and steric effects, because of the 
narrow shape of the former. In contrast to major groove small molecules preferentially 
interact with the minor groove due to little steric interference [304]. Moreover, minor 
groove-binding molecules generally have aromatic rings connected by single bonds that 
allow for torsional rotation in order to fit into the helical curvature of the groove. The 
resulting relative binding energy of docked ligand [C4FnN3O2SCUCl] and complexes 
[C14H12N3O2SCuCI], 	[C14H12N3O2SZnCI], 	[Ci6H16N3O2SCuSnCI] 	and 
[C1èI16N3O2SZnSnCI] with DNA were found to be —192.4, —234.3, —261.4 and —248.6 
eV, respectively, correlating well with the experimental DNA binding results which is 
also in accordance with our hypothesis that heterobimetallic complexes are more 
prominent DNA binders than the monometallic in comparison to the free ligand. The 
results obtained from molecular docking corroborate the experimental results obtained 
from spectroscopic investigations. 
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Conclusion 
The present study reports the synthesis, structural characterization and comparative DNA 
binding profile of monometallic ([C14H12N3O2SCuCl] and [C14HI2N302SZnCI]) and 
heterobimetallic ([C)6H16N302SCuSnCI] and [C 6H16N302SZnSnCI]) complexes derived 
from the Schiff base ligand containing 5—amino-2—mercaptobenzimidazole and 
salicyaldehyde scaffold. The results of in vitro DNA binding studies demonstrate that the 
heterobimetallic complexes exhibit higher propensity for binding to CT DNA than the 
monometallic complexes and Schiff base ligand via electrostatic mode of interaction via 
phosphate sugar backbone of the DNA double helix. The gel electrophoresis assay 
revealed that the complex [C 6H 6N302SCuSnCI] cleaves the DNA via oxidative, while 
the DNA cleavage by complex [C 6Hi6N302SZnSnCI], follows hydrolytic pathway and 
approaches towards the minor groove of DNA helix. Furthermore, molecular docking 
studies were performed with molecular target DNA to validate the minor groove binding 
events. 
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